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Abstract 
The Maillard reaction represents a complex series of processes, initiated on reaction of a 
carbonyl moeity with an amine. Amongst the vast array of products (advanced glycation end 
products, AGEs) are protein crosslinks, which can foml on reaction of a-dicarbonyls with 
lysine and arginine residues, to form molecular bridges between proteins. It is thought that 
these crosslinks affect the native function of the protein, due to a structural change in the 
protein, and they have been implicated in the progression of some age-related diseases. 
Little is lmown about the precise amino acid requirements for protein crosslinking. Thus, this 
thesis sought to detelmine which amino acids were critical for crosslinking to occur. A lysine-
containing (arginine-free) protein and an arginine-containing (lysine-free) protein were 
reacted with three a-dicarbonyl compounds, methyl glyoxal, glyoxal and diacety1. It was 
demonstrated, for the first time in vitro, that an arginine residue is not essential for protein 
crosslinldng to occur. Only an N-terminus or a lysine residue is required for crosslinldng with 
the three a-dicarbonyls tested. 
A model protein, RNase A, which contains both lysine and arginine, was also incubated with 
the three dicarbonyls. Parallel measurements on crosslinking and activity were performed in 
order to test the assumption that crosslinking affects the function of the protein. To establish 
whether the loss funetion was a direct result of the crosslinking process, or a co-incident 
event, two previously reported crosslinldng inhibitors, aminoguanidine and 3,5-
dimethylpyrazole-l-carboxamidine, were included. The results demonstrated that although 
crosslinldng of RNase A could be inhibited by these compounds in the presence of a-
dicarbonyl, the activity of RNase A was not necessarily preserved. Inhibition of crosslinking 
may not preserve the funetion of the protein, as evidenced by the RNase A incubated >'lith 
methylglyoxal and 3,5-dimethylpyrazole-l-carboxamidine. This loss in activity but inhibition 
of crosslinldng may be explained by the presence of non-crosslinldng AGEs that have formed 
on the protein, rendering it inactive. These results are significant when considering any 
approach to intcrvention of the Maillard reaction. 
Also examined was a rcccntly-discovered enzyme, amadoriase I, which has been shown to 
reverse the early stages of the Maillard reaction under some experimental conditions. A time-
resolved assay was developed that allowed for accurate determination of ldnetic parameters 
and purification of amadoriasc I. By this method, amadoriase I was shown to have a Km of 11 
)!M for fructosyl propylamlne, a lmown substrate, and a kcatlKm of 3.25xlO\ both of which 
differ from previous literature reports. This assay was also used to successfully measure the 
activity of two mutants, H357N and S370A, which were created in order to determine which 
amino acid residues within amadoriase I are critical for catalysis. Both mutants were 
catalytically inactive, demonstrating their importance in amadoriase I. 
Finally, a second assay was developed in order to determine whether amadoriase I could act 
on a mildly glycated protein. Amadoriase I is reported not to turnover glycated protein, the 
physiologically relevant substrate. However, past experiments have involved conditions that 
favour formation of a heavily glycated protein, whieh may be inaccessible to amadoriase L 
The novel assay method involved direct assessment of activity of the protein substrate, before 
and after treatment with amadoriase I. The results confimled previous studies that amadoriase 
I could not use glycated protein as a substrate, even in the case of a mildly glycated protein. 
The assay method was also employed to search for a potential amadoriasc enzyme from a 
Pseudomonad which had been isolated from raw mille. The crude extract, however, did not 
show any deglycating activity as assessed by this assay and the time-resolved assay. 
The studies undertaken in this thesis will inform design of therapeutic strategies aimed at 
inhibiting or undoing the damaging effects of Maillard chemistry in vivo. 
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Chapter One 1 
Chapter One 
Introduction 
1.1 Background 
The Maillard reaction encompasses a complex network of non-enzymatic reactions 
that are initiated by the condensation of an amine with a carbonyl compound. A 
multitude of products can be formed during this process. Due to the ubiquitous nature 
of both starting materials, the Maillard reaction has far-reaching consequences, from 
food chemistry to involvement in medical science (1). 
Proteins contain a number of amines, for example, the N-terminus, lysine and arginine 
residues, which provide sites for the covalent attachment of sugars. This process of 
attachment, termed protein glycation, leads to a change in protein structure, which can 
in turn affect protein function (2-4). 
One specific type of glycation results in the formation of protein crosslinks. These 
crosslinks are generated via bridging of the protein-bound amines by carbonyl 
containing compounds. Protein crosslinks are thought to result in the impairment or 
loss of the native activity of the protein (5). However, surprisingly little is know 
about which amino acids are required for crosslinking to occur. Moreover, although 
protein crosslinking is assumed to have a deleterious effect on protein function, this 
has not yet been rigorously tested. The work detailed in this thesis sought to test this 
assumption and identify the structural requirements for protein crosslinking. The 
results described will be significant for future studies on attenuation of the Maillard 
reaction. 
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1.2 Initial stages of the Maillard reaction 
1.2.1 Classical descriptions of the Maillard reaction 
Since its discovery early last century (6), our knowledge of the mechanisms involved 
in the Maillard reaction has steadily increased. The initial step involves reaction of a 
carbonyl compound with a free amine, which appears upon first inspection seems to 
be a relatively simple event. To date, however, a complete reaction scheme cannot be 
presented (7). 
C. Maillard pioneered work in this area in 1912, with the observation that on 
heating sugars with amino acids, a yellow-brown colour developed (6,7). Elucidation 
of the chemical pathways underlying this browning phenomenon was undertaken by 
Amadori (8), Kuhn and Weygand (9), Simon and Kraus (10), Heyns et al. (II), and 
Hodge and Rist (12). This culminated'in the publication of the "classical" pathway, 
which is also referred to as the Hodge pathway (Figure 1.1) (1,12). The first step 
involves the nucleophilic attack of an amine at the carbonyl carbon. The reaction 
product is subsequently dehydrated to form an imine (Schiff base) (Figure 1.1). 
Studies have shown that the imine generally exists as a cyclic glyeosylamine (13). 
The labile imine then tautomerises to the enaminol, which can undergo further 
reaction to form either the stable Amadori product (from reaction of an aldose sugar) 
or Heyns product (from reaction of a ketose sugar) (Figure 1.1) (1). 
The availability of amines within proteins for modification by carbonyl compounds 
means that the Maillard reaction is biologically relevant. Indeed, it has been 
suggested that the Maillard reaction is involved in the pathophysiology of some 
diseases, such as cataract formation (2,14). In the early stages of Maillard research 
from a medical perspective, the reactive carbonyl compounds studied were reducing 
pentose and hexose sugars (14,15). This was mainly due to the influence of food 
chemistry, where studies generally focused on these sugars. More recently, the scope 
has broadened to include a-dicarbonyls (4), ascorbate and its oxidation product 
dehydroascorbate (16), polyol and glycolytic pathway (17) and lipid oxidation 
products (18). Some of these compounds result in reaction pathways that diverge 
from the classical route (section 1.4). 
Chapter One 3 
Physiological amines that can participate in the Maillard reaction include nucleotides, 
aminophospholipids, and protein (1,19,20). Proteins are rich in substituents such as 
lysine and arginine residues, which contain amine moieties in their side chains that are 
modified during the Maillard reaction (21,22). Histidine, proline and tryptophan 
contain secondary and/or tertiary amines which can participate in this chemistry but 
are less reactive (1,23,24). 
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Figure 1.1: The "classical" pathway describing the initial stages of the Maillard 
reaction, where glucose reacts with an amine to form an Amadori product. R 
represents the remammg amme skeleton, e.g. remainder of lysine 
-(CH2)4CH(NHz)C02H. Acyclic forms of the sugar and derivatives have been used 
for clarity. From Ledl et al. (1). 
After formation of the Amadori or Heyns product, the mechanistic details of the 
Maillard reaction are not as well-defined. There is a vast range of reactions such as 
cyc1isation, oxidation and condensation that can occur. These processes result in the 
generation of a complex array of compounds dubbed advanced glycation end products 
(AGEs) (25). 
1.3 Later stages of the Maillard reaction - formation of advanced glycation end 
products (AGEs) 
A number of AGEs have been isolated and identified in human tissue, where they are 
though to have deleterious consequences for the target protein (Figure 1.2) (26-29). 
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Glucosepane GOlA Vesperlysine A (lM-1) 
+ CH3 H 0 NH2 
HN-): ~N~O- ~NJlNTIO-~NAN 0 
H 
H H 0 
MG-HI CMl CMA 
H~OH 
l 
MODIC pyrraline Pentosidine 
Figure 1.2: A selection of advanced glycation end products from the literature (15,30-
37). Abbreviations: GOLA, N6-{2-[(5-amino-5-carboxypentyl)amino]-2-
oxoethyl} lysine; CML N8-carboxymethyl-lysine; CMA, JIll -carboxymethyl arginine; 
MODIC, 2-arnmonio-6-( {2-[( 4-ammonio-5-oxido-5-oxopentyl)amino ]-4-methyl-4,5-
dihydro-1H-imidazol-5-ylidene}amino)hexanoate; MG-Hl, N"-(5-hydro-5-methyl-
imidazolon-2-yl)-omithine. 
Those structures detailed in Figure 1.2, excluding the remainder of the protein, are 
relatively small in size compared to a class of AGEs or Maillard reaction products, the 
melanoidins. These are generally restricted to food systems, where they are thought 
to contribute to a class of high molecular weight coloured products and exist at 
molecular weights up to 10 kDa (38,39). 
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Although a number of AGEs have been identified in vitro and subsequently isolated 
ex vivo, many remain uncharacterised (27). As our knowledge increases in this area, 
it becomes evident that conventional methods undertaken to isolate AGEs may not be 
suitable for the isolation of other, as yet undefined, products. Past studies have 
exploited properties of AGEs that have made them amenable to isolation, for 
example, the fluorescent properties of pentosidine (37). Following successful 
isolation, the product can be identified by NMR and mass spectrometry. However, 
some suggest that major AGEs are non-fluorescent and non-ultraviolet active, 
presenting a significant barrier in the search for novel AGEs (40). 
Problems with characterisation of AGEs can also arise from the environment in which 
the AGEs are isolated. Model systems involving proteins may result in the formation 
of high molecular weight insoluble material, and isolation of the AGE of interest can 
prove difficult. Previously, isolation of AGEs generally involved treatment of the 
glycated protein with 6 M acid digest (26,37). This leads to the selection of only acid-
stable AGEs and, possibly, to the generation of artifactual products that have been 
modified by the work-up procedures (32) .. However, advances in methodology, such 
as enzymatic digests in place of acid, have meant that some of these previously-
undetectable crosslinks have been elucidated (31). 
1.4 Deviation from the Hodge pathway 
As more has become known about Maillard chemistry, it becomes evident that more 
than one pathway is in operation in the early stages of the reaction. These discoveries 
have aided our understanding of AGE formation, since an AGE can be formed via a 
number of differing routes. 
1.4.1 The contribution o/glucose autooxidatioll products to the Maillard reaction 
The elucidation of a pathway for formation of a-ketoaldehydes from autooxidation of 
glucose led to the proposal that these a-keto aldehydes may participate in the Maillard 
reaction. This was confirmed by Wolff and Dean, who showed that a-keto aldehydes, 
formed on glucose autooxidation, contributed to protein glycation (41). This work 
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was extended by Wells-Knecht et al. and Thomalley et al. who described the 
formation of glyoxal and methylglyoxal from glucose in vitro (42,43) (Figure 1.3). 
=I~H HO  
H OH 
H OH 
CH20H 
Retro-aldol 
conde~sation / 
Erythrose '----/ 
Glucose 
°HO 
H H 
Glyoxal 
p-Elimination 
-H20 
Methylglyoxal 
Figure 1.3: Formation of glyoxal and methylglyoxal by auto oxidation of glucose 
(42,43). 
This new pathway resulted in a re-evaluation of the Maillard reaction as, until this 
point, the Amadori or Heyns product was the only known route to AGE formation. It 
is now evident that a number of AGEs can be formed from methyl glyoxal and glyoxal 
(25,42,44) (Figure 1.4). These products are generally dubbed advanced glycoxidation 
end products (42). 
+ 
Glyoxal 
+ 
Methylglyoxal 
Protein backbone 
H2N~ 
lysine 
Protein backbone 
H2N~ 
lysine 
Protein backbone 
'OITN~ 
o H 
CMl 
CH
3 
Protein backbone 
'00N~ 
o H 
CEl 
Figure 1.4: Two AGEs formed on auto oxidation of glucose. Abbreviation: CEL, Nt: -
carboxyethyl-lysine; CML, Nt:-carboxymethyl-lysine (42,44). 
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1.4.2 The Namiki pathway 
The Namiki pathway describes retro-aldol condensation of the Schitlbase adduct and 
has been shown to yield glyoxal (45) (Figure 1.5). Further reaction ofthese products 
can result in the formation of the AGE N'i-carboxymethyl-lysine (CML) and protein 
crosslinks (Figure 1.5) (45). It has also been reported that the major source of one 
dicarbonyl formed in glucose-amine model systems, glyoxal, is neither through 
autooxidation of glucose nor the break-down of the Amadori product, but through the 
Namiki pathway (45). 
HtHC=~~R 
HO H 
H OH 
H OH 
CH20H 
Schiff base (Imine) 
Retro-aldol 
condensation + 
Figure 1.5: Proposed reaction scheme of the Namiki pathway involving the retro-
aldol condensation of the Schiff base (imine) and its reaction products. After Glomb 
and Monnier (45). R represents the remainder of the amine skeleton. 
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1.4.3 The role of Michael additions in the Maillard reaction 
Another pathway within the Maillard reaction involves the reaction of lipid 
peroxidation products to yield advanced lipoxidation products (ALEs), similar to 
AGEs. The formation of some of these products is thought to involve differing 
chcmistry to that discussed thus far, with the formation of adducts via Michael 
addition of lysine residues to lipid peroxidation products, such as 4-hydroxynonenal 
(lINE) and crotonaldehyde (Figure 1.6) (23,46,47). 
A 
+ 
4-Hydroxynonenal 
+ 
4-Hydroxynonenal 
Free amine 
Putative protein crosslink 
Free amine 
y 
HN 
/ 
Michael adduct 
Isolated end product 
LHNE 
Schiff base 
h~~,"<' ,ddliloe 
H3C, h ~ 
(CH2)4 0 ~ 
Putative protein crosslink 
Figure 1.6: Proposed pathways on reaction of a lipid peroxidation product with an 
amine via A, Michael addition (and subsequent Schiff base formation in some cases), 
(48) or B, Schiff base formation followed by Michael addition (49). Abbreviation: 
LHNE, 3-(lt-Iysino)-4-hydroxynonan-l-01. After Uchida et ai. (50). 
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There are two routes to the formation of end products of the reaction on incubation of 
protein with these lipid peroxidation products: Michael addition and Schiff base 
formation (Figure 1.6) (23). Some suggest that after initial Michael addition of the 
side chain of amino acids such as lysine, cysteine or histidine to the target 
a,~-unsaturated carbonyl compound (such as HNE), a secondary reaction can occur 
that will involve reaction of a protein-bound amine with the free CI carbonyl to yield 
a Schiff base (Figure 1.6 A) (48,50). Others have suggested that the formation of the 
Schiff base pre-empts the Michael addition, and that the isolated Schiff base Michael 
adducts, formed on reaction of amine with HNE, can be completely reversed (Figure 
1.6 B) (49,51,52). 
1.4.4 Strecker degradation 
The Strecker degradation appears to be confined to the area of food chemistry, where 
Maillard chemistry plays an important role. Strecker degradation involves 
degradation of a-amino acids on reaction with carbonyl compounds, ranging from 
glucose to a-dicarbonyls, to yield an aldehyde with one carbon fewer than the a-
amino acid (Figure 1.7) (1). Studies in this area have been generally restricted to free 
amines, not those that are protein-bound (53,54). However, oxidative deamidation of 
protein-bound lysine residues has been reported and is thought to occur via a 
Strecker-type reaction (55). 
Methylglyoxal Phenylalanine ~co, 
Figure 1.7: Strecker degradation of phenylalanine on reaction with methylglyoxal 
(53). 
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1.4.5 Which pathways are of most physiological importance? 
There are a number of differing pathways that can lead to the same product. The 
formation of CML is used here as an illustrative case study. In vitro studies have 
shown that CML can form in a number of ways. The formation of CML was first 
reported by Ahmed et al., who suggested that CML was to generated solely from the 
reaction of glucose with an amine via metal-catalysed break-down of the Amadori 
product (Figure 1.8) (15, 56). However, following the discovery that glucose 
autooxidation could result in glyoxal, a route to CML formation from the reaction of 
glyoxal with lysine was proposed. FOlmation of CML was thought to occur via either 
Cannizarro rearrangement or enolisation, dehydration and elimination reactions, of 
the Schiff base adduct formed on reaction oflysine with glyoxal (Figure 1.8) (42). In 
the same year, CML was shown to form through degradation of a glucose-lysine 
Schiff base (Figure 1.8) (45). 
Amadori product 
H~tHC=~H 
H OH 
H OH 
CHzOH 
Glucose 
1 
Retro-aldol 
condensation 
°HO 
H H 
Glyoxal 
1 + Lysine / 
Protein backbone 
-OTIN~ 
o H 
CML 
r + Lysine 
o 
H~OH 
Glycolaldehyde formed from 
the myeloperoxidase system 
HtHC=~~R 
HO H 
H OH 
H OH 
CHzOH 
Schiff base 
/
Retro-aldol 
condensation 
Figure 1.8: Current pathways to the formation ofCML in vivo (15,42,45,57). 
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The same work also reported that, the degradation of the Amadori product generated 
on reaction of glucose with lysine resulted in the formation of CML (45). The authors 
suggested that as there is a significant concentration of Amadori product in human 
tissue, the degradation of the Amadori product is the most physiologically significant 
route to CML formation, followed by formation via fragmentation of the Schiff base 
adduct. Both of these pathways to CML were proposed to be very much more 
significant than that involving the autooxidation of glucose (45). 
CML has also been identified on reaction of protein with hypochlorous acid (an initial 
product of the myeloperoxidase system) and serine, which is an excellent substrate for 
the reactions in the myeloperoxidase pathway (Figure 1.8) (57). Due to the fact that 
CML can be formed by lipoxidation products and through reaction of a-dicarbonyls, 
this product can be ascribed the acronym EAGLE (either advanced glycation or 
lipoxidation end product) (25). As more becomes known about the later stages of the 
Maillard reaction, many compounds that were traditionally referred to as AGEs now 
fall into the EAGLE category, including CML (25). Mathematical modeling based on 
existing in vitro studies has suggested that the route to CML via glyoxal, formed 
through the autooxidation of glucose, is of significant importance although the 
myeloperoxidase system is not considered (58). This conflicts with the earlier results 
from studies by Glomb and Monnier (45). 
1.5 Significance of the Maillard reaction 
The competing pathways outlined in the above sections result in a number of products 
which can have a dramatic effect in two quite different disciplines, food science and 
medical science, which will be discussed in turn below. 
1. 5.1 Implications for the food industry 
Preparation of foods can involve the presence of both starting materials, amine (such 
as protein or supplemented amino acids) and carbonyls (such as glucose). Food 
processing conditions can include high temperature and pressure (7), which result in 
the formation of many Maillard reaction products that can vary in concentration under 
differing reaction conditions (59). Many changes in the properties of food have been 
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attributed to the Maillard reaction such as browning, production of flavour and aroma 
compounds, bioactive compounds, changes in texture and a decrease in nutritional 
quality (7). Some of these provide a positive effect, whilst others have a negative 
effect. Figure 1.9 depicts a selection of Maillard products that are thought to 
contribute to some of the above phenomena, which were isolated under food 
processing conditions. 
o 
\ /; 
1-0xo-2,3-dihydro-1 H-indolizinium-6-olate 
Bitter tasting 
3-Hydroxy-4-(morpholino )-3-buten-2-one 
Antioxidant 
~) 
~SH 
N-(2-Mercaptoethyl)1,3-thiazolidine 
Popcorn-like aroma 
Acrylamide 
Carcinogen 
Figure 1.9: A selection of Maillard reaction products that have been isolated under 
food processing conditions (60-63). 
1. 5.2 Implications for medical science 
Until the 1970s, studies of the Maillard reaction were limited to the area of food 
chemistry. However, in the last 30 years, the formation of AGEs under physiological 
conditions has been extensively investigated. The focus of this research has 
broadened to include their role in the pathophysiology of diseases, such as diabetes, 
cataract formation and Alzheimer's. 
Current hypotheses 
Work in this area has resulted in the development of the hypothesis that AGEs that 
form in vivo can result in deleterious modification of structural proteins, enzymes, 
lipoproteins and DNA. These AGEs are thought to effect a change in structure, and 
thus function, of the target biomolecule (25). These modifications are implicated in 
some of the complications observed in diabetics, such as cataract formation (14). 
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This has been extended with the glycoxidation hypothesis, where oxidative stress is 
thought to play an important role in the formation of AGEs (64). An example of 
where this is important is the formation of the reactive a-dicarbonyls, methyl glyoxal 
and glyoxal from glucose, which have been shown to be reactive participants in the 
Maillard reaction (section 1.4.1). The lip oxidation hypothesis is also beginning to 
gain more attention. It proposes that products of lipid oxidation, such as 4-
hydroxynonenal, can react with proteins via lysine and histidine, to form advanced 
lip oxidation end products (ALEs) (section 1.4.3) (23,48). 
Contribution of AGEs to the pathophysiology of diseases 
Those researchers with a focus on the medical aspects of the Maillard reaction 
generally study age-related diseases such as cataract formation (2), Alzheimer's (65), 
and diabetes (66), particularly the latter due to the fact that this condition results in 
poorly regulated glucose levels. Simply aging also appears to result in a buildup of 
Maillard reaction products (67), albeit 'to a lesser extent than in those with diabetes 
(68). This is particularly true in long-lived proteins, such as collagen, where AGEs 
can build up due to the slow turnover ofthe protein (69). 
The eye lens contains a number of long-lived proteins including the a-crystallins. a-
Crystallins constitute a large proportion of the eye lens and are susceptible to 
modification via the Maillard reaction (2,70,71). Some of the AGEs formed on 
modification of a-crystallins are thought to playa role in cataract formation (72). The 
maintenance of the native protein structure is critical for the transparency of the eye 
lens. Modification in structure, and therefore organisation, within the lens results in 
light scattering and reduced transparency (73). It is thought that glycation could 
effect such a change in the structural organization of the eye lens (2). The AGEs 
outlined in Figure 1.10, isolated from human eye lens a-crystallins, are shown to be 
elevated as a result of ageing (27), and their concentration was further increased in 
patients with cataracts (27,74,75). 
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Figure 1.10: A selection of AGEs that have been isolated in lens tissue (36,37,75,76). 
Perturbation of cellular function by AGEs 
The effects of AGEs have so far focused on their direct impact on structural proteins. 
However, researchers have also examined modulation of cellular function following 
interaction of AGEs with cell surface binding sites. An early report in this area 
showed that AGEs caused a range of disturbances in cellular function (77). Attempts 
to isolate the protein that facilitated the entry of AGEs into the target cell resulted in 
the isolation of a 35 lcDa polypeptide, termed receptor for advanced glycosylation end 
products (RAGE) (77,78). Some have hypothesised that this receptor, along with 
other receptors known to bind AGEs, are "accidental receptors" in that they have the 
capacity to bind other ligands more efficiently than AGE-modified proteins. This is 
demonstrated by the RAGE receptor which binds amphoterin, a protein related to the 
metastasis of tumours, with a higher affinity than AGEs (79). Interestingly, RAGE 
has been shown to bind amyloid-~-peptide, resulting in enhanced neural toxicity, and 
RAGE expression is increased in affected neurons in the Alzheimer's brain (80,81). 
RAGE is also thought to activate the cellular cascade involving p21 ras and MAP 
kinase and modulate gene expression through NF-KB (82,83). Until recently, it was 
not known which particular AGEs were recognized by the RAGE receptor, only that it 
recognized AGE-modified proteins, which represent a heterogeneous mixture of 
AGEs. Work by Kislinger et al. has shown that CML can bind to RAGE, both in 
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vitro and in vivo, with activation of cell signaling pathways resulting in modulation of 
gene expression (84). 
Other receptors reported to bind AGE-modified protein are: the macrophage 
scavenger receptor (MSR), the receptor complex of OST-48, 80K-H and galectin-3 
(66,85). It is thought that these receptors contribute to clearing of AGEs from the cell 
(66). Indeed, it has been suggested by some workers that the MSR receptor on the 
macrophage acts to endocytose AGE-modified protein, and, with the aid of the insulin 
signaling pathway, results in effective elimination of AGE-protein (66,86). 
1.6 Protein crosslinking via the Maillard reaction in situ and in vivo. 
As the previous sections have outlined, the products of the Maillard reaction are many 
and varied. However, the remainder of this chapter, and thesis, will focus on protein 
crosslinks. Although some proteins are dependent on crosslinking processes for 
function, such as collagen (87), those involving the Maillard reaction are generally 
regarded as unfavourable. The vast majority of the crosslinks isolated to date involve 
lysine and arginine, and a more detailed summary of this literature will be presented 
in Chapter three. To date, there has not been a systematic study of the amino acid 
requirements for protein crosslinking. Therefore, this thesis aimed to assess the 
contribution of lysine and arginine in the crosslinking process by careful selection of 
well-defined starting materials. This information is valuable for designing therapeutic 
strategies for many diseases associated with Maillard crosslinks, including the 
following. 
1.6.1 Diabetes 
Diabetes is characterised by the lack of glucose regulation due to a deficiency in the 
secretion, or action, of insulin-the hormone that stimulates glucose uptake by body 
tissues (88). Poor control of diabetes can lead to high concentrations of glucose that 
may be available for participation in the Maillard reaction. Comparative studies with 
healthy humans have shown that crosslinks such as methylglyoxal lysine dimer 
(MOLD) and glyoxal lysine dimer (GOLD) are increased in some tissues of diabetic 
patients (89). There are a number of complications that arise during diabetes, such as 
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neuropathy (impainnent of sensory and motor nerves), uremia (a buildup of urea in 
the bloodstream), retinopathy (disease of the retina) and angiopathy (disease of blood 
vessels). Protein crosslinking has been implicated in at least some of these diabetic 
complications, due to their ability to induce tissue damage and increase stiffness of 
structural proteins, impairing their function (5,90,91). Interestingly, some crosslink 
breakers have been reported to reverse some of the above effects (92,93), including 
reducing cardiac tissue stiffness with a concomitant increase in cardiac function (92). 
1.6.2 Alzheimer's disease 
The ionnation of the aggregates that are characteristic of Alzheimer's disease is 
thought to be exacerbated by the Maillard reaction. Work by Smith et ai. detected the 
presence of the protein crosslink pentosidine in neurofibrillary tangle and senile 
plaques of Alzheimer's disease patients by immunocytochemistry (65). This is 
supported by another study that reported an elevated level of AGEs in Alzhemier's 
patients over those that did not have the disease (94). Finally, the polymerisation of 
the major protein in amyloid deposits, p-amyloid protein, has been shown to be 
accelerated by AGE-mediated crosslinking (95). 
1.6.3 The aging process 
As some proteins are slower to turn over than others, they are prone to glycation. 
Over time, these long lived proteins can become crosslinked as part of the aging 
process. Collagen is a good example, where pentosidine has been shown to increase 
with age (37,67). It is proposed that accumulation of these crosslinks results in 
increasing stiffness of collagen and impainnent of its function (96). In vitro studies 
have shown a concomitant increase of insolubility of collagen with crosslinking (97). 
1. 6.4 Cataract formation 
The earliest studies into the effect that crosslinking has on a protein were on the a,-
crystallin proteins within the eye, as discussed in section 1.5.2. The protein crosslinks 
MOLD and GOLD, fonned on reaction of methylglyoxal and glyoxal respectively, 
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with a-crystallin, were found to exist in the human lens and increase with time (26). 
Marked elevation in protein crosslinks in the lens are thought to be due to aging and 
are reported to be exacerbated in diabetics (98). 
1. 6. 5 The nature of cross links isolated thus far 
Although a range of crosslinks has been elucidated, it is thought that the majority 
remain undefined (40,99). This has been due to the limitations of the techniques 
developed to isolated protein crosslinks, as previously discussed in section 1.3. 
Traditionally, isolation of these crosslinks has involved the treatment of glycated 
protein with concentrated acid and prolonged reflux at high temperatures (26,37). 
This process creates an immediate bias for selection of acid-stable crosslinks and can 
also result in modification of the crosslink during the isolation process. However, 
with methodological advances, the structures of a number of acid-labile crosslinks 
have been elucidated (31,99). These new methods generally involve digesting the 
protein with enzymes, with subsequent analysis of the fragments by LCIMS, allowing 
for the elucidation of crosslinks that are colourless and non-fluorescent, such as 
glucosepane (Figure 1.10). Immunochemistry has also played a major role in the 
isolation and elucidation of acid-labile crosslinks (100). Some argue that quantifying 
AGEs via immunochemistry leads to difficulties, due to factors such as uncertainty of 
the specificity of the antibodies used (101). Although the process of synthesising 
possible AGEs in vitro and then searching for this molecule in ageing tissue has 
resulted in the isolation of a number of crosslinks, it still does not provide a total 
picture, because some of these isolated AGEs are physiologically unstable (27). 
1.6.6 Which carbonyl-containing molecules are effective at crosslinking? 
A number of carbonyl-containing molecules can participate in the Maillard reaction, 
from a-dicarbonyl compounds that can form on the break-down of sugars (e.g. 
glyoxal formation from retro-aldol condensation of glucose, section 1.4.1) to lipid 
oxidation products, such as 4-hydroxynonenal (section 1.4.3). There does not appear 
to be any strict requirements for a successful crosslinking carbonyl, although this has 
not been fully assessed and is thus examined in Chapter three. 
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Of particular interest over the last decade has been the a-dicarbonyl compounds 
methylglyoxal and glyoxal, which seem more physiologically relevant to the 
crosslinking process than glucose. These two molecules, along with the structnrally 
related compound, diacetyl, were selected for work in this thesis, due to their 
implicated role in physiological crosslinking reactions (Figure 1.11). As these 
compounds play a critical role in this thesis, a brief overview of these molecules in 
terms of their formation, catabolism and significance in the Maillard reaction is given 
below. 
Glyoxal 
H 0 
H3CXO 
Methylglyoxal Diacetyl 
Figure 1.11: The structnre of the three a-dicarbonyls under stndy in this thesis. 
Methylglyoxal 
Significance in the Maillard reaction . 
In recent years, a number of protein crosslinks have been isolated that are thought to 
involve methylglyoxal (26,30). The physiological concentration of methylglyoxal is 
thought to range between 256 nM in blood (2.4 /lM in diabetics), 1 /lM in plasma and 
15 /lM in urine in healthy human (102-104). However, up to 310 /lM has been 
reported where assay systems have quantified reversibly protein-bound methyl glyoxal 
along with unbound (105). Ninety-nine percent of methylglyoxal is thought to exist 
in reversibly bound state to protein or other biological ligands (4, I 05). This leads to 
the question of whether irreversible ad ducts through protein-bound amines can form 
and effect changes in the target protein. 
The metabolic flux of methylglyoxal 
A major route to methylglyoxal formation is via triose phosphates (Figure 1.12) (106-
108). This can occur either enzymatically, through triosephosphate isomerase (TIM) 
(109,110) or methylglyoxal synthase (111), or non-enzymatically, due to the unstable 
natnre of triose phosphates dihydroxyacetone-phosphate (DHAP) and D-
glyceraldehyde-3-phosphate (DGAP) (106). Interestingly, neither of the two enzymes 
mentioned share sequence similarity (l12), nor structural identity (113), although they 
Chapter One 19 
catalyse almost identical chemistry, only differing in the initial proton that IS 
abstracted (111). 
TIM catalyses the inter-conversion of DHAP to DGAP (Figure 1.12). Although 
highly efficient during the isomerisation process, TIM is not particularly efficient 
during the elimination reaction to form DGAP. As a result, the phosphoenediolate 
intermediate can leak from the active site and then be converted to methylglyoxal 
(Figure 1.12) (109,110). 
Methylglyoxal can also be formed enzymatically from glyceraldehyde 3-phosphate 
(107). Generation of methyl glyoxal from glyceraldehyde 3-phosphate has been 
considered artifactual, but is difficult to negate as initial reports on the subject have 
not been extended (114). The non-enzymatic formation of methylglyoxal from 
glyceraldehyde has also been reported (Figure 1.12) (115). 
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Figure 1.12: The major routes to methyl glyoxal formation in vivo (110,113,115). 
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Minor routes to methylglyoxal formation are summarized in Figure LB. Two 
enzymes found to produce methylglyoxal in vitro, semi carbazide-sensitive am me 
oxidase and acetol monooxygenase, have been isolated in rats (Figure L 13) 
(116,117). Routes to methylglyoxal formation via acetone have also been reported in 
microbes (118). 
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Figure 1.13: Minor routes to formation of methyl glyoxal in vivo (39,43,116,117,119-
121). R, amino acid side chain. 
Cells have developed a number of enzymatic (Table 1.]) and non-enzymatic 
mechanisms to deal with this potentially toxic compound. These enzymes show 
varying affinity for methylglyoxal (Table 1.1). 
Chapter One 
Enzyme 
Glyoxalase II 
Glyoxalase III 
L-G1yco1 dehydrogenase 
Methy1g1yoxa1 reductase 
Glycerol dehydrogenase 
Aldose reductase 
Aldehyde reductase 
Aldose reductase like enzyme 
Source 
Ubiquitous 
E. coli 
E. aerogenes 
Hen muscle 
C. beijerinckii 
C. difficile 
S. cerevisiae 
E. coli 
E. coli 
K. pneumoniae 
Human 
Glyoxal oxidase P. chyrysosporium 
Formaldehyde dehydrogenase C. boibinii 
Methy1g1yoxa1 dehydrogenase Sheep liver 
Gram negative bacteria 
21 
Methy1g1yoxa1 Km Ref 
66.5 flM (122) 
130 flM (123) 
Not reported (124) 
75mM (108) 
Not reported (125) 
Not reported (126) 
Not reported (127) 
5.88 mM (108) 
4mM (127) 
Not reported (128) 
Not reported 
8flM (129) 
l.2mM (130) 
130 flM (131) 
649 flM (132) 
2.8mM (133) 
l.2mM (134) 
40 flM (135) 
Not reported (118) 
Table 1.1: Enzymes that have been found to cata1yse the break-down of 
methy1g1yoxal. 
Pathways to the formation and break-down of methyl glyoxal have been well 
documented. A number of pathways can exist within an orgalllsm to combat 
excessive levels of methy1g1yoxal. It has been difficult to determine which are 
important, in terms of significant contribution to formation or detoxification of 
methy1g1yoxal. Although some groups have studied the flux of methyl glyoxal 
through a metabolic system (136), the significance of particular formation and 
detoxification pathways of methyl glyoxal in all organisms is still unclear. It has been 
suggested that a barrier to the understanding of metabolic flux, presence, and function 
of methy1g1yoxa1 in biological systems is the poor performance of assay techniques 
designed to quantify methy1g1yoxa1 (107). 
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Glyoxal 
Significance in the Maillard reaction 
The physiological concentration of glyoxal has been reported to be 132 J.!M in healthy 
human urine and 229 nM in human plasma (104,137). Little is lmown about whether 
glyoxal exits as a predominantly free or protein-bound species in vivo. 
Along with methylglyoxal, glyoxal has become a focus as a potent reagent in Maillard 
chemistry. This a-dicarbonyl has been shown to be involved in the formation of 
protein crosslinks (26,30,31). Glyoxal is also responsible for the formation of some 
non-crosslinking adducts with protein, through lysine and arginine residues (138,139). 
These latter non-cross linking AGEs may also effect a change in function, like their 
crosslinking counterparts. 
The metabolic flux of glyoxal 
Glyoxal can be formed by many of the routes that have been mentioned for 
methylglyoxal, such as on autooxidation of glucose, retro-aldol condensation of the 
Schiff base, metal-catalysed oxidative break-down of Amadori products, and from 
UV irradiation of lipids (39,42,43,45,56,120,140-143). Glyoxal may also be 
generated by a free radical mechanism, through reaction of glucose with peroxynitrite 
(43,144). mterestingly, only one enzyme, a manganese peroxidase enzyme, has been 
isolated that generates glyoxal (145). 
Some enzymes from Table 1.1 also exhibit an affinity for glyoxal, such as glyoxal 
oxidase, hen L-glycol dehydrogenase, and sheep methylglyoxal dehydrogenase 
(125,135). Substrate studies for two of these enzymes, hen L-glycol dehydrogenase, 
and sheep methylglyoxal dehydrogenase, showed that although glyoxal could bind to 
these enzymes, the affinity was not as strong as other substrates that were examined 
(126, 136). 
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Diaeetyl 
Significance in the Maillard reaction 
Diacetyl has had little coverage in the literature from the perspective of the Maillard 
reaction. It is of interest to food chemists due to its contribution to the formation of 
aroma compounds (146). Diacetyl has the capacity to crosslink a model protein, 
although the structures of these crosslinks have not been elucidated (16). Its presence 
has been reported in rats, where it is present in concentrations of 85 nM, 48 nM and 
389 nM in heart, kidney and liver tissue respectively (147). 
The metabolic flux of diacetyl 
Diacetyl is formed during the fermentation of milk by Laetoeoeeus laetis, where its 
stability is dependent on a variety of factors, including pH and presence or absence of 
oxygen (148,149). It can also be fomled in beer, via the metabolic processes 
undertaken by the yeast. It has been isolated in model systems that mimic food 
processing conditions, through fragmentation and subsequent reaction of glucose, and 
has also been isolated in oxidised edible oil (146,150,151). Production of diacetyl has 
also been reported during nucleic acid oxidation (152). 
Some enzymes that have been mentioned in the detoxification sections of 
methylglyoxal and glyoxal are also able to tum over diacetyl. These include L-glycol 
dehydrogenase and glycerol dehydrogenase (153,154). Diacetyl reductase has been 
isolated in microbes and mammals, where it converts diacetyl to acetoin in the 
presence ofNADH (155). 
1.7 Inhibition of the Maillard reaction 
The Maillard reaction can potentially lead to a number of deleterious effects in the 
human body, as outlined in sections 1.5 and 1.6. Thus, intervention in the reaction is 
an important area of research. The implementation of strategies detailed below has 
shown success in attenuating some physiological manifestations of the Maillard 
reaction, such as the formation of AGE-crosslinked amyloid plaques (95). However, 
some that have shown early success have been eliminated as effective intervention 
approaches due to their chemical instability (156). 
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As more became known about the differing stages of the Maillard reaction, a number 
of Maillard reaction inhibitors were designed for intervention at particular points in 
the Maillard scheme. The points of "attack" are outlined in Figure 1.14. The types of 
inhibitors will be considered in the classes outlined by Khalifah et al. (157). 
"Type A" inhibitors compete for ammes that are capable of participation in the 
Maillard reaction. An example is pyridoxal phosphate, which sequesters amines so 
that they can no longer participate in the Maillard reaction (157). These types of 
inhibitors are not particularly advantageous from a therapeutic standpoint, due to their 
non-specific nature with respect to the target amine. 
I B) e.g. Carnosine II A) e.g. Aspirin 
~ ~ 
Sugar 
C) e.g. Pyridoxamine 
Hy N-R1 
H----j-OH 
R2 
Schiff base 
C) 
K a-diCarbOny~ 
IT 
D) e.g. Aminoguanidine 
C) 
Advanced 
Glycation 
End 
Products 
(AGEs) 
I E) e.g. Arnadoriase I 
~ 
H~:H-R1 
R2 
Amadori product 
/ 
F) e.g. ALT-711 
Figure 1.14: The points of intervention in the Maillard scheme. A-F are defined in the 
text. After Khalifah et al. (157). The compounds employed for intervention at various 
steps are shown in boxes. 
"Type B" inhibitors, such as carnosine, work on the same principle, but act to trap the 
reacting carbonyl molecule, effectively sequestering it from reaction with protein-
bound amine (158). 
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"Type C" inhibitors (Figure 1.14), are a broader class that act to block pathways to 
formation of other potentially reactive Maillard participants. An example is 
pyridoxamine that acts to block autooxidation of some carbohydrates through its 
metal ion chelating ability (159). 
"Type D" inhibitors are thought to trap reactive a-dicarbonyl compounds before they 
can react with the amine (Figure 1.14). One such example is aminoguanidine, which 
can trap reactive a-dicarbonyls as triazines (120,160). 
A class of enzymes have been found to undertake the function of "type E" inhibitors 
(Figure 1.14). The amadoriase enzymes act on the Amadori product to reverse the 
early stages of the Maillard reaction (161). Work involving the "type E" inhibitors, 
the deglycating enzymes that have been shown to act on glycated low molecular 
weight amines, is still in its infancy. Currently, there is not an enzyme from the class 
of amadoriases that can act effectively on a glycated protein substrate (161), a 
shortcoming when considering these enzymes from a therapeutic perspective. 
Finally, the "type F" inhibitors are those that have been reported to act by cleaving 
protein crosslinks, and include phenacylthiazolium bromide and AL T -711 (92,162). 
The efficacy of these inhibitors has been subject scrutiny with mixed reports on their 
efficacy (5,93,156,163). 
Results from recent studies have challenged our current understanding of the mode of 
inhibition of some of the above compounds. For example, aminoguanidine was 
initially thought to react with the Amadori product (164). Later works showed it 
could react with free sugar to render it unable to react with amine (165), and the 
dideoxyosone intermediates (166). Until recently, it was thought that the major mode 
of amino guanidine inhibition was through binding to a-dicarbonyl compounds acting 
as a "type D" inhibitor, effectively sequestering them from reaction (160). In the last 
two years, it has been proposed that aminoguanidine and a number of inhibitors that 
act at differing stages of the reaction are effective due to their metal-ion chelating 
ability (i.e. a "type C" inhibitor) rather than their proposed action such as dicarbonyl 
trapping or crosslink breaking (159,167,168). 
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1.8 Thesis aims 
A brief overview of the complex nature of the Maillard reaction has been provided in 
this introduction. The complexities of the Maillard reaction result in a vast array of 
products, many of which remain undefined. Protein cros slinks , which comprise a 
proportion of these products, are thought to be responsible, at least in part, for the 
progression of some diseases. Surprisingly little is known about the amino acids 
requirements for this process, and the effect that crosslinking has on protein function. 
Therefore, this thesis aims to clarify the contribution of protein-bound amines, such as 
lysine and arginine, to protein crosslinking via three a-dicarbonyls, methylglyoxal, 
glyoxal and diacetyl. 
This thesis also probes the activity of a model protein, ribonuclease A (RNase A), 
following treatment with these dicarbonyls, with a parallel measure on crosslinking. 
To date, it has been assumed that a change in protein structure, through crosslinking, 
will result in a change of function of that protein, which forms the basis for the type 
"F" Maillard inhibitors, the crosslink breakers (section 1.7). Thus, an extensive study 
was undertaken to test this hypothesis. The proposed a-dicarbonyl trapping 
compounds amino guanidine and 3,5-dimethylpyrazole-l-carboxamidine, were 
included to test their efficacy at inhibiting crosslinking andior a loss in activity of the 
RNaseA. 
The Maillard reaction plays a role in the many aspects of cellular function and 
therefore, control of this chemistry is essential. The amadoriases have, thus far, not 
been shown to use glycated protein as a substrate. This may be due to the heavily 
glycated nature of previously-prepared protein substrate (161). This hypothesis was 
tested by assessment of the ability of amadoriase I to deglycate RNase A that was 
mildly glycated with methylglyoxal to create a more physiologically relevant 
substrate than those trialled in the past. A novel assay approach was developed to 
determine the efficacy of amadoriase I when using a glycated protein substrate. This 
assay was then employed to search for enzymes that could deglycate protein from a 
Pseudomonad, which was isolated from raw mille, a medium rich with sugar and 
protein. 
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In addition, two mutants of amadoriase I were created to gain a better understanding 
of residues in this enzyme that are critical for catalysis. In order to purify both mutant 
enzymes, along with the wild-type, a reliable time-resolved assay was successfully 
developed. 
1.9 Thesis overview 
Chapter two outlines the attempts undertaken to monitor the Maillard reaction, in 
vitro, through assessment of both lysine and a-dicarbonyl concentration over time, 
and SDS-PAGE electrophoresis. 
Chapter three addresses the specificity of the crosslinking reaction by examining the 
reaction of an arginine containing (lysine-free) and a lysine containing (arginine-free) 
protein with three a-dicarbonyls, methyl glyoxal, glyoxal and diacetyl. 
Chapter four examines the effect that glycation and crosslinking by the three a-
dicarbonyls have on the catalytic ability of a model protein, RNase A. 
Chapter five details the development of a novel assay approach to probing the ability 
of amadoriase I to use ribonuclease A, that has been mildly glycated with 
methyl glyoxal, as a substrate. Also detailed, is the extension of this method to 
isolation of a deglycating enzyme from a Pseudomonad grow on casein that had been 
incubated with lactose. The generation of two amadoriase I mutants and the assay 
developed for measurement of their activity (along with the wild-type) is also outlined 
in this chapter. 
Chapter six summarises the major findings of this thesis and future directions to be 
pursued from this work. 
Chapter seven outlines all experimental procedures undertaken during this thesis. 
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Monitoring the extent of the Maillard 
reaction in vitro 
2.1 Introduction 
38 
A number of avenues have been taken by researchers to monitor the progress of the 
Maillard reaction. This has ranged from measuring the extent of browning, to 
examining the loss of amino acids that are thought to playa critical role. This chapter 
aimed to assess the extent of the Maillard reaction in a protein model system through 
measurement of the concentration of two critical components: a-dicarbonyl 
compounds and amines, along with the extent of protein crosslinking. 
As discussed in chapter one, lysine and arginine residues are thought to playa major 
role in the Maillard reaction of proteins, due to the fact that they contain amines that 
are capable of nucleophilic attack on carbonyl compounds. Measurement of lysine 
concentration, in order to determine the extent of the Maillard reaction, has been 
undertaken by a number of groups (1-3). Free lysine possesses two NH2 
functionalities within its structure that are amenable to reaction, the a-NH2 and the E-
NH2. In a protein, the E-NH2 of the lysine residue is available for modification by a 
carbonyl compound, whereas the a-NH2 is involved in peptide bonding. Free 
arginine contains two possible points where a carbonyl can react, the guanidino 
functionality of arginine and the a-NH2. In a protein, only the guanidino group 
remains available. However, as proteins break down, the a-NH2 terminus may also 
become available for Maillard chemistry. 
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Amino acids containing secondary amines such as proline and tryptophan have been 
extensively studied in the food industry, but less so in the medical arena (4). The 
secondary amines of proline and of tryptophan have been reported to participate in the 
Maillard reaction under food processing conditions (4). A decrease in available 
tryptophan residues in lysozyme has been reported on incubation with glucose or a-
dicarbonyl, suggesting that protein-bound tryptophan can participate in the Maillard 
reaction (5,6). Histidine, which contains a secondary and tertiary amine, has been 
studied to some extent in the medical area (7,8). A drop in histidine has been reported 
on mild glycation of ~-lactoglobulin by glucose (9). 
In this chapter, studies were undertaken to gauge the extent to which proteins are 
crosslinked during incubation with a-dicarbonyls. In conjunction, the concentration 
of amine (with a particular focus on lysine) and carbonyl were measured during the 
reaction process. Comparison of crosslinking rates with amine loss provides an initial 
insight into relative reaction rates for differing a-dicarbonyls. The methods outlined 
in this chapter provide the methodology for areas of work undertaken in ensuing 
chapters and are preceded by a brief review in each area, a-dicarbonyl quantification, 
lysine quantification and SDS-PAGE. 
2.2 Selection of a model protein for in vitro studies 
The target protein selected to quantify the extent of the Maillard reaction in vitro had 
to meet a number of requirements. It had to be stable, as the study of glycation can 
involve conditions outside those optimal for protein. It needed to exist in its native 
state under a variety of potentially unfavorable conditions, such as addition of organic 
solvent, pH drift and storage at physiological temperatures in an ex vivo situation for 
prolonged periods. Specifically, a protein was required that would be stable at 37°C 
for up to seven days, and on addition of solvents such as DMSO (Chapter four). 
Bovine pancreatic ribonuclease A (RNase A, B.C. 3.1.27.5, "A" denotes the 
predominant fonn of the enzyme in bovine pancreas) was an excellent candidate as it 
is highly stable (10), and commercially available. Another advantage of using RNase 
A is that a great deal is known about this protein, thanks in part to its stability. RNase 
A was the first protein to have its amino acid sequence correctly determined and was 
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the third enzyme to have its 3-dimensional structure resolved by X-ray 
crystallography (10). RNase A, with a molecular weight of 13683 Oa, is relatively 
small and exisls as a monomer, although oligomeric forms have been isolated (11-13). 
The X-ray structure of RNase A is depicted in Figure 2.1. Essentially the protein is 
comprised of two ~-shcels surrounded by three a-helices (12). 
LV' 91 
Figure 2.1: The tertiary structure of RNase A at 1.26 A (14), with lysine residues 
shown in navy and arginine residues shown in grecn. The image was produced from 
the POB file 7RSA using MOLMOL software (15). 
RNase A has been employed by researchers working in the Maillard field for a 
number of differing purposes such as, studies involving crosslinking (2,16,17), non-
crosslinking modifications by sugars (1,18,19), screening of pOlential Maillard 
inhibitors (19), and assessment of activity of the native enzyme following glycation 
(Chapter four) (1,20). 
RNase A possesses eleven free amino groups, originating from the [-amino groups of 
len lysine residues, and a terminal [i-amino group (Figure 2.1). RNase A also 
conlains four arginine residues within its structure (Figure 2.1) . Previous studies have 
shown modificalion of some lysine residues (1,16) and arginine residues (21), within 
RNase A by sugars. 
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2.3 Attempts to quantify a-dicarbonyl concentration in a model system 
2.3.1 Background 
This section outlines attempts to quantify a-dicarbonyl concentration following their 
incubation with RNase A. As a-dicarbonyls are consumed during reaction with 
functional groups of RNase A (e.g. lysine), a decrease in a-dicarbonyl concentration 
was expected. A search of the literature revealed that the loss of a-dicarbonyl in the 
context of the Maillard reaction had not been studied. Measurement of a-dicarbonyl 
concentration in the Maillard area has generally been undertaken from another 
perspective. Assays have been employed to measure the rate of a-dicarbonyl 
formation as a result of retro-aldol condensation of glucose, or the Schiff base 
intermediate fonned during the Maillard reaction (22-25). 
2.3.2 Literature review of existing methods 
In order to quantify a-dicarbonyl concentration, a robust assay was required, and 
consequently, assays employed to accurately quantify a-dicarbonyl compounds were 
reviewed. Some have made the observation that a lack of knowledge of the flux of a-
dicarbonyls in biological systems is related to inaccurate and unreliable assays (26). 
Thus, selection of an appropriate assay required careful consideration. 
Enzymatic determination of a-dicarbonyl concentration 
Some of the very earliest attempts to quantify a-dicarbonyl compounds involved 
enzyme assays. An assay that was developed in 1957 to measure methylglyoxal has 
still found use decades later (27,28). This method uses the glyoxalase I enzyme, 
which catalyses the formation of a thioester, lactoylglutathione, at 240 nm (Figure 
2.2) (29). The increase of product is proportional to the amount of a-dicarbonyl 
present in the sample. Glyoxalase I has been found to have a very broad substrate 
specificity, exhibiting the ability to bind substituted phenyl glyoxal and glyoxal, the 
fonner binding more efficiently than methylglyoxal (30,31). This method was not 
employed however, as the enzyme is specific for aldehydes and keto aldehydes, and 
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could 110t therefore be used to monitor the concentration of the diketo compound 
diacetyl. 
Glyoxalase I 
Reduced glutathione 
+ 
Lactoylglutathione 
°HO 
H CHa Measured at 240 nm 
Methylglyoxal 
Figure 2.2: The conversion of methyl glyoxal and glutathione to lactoylglutathione by 
glyoxalase I. After Creighton et al. (32). 
Radioisotopic determination of a-dicarbonyl concentration 
Walton and McLean proposed a double-isotope assay to quantify methyl glyoxal in 
tissues. In a solution containIng other a-dicarbonyl compounds, the assay was 
specific for methyl glyoxal, providing that the concentration did not exceed 1 mM 
(33). Glyoxal could not be successful quantified by this approach, and diacetyl was 
not examined, which excluded this method as a viable option. 
Derivitisation agent-based determination of a-dicarbonyl concentration 
A number of derivitising agents have been employed in the past to quantify the 
concentration of a-dicarbonyl compounds (Figure 2.3). The general strategy is to 
find an agent that will fit the following criteria: highly specific for the target 
molecule; possesses a unique property such as fluorescence on derivitisation, for 
effective detection; applicable to a method that is efficient and accessible; and [mally, 
where possible, be commercially available at a reasonable price. 
One weakness of derivitisation assays employed to quantify a-dicarbonyls, is the 
potential for interference from other compounds within the sample (34). For example, 
a high concentration of trioses have been shown to interfere with 2,4-
dinitrophenylhydrazine (2,4 DNP) (Figure 2.3) and aminonicotinic acid assays 
(35,36). The use of separation techniques such as HPLC reduces the possibility of 
interference (24,37-44). Additionally, automated HPLC provides a less labour 
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intensive means for determining a-dicarbonyl concentration. GC can also be 
employed to separate a-phenylenediamine (aPDA) derivatives of a-dicarbonyls 
(45,46). However, some HPLC- and GC-based assays, can be time-consuming due to 
long derivitisation periods. 
O NyR ~I ~ N R 
Quinoxaline 
o 
RXN"-NH~N(CH3b 
R "wNHrrtt(CH3h 
o 
Hydrazone 
2H20 
H WHN~N(CH) 
2 II + 33 cc~ NH2 a NH2 
o·Phenylenediamlne 
o 
Hydrazlne 
(e.g. Girard T reagent) 
H3CO~NXR 
H3CO~N R 
DDQ 
H20 
N02 H £jN~O I ~ R 
02N N 
2,4-Dinitrophenylhydrazone 
Pteridin 
Figure 2.3: A selection of trapping reagents employed to quantify a-dicarbonyl 
compounds (25,28,34,37,38,47-49). Abbreviations: R, functional group of a-
dicarbonyl compound; TRI, 6-hydroxy-2,4,5-triaminopyrimidine; DMB, 1,2-diamino-
4,5-dimethoxybenzene; DDQ, 2,3-dimethyl-6, 7 -dimethoxyquinoxaline; PFBHA, 0-
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(2,3,4,5,6-pentaflurobenzyl)-hydroxylamine. Bold structures and text denote 
derivitising agents. 
In some instances, such as for Girard T and 1,2-diamino-4,5-dimethoxybenzene 
(DMB) (Figure 2.3), formation of the derivitisation product requires a low pH 
(23,28,34). Girard T has been employed in the Maillard field (22,50,51). However, 
lowering the pH may alter the distribution of AGEs in the sample e.g. those that are 
acid labile may survive the assay conditions (section 1.6.1) (3). 
The stability of adducts formed after derivitisation is critical for accurate 
determination of a-dicarbonyl concentration (38). Some adducts, such as triazines 
that are formed on reaction of a-dicarbonyl with aminoguanidine, (Figure 2.3) have 
been reported to be unstable under some assay conditions. The reactivity of the 
trapping reagent must also be considered. Aminoguanidine has been shown to be 
slower at trapping a-dicarbonyl compol!nds than other reagents that perform a similar 
function (25). Both of these issues may lead to erroneous results. 
Participation of the derivitising agents themselves in the Maillard reaction has been 
reported (25). For example, amino guanidine has been shown to catalyse retro-aldol 
fragmentation of higher sugars. This can lead to increased amounts of methyl glyoxal 
detected with amino guanidine over other derivitising agents (25). To achieve 
accurate measurement of a-dicarbonyl concentration, the time at which the 
derivitising reagent is added must be carefully considered. Studies have shown that 
addition of trapping reagent at the start of a reaction can result in interference of the 
product spectrum by the trapping reagent, due to either its redox capabilities or 
becasue it may contain amine and thus participate in the Maillard reaction (25). 
Alternatively, addition of derivitising agent at various time points of sampling can 
affect the products (25,40). 
2.3.3 o-Phenylenediamine assay (oPDA) ofglycated samples 
WhyoPDA? 
The derivitising agent oPDA (Figure 2.3) was selected to measure the a-dicarbonyl 
concentration in a-dicarbony1-treated lysine or RNase A incubations. The method 
employed was derived from and Kenyon, and involved quantification of the 
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resultant quinoxaline derivatives by spectrophotometric assay (52). The conditions of 
the assay were favourable for quantification of reversibly bound methyl glyoxal (38). 
This method was selected on the basis of its sensitivity, in comparison to existing 
methods (e.g. 2,4 DNP), and that it avoids extraction that is required for some GC and 
HPLC methods (52). Other factors that contributed to its selection were that the 
adducts formed are found to be stable (25), that it was fast and required only readily 
available equipment. Finally, oPDA was commercially available at a reasonable 
pnce. 
Quantification of a-dicarbonyl concentration in lysine + a-dicarbonyl model 
incubations 
The oPDA method was first investigated with lysine, which contains two free amine 
moieties, in order to investigate the efficacy of this method at gauging the extent of 
the Maillard reaction,before progressing onto a more complex model system 
involving RNase A 
Following inspection of the calibration curves for each a-dicarbonyl (Figure 2.4 A, E, 
C), final assay concentrations were selected for the assay that were in the linear region 
of the calibration curves. Lysine samples containing a-dicarbonyl, following 
incubation, were diluted appropriately and the concentration of a-dicarbonyl 
determined. The assay included a no-lysine control incubation, which gauged the 
quantity of a-dicarbony1 loss through non-Maillard mechanisms e.g. se1f-
condensation of the a-dicarbony1s, or their reaction with water. A no-a-dicarbonyl 
incubation was included to eliminate any possible interference in the assay by lysine 
itself. Interference by reaction products generated during incubation of lysine with a-
dicarbony1, and also the a-dicarbonyl itself, at the wavelength the assay was 
performed and was found to be negligible. 
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Figure 2.4: Calibration curves for A, methylglyoxal; B, glyoxal; C, diacetyl; with 
oPDA, constructed to determine the concentration of each respective dicarbonyl after 
incubation with lysine or protein. All points are an average of triplicate samples with 
error expressed as standard error of the mean. (In the above case error is small and 
thus error bars are obscured by each data point). 
Figure 2.5 A shows that methylglyoxal exhibits a noticeable decrease in concentration 
over time, with only 30% of methyl glyoxal remaining after 7 days of incubation with 
lysine, suggesting that approximately 70% of methyl glyoxal is consumed. However, 
the methylglyoxal-only samples also exhibited a drop in concentration, indicating a 
consumption of approximately 30% of methyl glyoxal by non-Maillard reactions, such 
as polymerisation reactions (53). This is not unexpected, as all dicarbonyls studied 
here have been shown to polymerise (53-56). 
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Figure 2.5: Percentage a-dicarbonyl remaining over time for A, methylglyoxal; B, 
glyoxal; C, diacetyl; with oPDA, in the presence or ahsence of lysine. Readings for 
each time point represent an average of triplicate samples. Error is expressed as 
standard error of the mean for triplicate samples. 
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Glyoxal and diacetyl also showed a decrease with and without lysine (Figure 2.5 B 
and C). The difference in a-dicarbonyl concentration between samples containing 
amine and those not, is much smaller. After 7 days of incubation, glyoxal 
concentration was at approximately 70% with the no-lysine control at around 90%. 
This was mirrored by diacetyl, with the only difference being a larger decrease in the 
no-lysine samples (85%). Hence, the decrease in glyoxal and diacetyl concentration, 
under the incubation conditions employed in this work, was via non-Maillard 
processes. From this work, the order of a-dicarbonyl reactivity with amine appears to 
be methylglyoxal» diacetyl ;::::: glyoxal. 
Quantification of a-dicarbonyl concentration of RNase A + a-dicarbonyl incubations 
The next phase involved examining a-dicarbonyl concentration in a more complex, 
physiologically relevant system involving protein. RNase A (25 mg/mL, 20 mM 
amine) was incubated with a-dicarbonyl (130 rnM, 1 mol amine: 6 mol a-
dicarbonyl). This high ratio was selected to ensure glycation occurred over an 
appropriate period of time with minimal decrease in protein concentration due to 
break-down under the incubation conditions (16). On inspection of Figure 2.6, as 
with the lysine incubations, it becomes clear from the methylglyoxal and diacetyl 
assays (Figure 2.6 A and C respectively) that a-dicarbonyl loss in the absence of 
protein is similar to that in incubations that contain protein. Glyoxal concentration 
does not appear to decrease over time in the presence or absence of protein (Figure 
2.6 B). Methylglyoxal was again the most reactive, with around 40% percent of 
methylglyoxal consumed immediately on incubation with protein, whereas the control 
was effectively 100%. Diacetyl appeared to be less reactive compared to 
methylglyoxal, reaching around 45% consumption after 1 day of incubation under the 
same conditions. 
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Figure 2.6: Percentage a-dicarhonyl remaining over time for A , methylglyoxaL B, 
glyoxal; C, diacetyl ; with oPDA in the presence or absence of RNase A. Readings for 
each time point represent an average of three samples. Error is expressed as standard 
error of the mean of triplicate samples . 
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2.3.4 p-Hydroxybenzoic acid hydrazide (HBH) assay of glycated samples 
In order to corroborate the results gained for the oPDA method, a second method was 
trialled to determine a-dicarbonyl concentration. This method involved derivitisation 
of the a-dicarbonyl in question with HBH (Figure 2.7), to yield a coloured product 
(57,58). It is not reported whether this measures either free or both free and 
reversibly bound a-dicarbonyl. This method provided a simple, relatively fast means 
for measuring a wide concentration of a-dicarbonyls and did not require any 
specialised equipment to run. 
a-Dicarbonyl HBH Chromophore absorbs at 420 nm 
Figure 2.7: The reaction betweenp-hydroxybenzoic acid hydrazide (HBH) and an a-
dicarbonyl (57,58). 
The assay was adapted to measure the concentration of the three a-dicarbonyls of 
interest. The source paper outlined two methods for concentration determination, 
only differing in concentration range for the calibration curves (57). Calibration 
curves for both procedures are outlined in Appendix one, Figure 1. 
The first form of the literature assay required high concentrations of a-dicarbonyl. 
Due to the fact that incubations were prepared in small amounts, low volumes of each 
initial incubation were used, in order to conserve sample. As dilution of the sample 
for assay was minimal, only small volumes were used throughout most of the 
procedure. As a result, this method introduced a large amount of error (Appendix 
one, Figure 2). Therefore other than an immediate drop in concentration of a-
dicarbonyls, little can be drawn from these results. 
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The second method used a higher concentration of HBH and lower concentration of 
a-dicarbonyl, so that the initial incubation mixture could be diluted into a larger 
volume of solution, in an attempt to circumvent the error issue . A representative 
graph of these analyses is outlined in Figure 2.8. These experiments, in general, 
resulted in less error within the assay than the first HBH method (see Appendix one, 
Figure 3 for calibration curves). The results also corroborated those obtained using 
oPDA as a derivitising agent. The a-dicarbonyl-only incubations paralleled those a-
dicarbonyl incubations that also contained amine in the form of protein (Figure 2.8). 
The results with methylglyoxal showed similar results to those depicted with diacetyl, 
a concomitant decrease in the methylglyoxal only and mcthylglyoxal + RNase A 
samples. The results for glyoxal are reported in Appendix one, Figure 4. This 
suggests that polymerisation of a-dicarbonyls, in the absence of the Maillard reaction, 
results in an almost equivalent loss of reactant. Thus, the loss of a-dicarbonyl on 
addition of protein docs not provide a useful measure of the Maillard reaction rate. 
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Figure 2.8: Percentage diacetyl remaining over time, in presence or absence of RNase 
A in incuhations . Readings for each time point represents an average of three samples. 
Error is expressed as standard error of the mean of triplicate samples. 
This section has detailed attempts to quantify the a-dicarbonyl concentration during 
the Maillard reaction. Initial studies with oPDA highlighted the reactive nature of 
these molecules , where in some cases the a-dicarbonyl s were equally as efficient at 
reacting with water and/or themselves as with free lysine or protein. This finding was 
corroborated by experiments using an alternative derivitising agent, HBH. Thus, this 
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approach to quantifying the extent of the Maillard reaction appears to be limited by 
the reactive nature of these a-dicarbonyls in solution. 
2.4 Attempts to quantity lysine concentration in a model system 
2.4.1 Why lysine? 
Since quantification of a-dicarbonyls met with limited success, the other critical 
reaction substituent, the lysine residue, was quantified via its amine moiety. Lysine 
was selected over arginine because of difficulties that can be encountered when 
measuring arginine concentration (59). 
2.4.2 Review of existing methods of lysine quantification 
Monitoring the decrease of lysine residues over time in protein that has been reacted 
with a carbonyl compound is one way to gauge the rate of the reaction. Using such an 
approach, the amino terminus has also been shown to participate in the Maillard 
reaction (1). In some proteins, initial Schiff base formation has been reported to be 
more favourable with the N-terminus than with protein bound lysine. However, the 
subsequent formation of Amadori product at the N-terminus occurs to a lesser extent 
(1). There are many approaches that have been taken to quantify lysine content. The 
techniques examined below are those that have been applied in the Maillard arena. 
Biological and microbial approaches to lysine quantification 
As lysine is an essential amino acid, many researchers have been interested in the 
conditions where this amino acid is limiting to the growth of an organism. There is a 
raft of biological assays that have been undertaken to assess how effective a food 
source can be at providing lysine and thus stimulating growth (60,61). These assays 
are specific to lysine residues, differentiating between it and the N-terminus. Often 
these assays involve a number of variables and can be time-consuming and expensive 
(62). 
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Microbiological approaches to determining lysine conccntration have been suggested 
which would involve measurcment of activity of lysinc-induced enzymes within 
bacteria. However, this can cause problems with enzymes that can act on glycated 
lysine and thus may be unsuitable for estimation of lysinc where the Maillard reaction 
is involved (60). Particular care must also be undertaken to exclude any 
contaminating bacteria which may interfere with the assay. 
Another approach to quantifying lysine has involved lysine oxidase, which catalyses 
the conversion of L-lysine, water and oxygen to 2-oxo-6-aminocaproic acid, hydrogen 
peroxide and ammonia (63). The reaction products have been measured a number of 
ways including spectrophotometry, chemiluminesence, fluorimetry and 
electrochemistry (63). 
Maillard product dependent approaches to lysine quantification 
A traditional method for estimation of lysine content, amino acid analysis, involves 
refluxing the glycated protein in 6 M acid at 110°C (18,64). For reasons outlined in 
the Chapter one, this may lead to inaccuracies in measured lysine content. However, 
furosine, a product formed under amino acid digest conditions, has also been used as a 
marker to quantify the extent of the Maillard reaction and is easily separated and 
quantified (Figure 2.9) (60). If quantitative conversion of Maillard reaction products 
to furosine is assumed, quantification of reactive lysine (lysine with the 8-NH2 
available) and inactivated lysine can be achieved (either as an early or late Maillard 
reaction product) (65). This approach has been used to measure lysine damage in 
whole milk and whey proteins (65,66). However, it can be difficult to determine a 
decrease in lysine via this method as it assumes that all lysine residues are present as 
fructoselysine, precluding measurement of other Maillard reaction products (67). 
HIH ~~C02' 
o NH3+ 
HO H 
H OH 
H OH 
6 M acid digest 
CH20H 
Fructoselysine Furosine 
Fig 2.9: Formation of furosine on reaction with fmctoselysine (an Amadori product) 
(60). 
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Dye-based approaches to lysine quantification 
Dye binding assays have received limited coverage in the literature in terms of 
quantifying lysine. One example is Acid Orange 12 (Figure 2.10), an azo dye that 
contains a negative charge which is though to interact with the positively charged 
amine oflysine (along with those on arginine and histidine) (60). One study favoured 
this assay over other assay methods due to its convenience, speed and higher 
sensitivity relative to the existing methods available at the time (68). This method 
does, however, require the usc of a low pH (pH, 1.25), which may alter the 
proportions of the Maillard reaction products of lysine (69). 
Q-N:::N-Q Acid Orange 12 
~ 803-
Figure 2.10: The structure of Acid Orange 12 which allows for possible interaction 
with lysine (60). 
Derivitisation-based methods to quantifY lysine 
All of the assays discussed thus far have involved quantification of different forms of 
lysine. A number of different groupings of lysine can be considered: "reactive lysine" 
which contains a free s-NH2 that will react under assay conditions; "available lysine", 
which is biologically available for protein synthesis; and "total lysine", which 
comprises reacted and unreacted lysine (60). The assays outlined below measure 
"reactive lysine", following incubation of lysine or protein with carbohydrates. Many 
of these assays rely on the principle of derivitising lysine in order to obtain a 
compound that can be determined by spectrophotometric or chromatographic means 
(70-72). Some of these derivitisation methods, however, involve addition of acid or 
base which may result in the disruption of protein structure and a change in the profile 
of the Maillard products in the solution studied (62). 
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1-Fluoro-2,4-dinitrobenzene (FDNB) was the first derivitising agent employed for 
measuring reactive lysine (Figure 2.11) (69). There are difficulties associated with 
this method, such as considerable inter-lab variation of values generated by this 
method (65,69). 
2-Cyanobenz-[f]-isoindoles 
CN ~H ~H 
° Napthalene-2,3-dicarboxaldehyde 
02NlCC~ N02 
Ih 
F 
1-Fluoro-2,4-dinltrobenzena 
(FDNS) 
DNP-Lysine 
HN ~ 
J-HN-\ 
H2N 
Homoarginine 
HN"C",O'CH 
I 3 
NH2 
o-Methyl isourea 
protein backbone 
Fluorescent pyrrolinone 
Fluorescamine 
2,4,6-Trinitrobenzene 
sulfonic acid (TNSS) 
TNP-Lysine 
Figure 2.11: Common derivitising agents employed in the literature to quantify 
"reactive lysine" (60,71,76,79). Derivitising reagents are depicted in bold. 
Abbreviations: DNP, dinitrophenyl; TNP, trinitrophenyl. 
Another derivitising agent used extensively in the literature to quantify lysine is 2,4,6-
trinitrobenzene sulfonic acid (TNBS, Figure 2.11) (71). It has also been used to 
modify lysine in studies probing the mechanism of some enzymes (73-75). a-Methyl 
isourea, also used to quantify lysine, converts lysine to the acid-stable homoarginine 
(Figure 2.11). Some have suggested, however, that this method can lead to 
underestimation due to incomplete guanidination of lysine (72). Fluoresecamine 
assays (Figure 2.11) have the advantage of being fast and sensitive, relative to older 
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methods involving the use of ninhydrin (76,77). However, these assays can encounter 
problems due to differing interference intensities of derivitised amino acids (78). 
Naphthalene-2,3-dicarboxaldehyde (Figure 2.11) has also been used to quantify lysine 
(78). It reacts with primary amines (in the presence of cyanide) to yield a stable 
fluorescent 2-substituted cyanobenz- (t)-isoindoles. This assay is even more sensitive 
than fluorescamine and does not require a long derivitisation period (78). 
0-Phthaldialdehyde (oP A) was first used to derivitise amino acids for a fluorimetric 
assay (Figure 2.12) (80). The 1-alkylthio-2-alkyl-substitued isoindoles are the 
products responsible for fluorescence observed on reaction of p-mercaptoethanol with 
oPA, and is the product measured in spectrophotometric assays (Figure 2.12) (81-84). 
Fluorescence is reported to be highly dependent on the presence of p-
mercaptoethanol, as is the spectrophotometric variant of the assay (82). The 
spectrophotometric assay using oP A provides a simple and relatively fast method of 
lysine quantification. Another factor in the favour of this assay is that there is no 
requirement for addition of acid (1,19,64,85,86). Due to these considerations, this 
assay was selected to quantify lysine in studies outlined below. 
~" VlyH 
° 
o-Phthaldialdehyde 
+ 
p-Mercaptoethanol 
HOl 
ce
s protein backbone 
,-:/ ;;c-- N-< 
~ ::-... 
1-Alkylthio-2-alkyl-su bstituted isoindole 
Figure 2.12: Reaction of oPA with amine and p-mercaptoethanol. After Simons and 
Johnson (81) and Svedas et ai. (82). 
2.4.3 Determination oflysine content of RNase A + a-dicarboltyl incubations 
Background to the o-phthaidiaidehyde (oPA) assay 
Since its inception, the oPA method has been extensively used in HPLC-based assays 
in order to quantify amine concentration (3,87-89). fu the case of RNase A, nine of 
the eleven available amines react with oP A using a spectrophotometric derivative of 
the assay (16,17). It has been proposed that the remaining two are unable to react due 
to steric considerations (90). 
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Incubation conditions and calibration curve construction to determine lysine 
concentration 
The oPA method used for lysine estimation of glycated RNase A follows the method 
developed by Fayle et al., building on an existing method (16,84). 
An RNase A coneentration of 25 mg/mL (20 mM amine equivalents, lysine and N-
tennius), a concentration previously used in this laboratory (16,91), was used for the 
experiments detailed below. A starting concentration of 130 mM was selected for 
each a-dicarbonyl compound. The calibration curves were constructed in order to 
calculate the eoneentration of lysine residues in glycated samples (Figure 2.13). 
Interpolation of lysine concentration for the absorbance of 2 mg/mL RNase A from a 
lysine calibration curve (Figure 2.13 B) confinns that nine of the eleven available 
amine groups present in RNase A react with oP A. 
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Figure 2.13: Calibration curves for lysine estimation via the oPA assay for A, RNase 
A; B, lysine. Readings are an average of triplicate experiments. Within each 
experiment, triplicate samples of each concentration were prepared. Error is 
expressed as the standard error of the mean of triplicate experiments. 
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Lysille collcentration ill RNase A + a-dicarbonyl incubations 
The decrease in lysine concentration in protein incubated with methylglyoxal, glyoxal 
or diacetyl was measured using the oPA method (Figure 2.14). 
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Figure 2.14: Percentage lysine remaining in RNase A on incubation with A 
methylglyoxal; B, glyoxal; e, diacetyl. Abbreviations: MG, mcthylglyoxaL G, 
glyoxal; 0, diacetyl; Fe, frozen control; Ie, incuhated control. Each point is an 
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The majority of amine modification of RNase A occurred within the first day of 
glycation with methylglyoxal (Figure 2.14 A). Decreases in amine concentration after 
incubation with glyoxal and diacetyl are less obvious. Under the experimental 
conditions employed in this work, little change in free amine is seen over time (with 
respect to each day and the frozen control) as shown in Figure 2.14 Band C. 
However, on closer inspection, there is a large difference in the final day incubation 
containing a-dicarbonyl, compared those incubations that did not contain a-
dicarbonyl ( i.e. the incubated control). 
1n almost all assays, it was noted that the incubated control had a higher concentration 
of amine than the frozen control (Figure 2.14 A, B, C). The only experimental 
difference between the two controls was that one had been incubated at 37°C for 
several days, whilst the other was stored immediately at -20°C. Figure 2.15 
emphasises this point, showing that lysine is lost to some extent on treatment of 
RNase A with each a-dicarbonyl. 
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Figure 2.15: Percentage of free amine groups remaining in RNase A incubated in the 
presence (G, D, MG) or absence of a-dicarbonyl (IC(G), IC(D), ICMG)). 
Abbreviations: G, glyoxal; IC(G), incubated control from glyoxal experiments; D, 
diacetyl, IC(D) incubated control from diacetyl experiments; MG, methyl glyoxal, 
IC(MG) incubated control in methylglyoxal experiments. Readings are expressed as 
percentage relative to frozen control for each dicarbonyl. Error is expressed as 
standard error of the mean for triplicate experiments, 
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An explanation for the apparent elevated levels of lysine residues detected in the 
incubated control may be due to the break-down of RNase A. Break-down of RNase 
A may generate available amine termini that were previously involved in peptide 
bonds. These termini will be detected in the assay as oP A can react with 
leading to inflated lysine values. 
a-NHz 
The competing processes of protein break-down and am me reaction with a-
dicarbonyl compounds may result in an underestimation of amine loss, and thus 
misleading conclusions (Figure 2.16). 
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Figure 2.16: The relationship of RNase A break-down to observations made during 
amine count experiments. Rl, R2 = amino acid side chain, X remainder of carbonyl 
moiety. 
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Interestingly, RNase A, a protein known for its stability, appears to be susceptible to 
break-down. Thus, this effect may be more pronounced in less stable proteins and the 
results from in vitro experiments must be interpreted with caution. At least one report 
has shown protein break-down during in vitro Maillard studies, when examining 
wheat proteins (92). 
On inspection of the results from this section and the previous section involving a-
dicarbonyl quantification, a consistent picture emerges. Although both methods 
showed some limitations, each showed that of the three a-dicarbonyls, methylglyoxal 
was the most reactive, and that glyoxal and diacetyl reactivites were evenly matched 
in the context of the Maillard reaction. 
2.5 Crosslinking of RNase A as assessed by sodium-dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) analysis 
In order to corroborate the a-dicarbonyl and lysine studies undertaken to gauge the 
extent of the Maillard reaction, SDS-PAGE was employed to assess the 
macromolecular effect of reaction of a-dicarbonyls with protein. SDS-P AGE enables 
the detection of high molecular weight aggregates that have been reported during the 
Maillard reaction (16). SDS-PAGE allows for the resolution of multimeric states of a 
protein under reducing conditions which are unfavourable for disulfide bonds, thus, 
only non-disulfide crosslinks are detected. In tandem with lysine and a-dicarbonyl 
estimations, this methodology provides a powerful tool for further probing the extent 
of the Maillard reaction and provide clues to the reactivities of the a-dicarbonyl 
compounds. 
2.5.1 Background to SDS-PAGE methodology 
Electrophoresis is a relatively simple, yet highly sensitive, separation technique (93). 
For SDS-PAGE, the percentage of acrylamide and bis-acrylamide dictates the pore 
size of the gel constructed using these compounds. Gradient gels differ in acrylamide 
concentration within the gel itself (such as 8-16% gels) results in large pores at the top 
of the gel, where acrylamide concentration is low and small pores at the bottom of the 
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gel where aerylamide eoneentration is mueh higher. The advantage of varying the 
concentration of acrylamide allows for the separation of proteins from a wide range of 
molecular weight, on a relatively small gel, in a short period of time. The addition of 
SDS increases the solubility of the sample and confers a uniform negative charge 
density on the protein allowing for migration solely based on size, not charge (93). 
SDS-P AGE crosslinking has received some coverage in the medical arena with 
respect to the Maillard reaction (2,7,94), and has also begun to fmd use in food 
chemistry studies (92). 
2.5.2 SDS-PAGE analysis of RNase A incubated with a-dicarbonyl 
SDS-P AGE was used to assess the macromolecular structure of RNase A following 
glycation. Figure 17 shows a typical result depicting the extent to which RNase A 
was crosslinked by methylglyoxal, glyoxal and diacetyl. 
Some of these results appear to confinn the theory that was proposed on inspection of 
the lysine count data, that the RNase A was breaking down over time. This is 
manifested on the SDS-PAGE gels by a large degree of smearing under the molecular 
weight of RNase A, indicating protein fragments. Figure 2.17 C highlights this 
particularly clearly, with a steady increase in fragments over time (beginning from 2 
hours of incubation). 
On inspeetion of Figure 2.17, it is evident that a small proportion of control RNase A 
is present in the dimeric form. This dimeric form of RNase A is well documented in 
the literature and is thought to be fonned during the purification of RNase A 
(11,95,96). Recent work has found that RJ\Jase A exists in its domain swapped 
(dimeric) fonn at a near neutral pH (97). 
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report ed effect on in Tcasing the rate of g lycalion (9X .99 ). Th e contrihution of 
phosphate to the ex t nt of crosslinking was cx.amined for \, ork to be undertaken in 
Chapter five, where a mi ldl l glycated Rase was prepared by inc ubat ion "..'ith 
meth 19lyoxal. This gJ 'cated protein was Llsed a~, a substrate Cor amadoriasc I in 
() rder to develop a noveJ assay to measuring amadoriase l activity. Phosphate \A:as 
inc luded in these incubat ions as it was fou nd to stahilise amadoriase I. The addition 
of ph sphalc to Incuhation reactions resulted in clillcrent crosslinki ng rates (Figure 
2. ! 8) . Inclus ion or phosphate in glycat iull incubations was also sho J1 tu make a 
significunt LlilTerence in the mcan amine concentration compared to those that did not 
clHllain phosphate (P<O.OS) (Appendix ne, Table j). Phosphate also appeared to 
have a protect ive effec t against the break-down of RNase A. 
29 kDa 
14.2 
monomer 
M MR+P MR-P IC+P IC-P 
Figure 2.18: 8 - 1 6~ SOS-PAGE gel comparing the relative rates of" RN ase A 
cross li nk ing in the presence or absence of [00 mM phosphate huller (p i-\' 7.4) after 24 
hours or incuhat ion. bbrcviations: MR+P, methy lg[ yox~tl (!O mM) + RNase A (25 
mg/m L) III 100 111 M phosphate huller; MR-P. ll1ethylglyox~tl + RNase A in the 
absence or phosph ate: Ie + P, R ase A incubated contrul In the rresel1ce or 
pho. phalc. I - P. RNase A incubated control in the ab~ence of phm.phatc. 
Th onl f;.lCtor to yield a signi ricmll di rference in the means or lysine concentration 
\\a '; phosphat ' (Appendix one. Tab le I), corrllh(lrat ing the re:-. ults of rhe S S-PAG E 
analysi s 01 thc same incubat ions (Fi gur 2. 18). n inc rease in hrown ing in the 
phosphate-containing incubations relat ive to thos that d id not, was also ob:-.erved. 
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2.6 General discussion and conclusions 
The oPDA assay that was undertaken to quantify the concentration of a-dicarbonyls 
has its merits such as its sensitivity, reproducibility, simplicity and negligible 
interference. However, the properties of the a-dicarbonyls themselves meant that this 
assay could not be used as a measure of the extent of the Maillard reaction. As stated 
previously in section 2.3, a-dicarbonyls decreased in concentration over time only in 
the presence of water, indicating the a-dicarbonyls (such as methyl glyoxal and 
diacetyl) were reacting with themselves and/or the water to give other products. 
Figure 2.19 represents what may be occurring in the incubations that led to the 
observation of a decrease in a-dicarbonyl concentration in the absence of amine. 
A 
+ 
B 
x3 
RX"~ 
R 0 
OBSERVATION: 
A decrease in a-dicarbonyl 
concentration as observed the by 
oPDA assay 
OBSERVATION: 
A decrease in a-dicarbonyl 
concentration as observed by the 
oPDA assay 
Figure 2.19: A decrease in a-dicarbonyl concentration in amine-containing 
incubations may be due to two competing processes A, glycation or B, self-
condensation (56). 
a-Dicarbonyl compounds are known to be highly reactive molecules and thus may be 
paliicipating in a number of reactions, including the Maillard reaction. To what 
extent these pathways operate with respect to one another under different conditions 
(e.g. Maillard reaction vs. self-condensation of a-dicarbonyl compounds) is largely 
unknown. This work has shown a decrease in a-dicarbonyl concentration, can be due 
to the Maillard reaction, but in some cases is closely matched with a decrease through 
other pathways. Assays that have been employed to measure the generation of a-
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dicarbonyl compounds allow for the quantification of a-dicarbonyls over a short 
period oftime. Unlike the approach taken here, these do not encounter problems with 
measuring subtle decreases in a-dicarbonyl concentration in a solution containing a 
large amount of unreacted a-dicarbonyl (23,25), This presented a difficulty with the 
approach undertaken here where the difference between a-dicarbonyl concentration in 
the presence and absence of RNase can sometimes be very small. Thus, concluding 
that a certain percentage of a-dicarbonyl drop is due to the Maillard reaction can be 
difficult. This assay may be more useful for more stable sugars which will be slower 
to undergo self-condensation, 
As the attempts at measuring the extent of the Maillard reaction through measuring a-
dicarbonyl concentration proved unsuccessful, attention was shifted toward the other 
reactant, amine in the form of lysine. A number of researchers have placed emphasis 
on .lysine as a critical reagent in Maillard chemistry, where studies have been 
undertaken in systems that involve only lysine and a carbonyl compound (100-103), 
Introduction of protein to the equation allows for the simultaneous study of a number 
of amino acids in terms of their contribution to the Maillard reaction. The results 
detailed here, successfully showed that reaction of methylglyoxal with protein showed 
a drop in amine concentration, with glyoxal and diacetyl showing less reactivity 
toward amine. This process seems to be offset by the break-down of RNase A over 
time, thus perhaps resulting in an underestimation of the true rate of amine loss. 
However, both a-dicarbonyl and lysine studies showed that methylglyoxal was much 
more reactive than glyoxal and diacetyl, which had similar reactivities. 
The crosslinking results obtained in this chapter successfully provided further 
information with respect to the extent of the protein crosslinking via the Maillard 
reaction, and a system for measuring the specificity of this process by the three a-
dicarbonyls. Methylglyoxal was found to crosslink RNase A extensively in a very 
short period of time and at a much faster rate than glyoxal or diacetyl. The lysine and 
crosslinking results suggest that in the presence of methylglyoxal, lysine is consumed 
in the crosslinking reaction, as lysine loss appears to parallel the crosslinking pattern. 
Lysine loss in diacetyl and glyoxal-treated samples appears to be much less 
prominent, as was mirrored by a less extensive crosslinking pattern than observed 
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with methylglyoxal. However, as minimal lysine modification of RNase A was noted 
in glyoxal-treated samples, some crosslinking was still observed, which may suggest 
crosslinking of protein via amino acids other than lysine. The results were surprising 
for glyoxal, which has been found to react with lysine to form crosslinks such as 
GOLD and GOLA (2,3). The reasons why methyl glyoxal reacted the fastest of the 
three a-dicarbonyls studied are further probed in Chapters three and four. 
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Chapter Three 
Chapter Three 
Which amino acids are required for 
protein crosslinking to occur? 
3.1 Introduction 
73 
The previous chapter analysed the extent of the Maillard reaction during incubation of 
RNase A with three a-dicarbonyls, providing an insight into the relative rates of 
reaction by monitoring the decrease of available lysine residues and the degree of 
crosslinking that accompanies these changes. This chapter focuses on the role of 
particular amino acids in the crosslinking process. As detailed in Chapter one, the 
Maillard reaction has a number of consequences for the food industry and the medical 
field. For the latter, protein crosslinking is a focal point, due to its presumed 
consequences for the function of the target protein (1). 
Within the extensive literature on the reaction of proteins with a-dicarbonyl 
compounds, little attention has been paid to the relationship of the stmctural features 
of these molecules and their rate of crosslink formation. It has been noted by Fayle et 
at. that methyl glyoxal is a highly reactive crosslinker and that this reactivity is not 
matched by the closely related compound, glyoxal (2). Chapter two confirmed this 
previous result and extended the study to include diacetyl, a stmcturally similar a-
dicarbonyl. It is intriguing that such a small structural change can have such dramatic 
consequences for crosslinking. Thus, this chapter aimed to address the stmctural 
features of small a-dicarbonyl compounds that result in effective crosslinking, by 
examining the reaction of glyoxal, methylglyoxal and diacetyl with defined protein 
substrates. 
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Although efforts have been undertaken to address the extent to which particular amino 
acids participate in the crosslinking process, no systematic study has yet been 
undertaken of the precise amino acid requirements for reaction to occur. Most 
research points to reactions involving lysine residues and arginine residues (3), but 
whether both amino acids are required, or whether the amino acid requirements 
change for different crosslinking moieties, has not been investigated in detail. 
3.2 A summary of amino acid involvement in crosslinlring via the Maillard 
reaction 
3.2.1 Artifacts and caveats 
A common method for examining the Maillard reaction is to employ relatively simple 
model systems that involve free lysine or arginine and a carbonyl compound (4-6). 
Froin the resulting mixture, products' are separated and characterised and then 
attempts are made to identify the newly-discovered AGE from tissue or in food. 
Whilst this approach has provided a wealth of information in terms of AGE structures 
and which amino acids are amenable to reaction, it tells little about the rates of 
glycation when more than one amino acid is present. 
Results from previous protein crosslinking studies must be interpreted with caution, 
since much research involving intact protein in a model system has relied on acid 
digestion of the protein (7,8). As outlined in Chapter one, acid digestion can result in 
a change in the molecu1ar composition of the sample under study, due to break-down 
of AGEs. Reducing these adducts with sodium borohydride, to increase stability, has 
been reported as a remedy (9); however, this approach can still lead to AGE break-
down (10). Although new methodologies, such as enzyme digests and alkaline 
hydrolysis have aided the isolation process, the problem has not been entirely solved 
(3). 
To circumvent the problems associated with the analysis of a complex mixture of 
products, a novel approach to examining the crosslinking phenomenon was taken. A 
range of starting materials was selected in order to establish precise structural 
requirements for efficient crosslinking. The reaction of each of the three a-dicarbonyl 
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compounds with somatostatin, an arginine-free peptide that contains two lysine 
residues (11), and renin substrate tetradecapeptide, which lacks lysine and contains 
one arginine (12), along with RNase A, which has both arginine and lysine residues 
(l3), was examined. 
3.2.2 Lysine residues 
Lysine residues have received the most attention in terms of their participation in the 
Maillard reaction. In food chemistry, a number of studies have been undertaken that 
involve reaction of lysine with a variety of sugars (2,14-18). Generally, conditions 
employed in the food chemistry arena are those that occur under food processing 
conditions (e,g. high pressure and high temperature) and may not be relevant to in 
vivo formation occurring in the human body, although they may have an affect in vivo 
if foods containing these AGEs are ingested (19). 
Some of the first crosslinks to be isolated were methylglyoxal lysine dimer (MOLD) 
and glyoxal lysine dimer (GOLD) (Figure 3.1), from the reaction of protected lysine 
with methyl glyoxal and glyoxal respectively (6). Since their discovery, they have 
been isolated from human lens proteins(6), some foods (20) and human serum (21). 
A number of other crosslinks are formed on reaction of lysine with carbonyl 
compounds, ranging from pentoses to a-dicarbonyls. These include threosidine (22), 
PenK2 (23), vesperlysine A (LM-1) (24), GOLA (25), Lys-hydroxy-triosidine (26) 
(Figure 3.1), some of which have been isolated from human tissue (25,27). 
Studies with a no-lysine mutant of a-crystallin revealed that crosslinking was 
observed on treatment with a number of sugars, but to a much lesser extent than the 
wild type, supporting the conjecture that lysine is an important residue in crosslinking 
reactions (28). Further, incubation of the no-lysine mutant with another lysine-rich N-
protected protein showed that crosslinking could occur between lysine and non-lysine 
residues. Moreover, results from this study suggested arginine could not crosslink 
with another arginine residue and that a histidine residue was not able to foml a 
crosslink with another histidine residue (28). 
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Figure 3.1: A selection of Lys-Lys crosslinks (6,22,24-26). Abbreviations: MOLD, 
methyl glyoxal lysine dimer; GOLD, glyoxal lysine dimer; GOLA, N'-{2-[(5-amino-
5-carboxypentyl)amino] -2-oxoethyl} lysine. 
The role of oxygen is important for directing the extent of crosslinking and amino 
acid specificity. Fu et al. found that crosslinking was dependent on the presence of 
oxygen (29). Under oxidising conditions, lysine and arginine were modified; 
however, under non-oxidative conditions, a similar loss in lysine was observed, but 
not arginine (29). From this study, it was concluded that lysine and arginine are 
important for the crosslinking process to occur, and that their consumption via the 
Maillard reaction varies with respect to oxygen availability (29). 
3.2.3 Arginine residues 
Along with lysine, arginine residues have been quantified to measure the extent of the 
Maillard reaction (30,31). A decrease in arginine residues during crosslinking has 
been reported in a number of studies (8,32-34). As more crosslinks are identified, it is 
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evident that a number of these involve both lysine and arginine residues. Lys-Arg 
crosslinks elucidated to date include pentosidine (35), Arg-Lys imidazole (ALI) (36), 
DOODIC, MODIC, GODIC, glucosepane (37,38) and Arg-hydroxy-triosidine (26) 
(Figure 3.2). 
O~H\(-f-N OH 
\ N \ OH 
NH I O~N 
~~ H H l ~ ~N N X~~ 
R N  Protein 
OH H 
ALI 
Glucosepane 
R H GODIC 
R::: CH3 MODIC 
backbone 
R CH2(CHOHhCHzOH::: DOGDIC 
HO ~ NH 
H f1 
Arg-hydroxy-triosidine Pentosidine 
Figure 3.2: A selection of Lys-Arg crosslinks (26,35-38). Abbreviations: 
ALI, arginine-lysine imidazole; OODIC, Nl-(2-{[(4S)-4-ammonio-5-oxido-5-
oxopentylJamino}-3,5-dihydro-4H-imidazol-4-ylidene)-L-lysinate; MODIC, Nl-(2-
{[(4S)-4-ammonio-5-oxido-5-oxopentylJamino}-5 methyl-3,5-dihydro-4H-imidazol-
4-ylidene)-L-lysinate1; DOGDIC, Nl- {2-([( 4S)-4-ammonio-5-oxido-5-
oxopentyl]amino}-5[(2S,3R)-2,3,4-trihydroxybutyIJ-3,5-dihydro-4H-imidazol-4-
ylidene)-L-lysinate. 
As for the Lys-Lys crosslinks, some Lys-Arg crosslinks from Figure 3.2 have been 
isolated in human tissue (36,39) and foodstuffs (20). However, one study reported 
little evidence of major lysine-arginine crosslinks in model studies with protected 
lysine and arginine residues (40). 
1 The tautomer of MODIC depicted in Figure 3.2 is not that which is generally stated in the literature. 
The literature tautomer, where the NE oflysine exists as an imine, is regarded as a less favourable 
conformation (Prof. Peter I. Steel Personal communication). 
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Arginine consumption via the Maillard reaction also results in non-crosslinking 
modifications. Methylglyoxal is reported to react preferentially with arginine, in 
some cases forming non-crosslinking AGEs (8,10,30). However, methods of 
quantification can lead to dramatically differing results in terms of arginine 
modification, which authors attribute to artifacts such as the break-down of acid-
labile AGEs that contain arginine during analysis, resulting in overestimation of 
arginine (30). 
3.2.4 Other amino acid residues 
Cysteine is a critical residue responsible for maintaining tertiary and sometimes 
quaternary structure of a protein via disulfide linkages. When two protein-bound, 
reduced cysteine residues are in close proximity and become oxidized, a disulfide 
linkage is formed between the two residues. With respect to cysteine's role in 
crosslinking via the Maillard reaction, 'little is known. Cysteine has received more 
attention in the food arena, where volatile Maillard reaction products formed on 
reaction sugars have been studied (41). One study has reported extensive loss of 
cysteine residues during the Maillard reaction (42), and two crosslinks have been 
proposed that involve cysteine and lysine residues (43,44) (Figure 3.3). Reversible 
modification of cysteine to form a hemithioacetal in protein has been noted elsewhere, 
although these modifications do not appear to contribute to crosslinking (30). 
Tressl's putative crosslink Pyrraline-Cysteine crosslink 
Figure 3.3: Proposed protein crosslinks involving cysteine (43,44). 
Tryptophan has received some attention in the food industry, where the reaction of the 
free amino terminus with glucose has been reported under food processing conditions 
(45). Tryptophan residues have been reported to be extensively modified during the 
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crosslinking of lysozyme by glucose, with glyoxal the only a-dicarbonyl shown to 
crosslink lysozyme (33). Interestingly, a study from the same workers reported that 
tryptophan residues of lysozyme were extensively modified by methylglyoxal, 
glyoxal and diacetyl, but suggested that lysine and arginine residues were more 
critical to crosslinking (46). Tryptophan participation in crosslinking has been 
reported elsewhere, but this method could not differentiate between radical 
crosslinking and crosslinking by electrophilic addition to amine (42). 
Early work by Slight et al. reported that a loss of arginine and histidine residues on 
lens crystallin crosslinking could in part involve Lys-His cross links (34). A decrease 
in histidine residues during crosslinking has been reported in other studies (42). To 
the author's knowledge, the structure of either a tryptophan or histidine-containing 
crosslink has not, as yet, been reported. 
3.3 Investigation of specific amino acid requirements for protein crosslinking 
involving a-dicarbonyls 
The weight of the protein crosslinking literature suggested that lysine and arginine 
were the main crosslinking participants and thus the role of these two residues was the 
focus of the crosslinking studies detailed in the remainder of this chapter. To study 
the role of these two residues, an arginine-containing, lysine-free; and a lysine-
containing, arginine-free peptide; and a protein containing both lysine and arginine 
residues were used. 
3.3.1 Reaction of somatostatin with a-dicarbonyls 
After an extensive literature search for an arginine-free protein that was readily 
available, somatostatin was selected. The sequence of the tetradecamer is as follows 
(11 ): 
Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys. 
Somatostatin has a number of functions, including inhibition of the release of growth 
hormone and thyrotropin from the pituitary, along with inhibiting the secretion of 
insulin (47), glucagon and gastrin (48). Somatostatin (25 mg/mL, 30.6 mM lysine 
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The rate of crosslinking of RNase A by dicarbonyls was as follows: methyl glyoxal » 
glyoxal;:::; diacetyl, which is in line with results reported by Fayle et al. (2). Other 
workers have also reported that methylglyoxal appears to extensively crosslink 
protein in a short time-frame (8,33). However, the results reported here are in contrast 
to a study undertaken by Kato et al. where the reactivity of cross1inking was as 
follows: diacetyl > glyoxal> methylglyoxal (46). The authors state that the extent of 
crosshnking was related to the extent of browning observed, which contrasts to results 
detailed here. Kato et al. used lysozyme, which contains 6 lysine and 11 arginine 
residues (50), and crosslinking reactions were undertaken in the presence of 
phosphate at 50°C. An increase in temperature will increase the rate of the Maillard 
reaction (51), along with the addition of phosphate to incubations (Chapter two) 
(52,53). These factors may help to explain the difference in crosslinking. The 
differing lysine and arginine content between proteins (RNase A; lO Lys, 4 Arg) may 
result in differing reaction pathways for the a-dicarbonyls, due to amino acid 
limitation, and may be manifested as different crosslinking rates. 
Interestingly, the RNase A formed insoluble masses immediately on incubation with 
methylglyoxal. Fomlation of such aggregates can be indicative of amyloid fibril 
fomlation and thus, the samples were tested for the presence of fibrils. Recently, it 
has been shown that a number of proteins have the capacity to form fibrils and that it 
may be a generic process within many proteins (54), thus, RNase A may be capable of 
forming fibrils on glycation. Fibril formation as a result of glycation has been 
reported on incubation of insulin with methylglyoxal (55), and on incubation of 
bovine serum albumin with either glucose, fructose or glyceraldehydes but, 
interestingly, not with glyoxylate (56). 
The presence of fibrils was measured using a Congo red dye, which binds to the 
ordered structure of the fibril. When viewed under a polarising light microscope the 
fibrils exhibit a green birefringence (57). This was not observed for the 
methylglyoxal + RNase A samples, but was with authentic, insulin fibrils that were 
prepared as a positive control. A second test was undertaken to confirm this using 
another amyloid-specific dye, Thioflavin T. Upon binding of fibrils, an increase in 
the excitation spectrum at 450 nm, and an enhanced emission spectrum at 
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approximately 482 nm are observed (58). Unlike the insulin fibril controls, a shift at 
the appropriate wavelengths was not observed in the methyl glyoxal + RNase A 
samples on incubation with Thioflavin T. Thus, the aggregates isolated in this work 
may be non-fibrillar in nature and form amorphous aggregates that have been reported 
in previous glycation experiments (56). To the author's knowledge fibril formation 
has not been reported in RNase A, which is generally noted for its stability. 
3.4 General discussion and conclusions 
The fact that glyoxal did not appear to form any crosslinks in the lysine-containing 
peptide may be due to the predominance of non-crosslinking AGEs, such as CML 
(Figure 3.12). Indeed, it has been reported that on reaction oflysine with glyoxal, the 
non-crosslinking CML was present in much greater quantities over crosslinking AGEs 
e.g. GOLA and GOLD (25). This is consistent with the results reported in this 
chapter. 
Lys Lys 
Lys Lys 
Lys-(xlink)-Lys 
Predominant 
e.g. MOLD 
Lys-non-crosslinking AGE 
Lys-(xlink)-Lys 
Lys-non-crosslinking AGE 
Predominant 
e.g. CML 
Figure 3.12: Addition of methyl glyoxal to an arginine-free protein may result in the 
predominance of crosslinks. Addition of glyoxal or diacetyl to an arginine-free protein 
may result in the predominance of non-crosslinking AGEs. Spheres represent the 
remainder of the protein. For clarity, N-terminus has been omitted, but could be 
interchanged with above Lys. 
In the absence of lysine, crosslinking by methyl glyoxal was not observed. This is 
consistent with the consensus that methylglyoxal reacts preferentially with arginine 
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over lysine (8,30), if these are arginine modifications that do not lead to crosslinking, 
such as argpyrimidine, carboxymethyl arginine and tetra-hydropyrimidine and 
imidazolone compounds (Figure 3.13) (4,59). This may account for the browning 
observed in non-crosslinking samples such as incubations of glyoxal and diacetyl with 
RST. 
Arg Arg 
aNHz I 
Arg Arg 
Predominant 
Arg-non-crosslinking AGE e.g. 
Arg-(xlink)-Arg 
H 
Arg-(xlink)-N 
Arg-(xlink)-N 
H 
H H 
N-(xlink)-N 
Argpyrlmldlne 
) 
Predominant 
A e.g. I rg GODle 
GOlA 
Arg-non-crosslinking AGE 
Figure 3.13: Methylglyoxal and diacetyl reaction with a lysine free protein may result 
in the predominance of a non-crosslinking AGE. Glyoxal, on the other hand, appears 
to favour the formation of a crosslinking AGE. Spheres represent the remainder of 
the protein. 
To the author's knowledge, there have not been any reports of arginine-arginine 
crosslinks mediated by methylglyoxal, although one has been reported involving 
glyoxal, but this requires furan-2-carboxaldehyde (60), not present in the above 
incubations. 
The finding that glyoxal is able to crosslink the lysine-free peptide, via the N-
terminus, whereas methylglyoxal cannot, was not predicted. Presumably, this reflects 
a subtle balance between competing reaction pathways, and perhaps the rapid reaction 
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of methyl glyoxal with arginine to form argpyrimidine renders it unavailable for the 
slower crosslinking reaction with the N-terminus (Figure 3,13), Glass and Pelzig have 
reported reversible modification of arginine residues by glyoxal under particular 
experimental conditions (61), The modification of guanidine, related to the functional 
moiety of arginine, by glyoxal in aqueous conditions has also been reported 
Bengelsdorf (62), In the same manner as methyl glyoxal-arginine modifications the 
majority of the glyoxal-mediated arginine modifications are also non-crosslinking in 
nature, However, if the reaction with glyoxal is more easily reversed than that with 
methylglyoxal, then this may account for the difference in behaviour between the two 
systems. Whether the glyoxal crosslink in this system is between the two N-termini of 
RST, or between one N-terminus and an arginine residue, is, to date, unclear. 
The observation that glyoxal is a less eflicient crosslinker of RNase A than 
methyl glyoxal is chemically consistent with the proposed mechanism for imidazolium 
formation (63), Reaction of methyl glyoxal requires a fragmentation reaction (Figure 
3.14 step 4) which is predicted to be more favourable than for reaction of glyoxal, due 
to increased relative stability of the substituted leaving group in step 4. Diacetyl was 
also observed to be less reactive at crosslinking than methyl glyoxal. Diacetyl 
contains two ketone moieties. Reaction of diacetyl to form an imidazolium crosslink 
would be hindered, as ketone groups would react more slowly than aldehydes in step 
2 (Figure 3.14), due to a combination of steric hindrance and reduced electrophilic 
reactivity of the carbonyl centres (64). 
I~ 
H3CXN ~H 2 
OH-
H "'.::::N ~CH3 
I 
R 
H'C~ 
H \ 
R 
MOLD 
I H 
• H3C -:;/N+*OH X ~-O 
H "'.:::: N H3C "-.J 
I 
R 
Figure 3.14: Proposed mechanism for formation of MOLD. R, lysine residues (63). 
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The most striking feature of the results reported in this chapter is perhaps not the 
relative rates> but the specificity of the reactions observed: small structural differences 
in the a-dicarbonyl moiety lead to a large change in amino acid requirements. 
This structure-activity study leads to two unequivocal conclusions. Firstly, that 
arginine is not essential for crosslinking to occur with a-dicarbonyls> as evidenced 
from the work with methylglyoxal and somatostatin. Secondly, that a free amino 
group, either as the N-terminus or as a lysine residue is required for protein 
crosslinking under these conditions, in this series. It can be fUlther speculated that the 
presence of both lysine and arginine residues, for example in RNase A, leads to the 
most efficient crosslinking, but that an excess of arginine residues leads to the 
predominance of non-crosslinking modifications, such as argpyrimidine. 
Perhaps most importantly, this study has shown that results from the crosslinking of 
one molecule cannot be extrapolated to predict the behaviour of another, however 
closely related. This is an extremely important observation when designing novel 
therapeutic strategies based on results from simple model systems in the laboratory. 
3.5 References 
1. Baynes, 1. W. (2000) Biogerontology 1, 235-246 
2. Fayle, S. E., Gerrard, J. A., Simmons, L., Meade, S. J., Reid, E. A., and 
Johnston, A. C. (2000) Food Chem. 70, 193-198 
3. Slatter, D. A., Avery, N. C., and Bailey, A. 1. (2004).1. Biol. Chem. 279,61-69 
4. Shipanova, LN., Glomb, M. A., and Nagaraj, R. H. (1997) Arch. Biochem. 
Biophys. 344, 29-36 
5. Ahmed, M. u., Frye, E. B., Degenhardt, T. P., Thorpe, S. R., and Baynes, J. 
W. (1997) Biochemistry 324, 565-570 
6. Brinkmann-Frye, E., Degenhardt, T. P., Thorpe, S. R., and Baynes, 1. W. 
(1998) .I. Biol. Chem. 273, 18714-18719 
7. Eble, A. S., Thorpe, S. R., and Baynes, 1. W. (1983) .I. Bioi. Chem. 258,9406-
9412 
Chapter Three 90 
8. Lee, K. W., Simpson, C., and Ortwerth, B. (1999) Biochirn. Biophys. Acta 
1453, 141-151 
9. Ortwerth, B. l, and Olesen, P. R. (1988) Biochirn. Biophys. Acta 956, 10-22 
10. Oya, T., Hattori, N., Mizuno, Y., Miyata, S., Maeda, S., Osawa, T., and 
Uchida, K. (1999) J. Bioi. Chern. 274, 18492-18502 
11. Burgus, R., Ling, N., Butcher, M., and Guillemin, R. (1973) Proc. Natl. Acad. 
Sci. USA 70, 684-688 
12. Skeggs, L. T., Kahn, l R., Lentz, K., and Shumway, N. P. (1957) J. Exp. Med. 
106,439-453 
13. Hirs, C. H. W., Moore, S., and Stein, W. H. (1960) J. Bioi. Chern. 235, 633-
647 
14. Rooney, L. W., Salem, A., and Johnson, J. A. (1967) Cereal Chern. 44, 539-
550 
15. Bailey, R. G., Ames, J. M., and Mann, J. (2000) J. Agric. Food Chem. 48, 
6240-6246 
16. Amoldi, A., Corain, A., Scaglioni, L., and Ames, J. M. (1997) J. Agric. 
Food Chem. 45,650-655 
17. Monti, S. M., Ritieni, A., Graziani, G., Randazzo, G., Mannina, L., Segre, A. 
L., and Fogliano, V. (1999) J. Agric. Food Chem. 47, 1506-1513. 
18. Hasenkopf, K., Roenner, B., Hiller, n., and Pischetsrieder, M. (2002) J. Agric. 
Food Chem. 50,5697-5703 
19. Erbersdobler, n. and Faist, V. (2001) Nahrung 45, 177-181 
20. Biemel, K. M., Buhler, II. P., Reihl, 0., and Lederer, M. O. (2001) Nahrung 
45,210-214 
21. Odani, n., Shinzato, T., Usami, J., Matsumoto, Y., Frye, E. B., Baynes, l W., 
and Maeda, K. (1998) FEBS Lett. 427, 381-385 
22. Prabhakaram, M., Cheng, Q., Feather, M. S., and Ortwerth, B. (1997) Amino 
Acids 12, 225-236 
23. Graham, L. (1996) Biochim. Biophys. Acta 1297, 9-16 
24. Nakamura, K., Nakazawa, Y., and Ienaga, K. (1997) Biochem. Biophys. Res. 
Commun. 232,227-230 
25. Glomb, M. A., and Pfahler, C. (2001) J. Bio!. Chem. 276,41638-41647 
26. Tessier, F. J., Monnier, V. M., Sayre, L. M., and Komfield, J. A. (2003) 
Biochem. J. 369, 705-719 
Chapter Three 91 
27. Tessier, F., Obrenovich, M., and Momlier, V. M. (1999) J. BioI. Chem. 274, 
20796-20804 
28. Zhao, R-H., Nagaraj, R H., and Abraham, E. C. (1997) J BioI. Chem. 272, 
14465-14469 
29. Fu, M. x., Wells-Knecht, K. J., Blackledge, J. A., Lyons, T. J., Thorpe, S. R, 
and Baynes, J. W. (1994) Diabetes 43, 676-683 
30. Westwood, M. and Thornalley, P. J. (1995) J Protein Chem. 14,359-372 
31. Ortwerth, B. J., and James, H. Y. L. (1999) Biochem. Biophys. Res. Commun. 
259, 706-710 
32. 0ldtani, A., Cho, R K, and Kato, H. (1984) Agric. BioI. Chem. 48, 1801 1808 
33. Cho, R. K., Okitani, A., and Kato, H. (1986) Agric. Bioi. Chem. 50, 1373-1380 
34. Slight, S. H., Feather, M. S., and Ortwerth, B. J. (1990) Biochim. Biophys. 
Acta 1038, 367-374 
35. Sell, D. R., and Monnier, V. M. (1989) J BioI. Chem. 264, 21597-21602 
36. AI-Abed, Y., and Bucala, R (2000) Bioconjug. Chem. 11, 39-45 
37. Lederer, M. 0., Gerum, and Severin, T. (1998) Bioorg. Med. Chem. 6,993-
1002 
38. Biemel, K M., Reihl, 0., Conrad, J., and Lederer, M. O. (2001) J BioI. Chent 
276,23405-23412 
39. Biemel, K. M., Friedl, A. D., and Lederer, M. O. (2002) J BioI. Chem. 277, 
24907-24915 
40. Nagaraj, R H., Shipanova, I. N., and Faust, F. M. (1996) J Bioi. Chem. 271, 
19338-19345 
41. Cerny, C., and Davidek, T. (2003) J Agric. Food Chem. 51,2714-2721 
42. Munch, G., Schicktanz, D., Behme, A., Gerlach, M., Riederer, P., Palm, D., 
and Schinzel, R (1999) Nat. Biotechnol. 17, 1006-1010 
43. Tressl, R., Wondrak, G., Kersten, E., and Rewicki, D. (1994) J Agric. Food 
Chem. 42, 2692-2697 
44. Nagaraj, R H., and Sady, C. (1996) FEBS Lett. 382,234-238 
45. ROMer, B., Lerche, H., Bergmul1er, \V., Freilinger, C., Scverin, T., and 
Pischetsrieder, M. (2000) J Agric. Food Chem. 48,2111-2116 
46. Kato, H., Chuyen, N. Y, Utsunomiya, N., and 0ldtani, A. (1986) J Nutl'. Sci. 
Vitaminol. 32, 55-65 
Chapter Three 92 
47. Gustausson, S., and Lundqvist, G. (1978) Biochem. Biophys. Res. Commun. 
82, 1229-1235 
48. Schalley, A. V., Dupont, A., Arimura, A., Redding, T. W., Nishi, N., 
Linthicum, G. L., and Schlesinger, D. H. (1976) Biochemistry 15, 509-514 
49. Reid, 1. A., Morris, B. J., and Ganong, W. (1978) Ann. Rev. Physiol. 40, 
377-410 
50. Canfield, R. E. (1963) 1. Bioi. Chem. 238,2698-2707 
51. Ledl, F., and Schleicher, E. (1990) Angew. Chern. Int. Ed. Engl. 29, 565-706 
52. Bell, L. N. (1997) Food Chem. 59, 143-147 
53. \Vatkins, N. G., Neglia-Fisher, C. 1., Dyer, D. G., Thorpe, S. R., and Baynes, 1. 
W. (1987)1. Bioi. Chem. 262,7207-7212 
54. MacPhee, C. E., and Dobson, C. M. (2000) 1. Am. Chem. Soc. 122, 12707-
12713 
55. Waterhouse, S. H., M.Sc. Thesis (2003) Controlling Amyloid Fibril Growth 
School of Biological Sciences, University of Canterbury, Christchurch 
56. Bouma, B., Kroon-Batenburg, L., Wu, y'-P., Brunjes, B., Posthuma, G., 
Kranenburg, 0., de Groot, P. G., Voest, E. and Gebbink, M. F. G. B. 
(2003) 1. BioI. Chern. 278,41810-41819 
57. Westermark, G. T., Johnson, K. H., and Westermark, P. (1999) Methods 
Enzymol. 309, 3-25 
58. LeVine, H., III. (1993) Protein Sci. 2,404-410 
59. Iijima, K., Murata, M., Takahara, H., Irie, S., and Fujimoto, D. (2000) 
Biochem.1. 347,23-27 
60. Hofmann, T. (1998) 1. Agric. Food Chem. 46,3896-3901 
6l. Glass, J. D., and Pelzig, M. (1978) Biochem. Biophys. Res. Commun. 81, 527-
531 
62. Bengelsdorf,1. S. (1952) J. Am. Chem. Soc. 75,3138-3140 
63. Brinkmann, E., Wells-Knecht, K. J., Thorpe S. R., and Baynes, J. W. (1995) 1. 
Chem. Soc. Perkin. Trans. 1,2817-2818 
64. Meade, S. 1., Miller, A. G., and Gerrard, 1. A. (2003) Bioorg. Med. Chem. 11, 
853-862 
Chapter Four 
Chapter Four 
Does protein crosslinking via u'" 
dicarbonyls affect enzyme function? 
4.1 Introduction 
93 
Chapter three began to address the cons~quences the Maillard reaction had on a target 
protein by examining protein crosslinking mediated by a-dicarbonyl molecules. 
Close attention was paid to the amino acid requirements for this process to occur, 
providing more clues to molecular detail of the Maillard reaction. This chapter 
further assesses the effect that the Maillard reaction has on a protein, by probing the 
relationship of protein crosslinking to the effect on the native function of an enzyme. 
Therapeutic strategies have been designed to inhibit ageing by preventing or reversing 
protein crosslinks, making the tacit assumption that loss of function is due to the 
crosslinking process, and further, that preventing crosslinking will maintain function. 
This assumption has yet to be rigorously tested. Nevertheless, it forms the basis for 
the development of a class of Maillard inhibitors that act to break protein crosslinks 
(1-4). However, these results have been the source of some debate (5,6). Along with 
the crosslink-breakers, compounds such as amino guanidine (7), are reported to trap 
reactive dicarbonyl species (8), sequestering them before they can react with the 
protein. More recently, it has been speculated that effectiveness of proposed 
dicarbonyl trapping and crosslink breaking compounds as AGE inhibitors may be due 
to other characteristics, such as metal ion chelating and radical trapping properties, 
which may provide an additive effect (9-11). The final section of this chapter 
addresses the effect of three purported Maillard inhibitors, by assessing their ability to 
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inhibit crosslinking and maintain native function of the target protein, in order to test 
the assumption that prevention of crosslinking will preserve protein function. 
4.2 Literature regarding the native function of a protein during the Maillard 
reaction. 
As enzymes playa key role in cellular function, an understanding of the effect of the 
glycation process on a protein is critical (10,12,13). Glycation of RNase A by 
methylglyoxal and glyoxal reduces native activity of the protein to 45% and 50% 
respectively, after one day of incubation in 200 mM MOPS buffer, with a 
dicarbonyl:protein ratio of 57:1 for methyglyoxal and 45:1 for glyoxal (14). Further 
studies with glucose have shown a 42% inactivation per mol of glucose per day, 
which preceded lysine loss (12). An active site lysine, Lys-41, was found to be 
preferentially modified by glucose to yield a catalytically deficient enzyme (12). A 
loss of enzymatic function of cellular homeostasis on glycation, such as glutathione 
reductase has been shown (13,15,16). Furthermore, modification of critical metabolic 
and blood clotting enzymes such as glyceraldehyde-3-phosphate dehydrogenase and 
lactate dehydrogenase has been reported on incubation with methylglyoxal and 
glyoxal (13,17,18). Glycated proteins themselves may further affect other protein 
function, as glycated proteins have been shown to inactivate protein that had not 
previously been exposed to sugar (13). The formation of covalently crosslinked 
human interferon during over-expression in bacterial systems has been reported. 
Following crosslinking, the interferon has been shown to lose its native antiviral 
activity (19). 
Although glycation may pose a serious threat to protein function, two reports have 
shown otherwise. Recent work studying glycation of heat shock protein-27 (HSP-27) 
showed that modification by methylglyoxal can protect against cell death through 
oligomerisation of HSP-27 (20). In other work, the modification of a-crystallins by 
methyl glyoxal, leading to arginine modification, results in a paradoxical enhancement 
in the chaperone function of these proteins (21). This later finding is thought to have 
evolved in the eye lens as a protective measure against age-related protein 
modifications. 
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Where crosslinldng studies regarding biological function are concerned, the majority 
of the literature has focused on crosslinking of structural proteins such as collagen and 
lens crystallins (22-25). Crosslinking of lens crystallins by sugar has been studied 
closely by many workers due to its slow turnover, and thus high content of AGEs 
(26). It is thought that crosslinking leads to a change in tertiary structure of lens 
crystallins, insolubilisation of protein and the gradual formation of cataracts (27,28). 
Loss of chaperone ability of a-crystallins has been reported on incubation with 
methyl glyoxal and glyoxal (29,30). Changes in other areas in the eye including the 
vitreous, cornea and retina have also been associated with AGEs (27). Glycation of 
some key elements of collagen may affect collagen N assembly and matrix-cell 
interactions in vivo (31,32). In collagen studies, it has been reported that loss of 
function cannot be solely accounted for by crosslinking, as only modification of a 
critical lysine residue is required (32). Cross linking of collagen by AGEs has been 
reported to decrease collagen digestibility, increase stiffness in the collagen network 
of cartilage and induce an expansion in molecular packing which can affect 
movement of fluid across arteries (23,32,33). Little is known about the molecular 
detail of the major crosslinks responsible for the effects observed in crosslinked 
collagen (34). 
In summary, the crosslinldng - function relationship has not been extensively probed. 
Thus, the following section explores this relationship by examining the effect that 
crosslinking had on the native function of a model protein, RNase A. 
4.3 Conditions employed to probe the crosslinking-function relationship 
In order to fully assess the effect of crosslinking on function of protein, a number of 
areas needed to be addressed, including selection of an appropriate protein and 
development of an assay to measure its activity following glycation. This section 
details both of these areas along with the inclusion of Maillard inhibitors to gain 
further information with respect to crosslinldng and activity. 
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4.3.1 Ribonuclease A catalytic mechanism 
The first step in probing the crosslinking - function relationship, was to select a 
model protein. RNase A was viewed as an excellent candidate for these studies due to 
reasons outlined in Chapter two, such as stability. Also, as enzymatic activity was 
under study, an added advantage was that the catalytic mechanism and amino acids 
involved in this process have been extensively studied. RNase A acts to cleave 
ribonucleic acid (RNA) at the P_05' bond. It is thought that this occurs via a 
transphosphorylation (Figure 4.1 A) and hydrolysis reaction (Figure 4.1 B). 
A 
HO, 3' RNA A: 
B Cor U 
RNA"-d 
HO OH 
" /~ (ifP~o rt5 
~OH 
:B 
Figure 4.1: Proposed mechanism of RNase A action. A, the transphosphorylation 
step; B, the hydrolysis step. A and B represent His12 and Hisl19 respectively (35). 
Abbreviations: C, cytosine; U, uracil. 
RNase A has a number of subsites that contain residues that are essential for correct 
binding and catalysis of polymeric substrates such as RNA (36). Critical substrate 
binding and catalytic residues within these subsites are outlined in Figure 4.2, some of 
which may be amenable to modification by carbonyls, such as Lys7, Argl0, Lys41 
and Lys 66, due to their available amine or guanidinium functionality. 
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Figure 4.2: The apparent subsites in RNase A and a bound molecule of RNA. P 
denotes phosphate subsites. B denotes base subsites. For clarity, ribose subsites have 
not been included. After Raines (37), with additional information from Leonidas et 
al. (38) and Nouges et al. (36). Abbreviations: A, adenine; G, guanine; C, cytosine; 
D, uracil. ? represents the fact that the residues of subsite B3 are not established. 
4.3.2 Review of existing methods to measure ribonuclease A activity 
Having selected RNase A as the protein for subsequent studies, a suitable RNase A 
assay was selected to assess the catalytic ability of RNase A following glycation by 
a-dicarbonyl compounds. As RNase A has been extensively studied, a number of 
options were available, some of which are detailed below. 
Studies assessing activity of RNase A have employed either its natural substrate RNA 
(39-41), a cyclic monophosphate (14,42), synthetic polynuc1eotides (43), or 
fluorogenic substrates (35). Assays generally measure either the rate of generation of 
nucleosides (43), or nucleotides (40,44). Some of these assays require estimation of 
initial rate due to end-point assay measurements, which can lead to over- or under-
estimation of initial rate (45). Another disadvantage in some available 
methodologies, such as those described by Anfinsen et al. and modifications thereof, 
is that they can be very labour and time-intensive (46). These assays have shown 
differing kinetic parameters depending on the substrate employed (44). In more 
recent years, measurement of RNase A activity by a fluorescence method has been 
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undertaken (47,48). When fluorogenic dinucleotide substrates are cleaved by RNase 
A, a large increase in fluorescence is observed. This can be measured over time and 
the subsequent data is used to calculate and initial rates (47). 
A different approach to standard colourimetric enzyme assays is taken by zymogram 
assays, which involves the incorporation of RNA into an agarose film, which is then 
exposed to RNase A in the presence of ethidium bromide, and the progress of RNase 
A action observed under UV light (312 nm) after electrophoresis. The principle is 
based on the fact that ethidium bromide fluoresces with only large RNA molecules, 
but not degraded RNA (49). The advantage of this method is that it is very sensitive, 
although it is a more qualitative approach, generally employed for detection of 
different isoforms of RNase A in nature, than other assays mentioned above. (49). 
The methylene blue assay is an excellent means for determining RNase activity in a 
complex mixture (37). It is possible to assay activity of a complex mixture, due to the 
fact that enzymatic digestion of RNA is measured at 688 nm, out of the absorption 
range of many biomolecules. The principle of the assay is that as methylene blue 
intercalates with RNA, a shift in absorbance maximum of the methylene blue 
monomer from 653 to 688 nm (intercalated) is observed (Figure 4.3) (50). On 
addition of RNase A, the chelated RNA is digested and the monomeric methylene 
blue monomer is liberated, causing a shift in absorbance to 653 nm (Figure 4.3). 
The assay was selected for a number of reasons. Firstly, the incubations under study 
were considered as complex mixtures, which this assay is ideally suited for, as they 
contained a-dicarbonyl compounds, RNase A and their reaction products. Secondly, 
enzymatic studies using the native substrate of the enzyme may provide more 
information regarding catalysis over synthetic substrates. Thirdly, the assay requires 
readily available materials and equipment and requires little preparation. Finally, this 
method allows the measurement of rate as the reaction progresses, as it is not an end-
point assay, and thus allows for a more accurate determination of initial rate. 
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Figure 4.3: Principle of the methylene blue assay. Intercalation of methylene blue 
into RNA between two adjacent bases results in an Amax at 688 nm. Cleavage of this 
complex by RNase A liberates the methylene blue monomer. Abbreviations: C, 
cytosine; G, guanine; U, uracil. 
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4.3.3 Addition of Maillard reaction inhibitors to study the effect of protein 
crosslin king on native function 
In order to establish whether the loss in function that accompames protein 
crosslinking was a direct result of the crosslinking process, or a co-incident event, two 
previously reported crosslinking inhibitors were selected: amino guanidine and 3, 5-
dimethylpyrazole-l-carboxamidine (DMPC) (Figure 4.4). 
Aminoguanidine 3,5-Dimethylpyrazole-1-carboxamidine 
Figure 4.4: Maillard inhibitors selected to probe the crosslinking-function 
relationship. 
Amino guanidine is a reported inhibitor of the progression of the Maillard reaction and 
has been found to be effective in a number of in vitro and in vivo experiments 
(7,51,52). The mode of action was initially proposed to be reaction with glucose, 
rendering the latter unable to react with amines (7), but more recently has been 
attributed to its ability to react with a-dicarbonyl compounds, such as those used in 
this study (8). DMPC has also been proposed as a Maillard reaction inhibitor, but is 
less well-characterised (53). Minimal information has been provided as to the 
mechanism of crosslinking inhibition by DMPC (53). 
4.3.4 Method development of the methylene blue assay to determine RNase A 
activity 
A calibration curve was constructed to determine the RNA concentration to be used 
for calculation of rate of RNA cleavage. The resultant calibration curve was 
hyperbolic in nature (Figure 4.5) which is consistent with that reported by Griener-
Stoeffele (50). 
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Figure 4.5: Calibration curve of RNA concentration using the methylene blue assay. 
Each point is an average of three samples with the experiment performed at least in 
triplicate. Error is expressed as standard error of the mean for triplicate samples. 
A concentration of 800 llg/mL RNA was selected for ensuing method development, in 
line with Greiner-Stoeffle (50). The next step was to determine whether enzyme 
concentration was proportional to rate of RNA cleavage. The RNase A concentration 
was varied from 0.05 to 0.4 llg/mL, whilst maintaining a fixed concentration of RNA 
(800 llg/mL). Analysis of the experiment shows a linear relationship between RNase 
A concentration and initial rate (Figure 4.6). 
0.09 R2:::: 0.9916 
0.08 
0.07 
(]) "2 0.06 
"§ :§ 0.05 
"ffi :::J 
:E ~ 0.04 
c 
......., 0.03 
0.02 
0.01 
0 
0 0.1 0.2 0.3 0.4 0.5 
RNase A concentration (~19/ml) 
Figure 4.6: Change in absorbance over time on varying RNase A concentration. 
Each point is an average of two samples with the experiment performed at least in 
triplicate. Error is expressed as standard error of the mean for duplicate samples. 
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In an attempt to determine Km and ~nax, RNase A was fixed at a selected final assay 
concentration, 0.15 /-lglmL, and the RNA concentration varied. During these 
experiments a reproducible loss in activity was noted at high concentrations of RNA 
(Figure 4.7). 
60 
50 
40 
.... 30 (J) 
> 0 
c 20 .... 
:::l 
.... 
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RNA cone (/-lg/ml) 
Figure 4.7: Rate of RNA cleavage with varying RNA concentration. RNase A 
concentration is 0.15 /-lg/mL. Each point is an average of two samples with the 
experiment perfonned at least in triplicate. Error is expressed as standard error of the 
mean of duplicate samples. 
A decrease in activity at high concentration of substrate for some enzymes has been 
observed (54). Product inhibition can be responsible for this phenomenon, and has 
been shown in work using RNase A with RNA as a substrate (55). A lower 
concentration of 600 /-lglmL of RNA was selected to overcome this problem and the 
method was further developed (Figures 4.8 A and B). Final concentrations of 600 
/-lg/mL RNA and 0.15 /-lg/mL RNase A were used for subsequent experiments 
undertaken to assess activity of RNase A following crosslinking by a-dicarbonyl. 
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Figure 4.8: A, Change in absorbance over time on varying RNase A concentration. 
Each point is an average of two samples with the experiment perfonned at least in 
triplicate. Error is expressed as standard error of the mean of duplicate samples. B, 
Rate of RNA cleavage with varying RNA concentration. RNase A concentration is 
0.15 j.tg/mL. Each point is an average of three samples with the experiment perfbnned 
at least in duplicate. Error is expressed as standard error of the mean of triplicate 
samples. 
With a successful method for quantifying RNase A activity in hand, the effect of CX,-
dicarbonyl compounds and Maillard inhibitors on the catalytic activity of the protein 
could be detennined. 
4.4 Analysis of activity and crosslinking of RNase A on incubation with CX,-
dicarbonyl in the presence or absence of Maillard inhibitors 
4.4.1 Amilloguallidille 
On incubation with methyl glyoxal, RNase A was found to exhibit a time dependent 
drop in activity with almost a total loss of activity after four days (Figure 4.9). RNase 
A incubated with methyl glyoxal in the presence of amino guanidine was observed to 
maintain activity over time (Figure 4.9), indicating that aminoguanidine protects the 
function of RNase A. As described in chapter two, crosslinking appeared to occur 
immediately after the methylglyoxal was added to RNase A (Figure 4.10 A). A 
marked inhibition of crosslinking was observed on incubation of RNase A and 
1200 
C/WjJ/cr FOllr /04 
mcthylglyoxal with ami noguanicline ( igure 4.10 B ). which IS consistent with 
previou s report s (52,56) . 
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Figure 4.9: RNa~e A activity nver 96 hours i"ullm,ving incuhation ",ith lT1cthylglyuxal 
in the presence (.), or absence ( l. of am inogu~mid ine . Bars indicate the average of 
dat ~ t g nerated from tri I licate readings. Error bars re presen t the standard error of the 
mean for the tri plicate read ing!.. X ax is: FC (0), RNa~e fro ze n control: 0-96. time in 
hours: IC (06 . RNase A incu hatecl control. Rate expressed as ~lg/mL of RN A cleaved 
P I' m ill . 
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Figure 4.10: 8- 16 SDS-PAGE ge ls of mcthyl glyoxal incubated with RN ase A in 
the absenl' e . or presence B, o i" arn inoguanidine. Abhreviations arc as follows: M, 
wilk r~mg marh T 0-06, hours of il1l"llhation timt' of dicarhony i with RN ase A at 
J7°C: Ie R ase A incubated l"lll1trul : FC, RNase A frozen cuntrol. 
dimer 
monomer 
Baseu on th ese r SlI 'Il S. crosslinking of RT\ a~c i\ hy mcthylglyox~lll'orresponds to lhe 
loss in activity ohserved in glycated RN a~ e A as aminoguaniuine appears to 
SUl'Cl~S~rllll y inhihit crosslin king: and native fUlIctioll is rctaincu. However. Ilon -
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crosslinking AGEs must also be considered in this process. The decrease in activity is 
gradual, with crosslinking occurring immediately, as shown in Figure 4.10 A. It may 
be that aminoguanidine not only inhibits crosslinking, but also non-crosslinking 
modifications of protein, that may be in part responsible for inhibition of RNase A 
activity. Results for diacetyl and glyoxal were less dramatic than for methyl glyoxal 
(Table 4.1). 
Dicarbonyl 
Methylglyoxal 
Glyoxal 
Diacetyl 
No Dicarbonyl 
Aminoguanidine No inhibitor 
Rate of reaction Crosslinking Rate of reaction 
(J-tg RNA/mL/min)h 
22.9 ± 0.4 +++ 
29.3 ± 1.7 + 
30.2 ± 1.1 + 
29.5 ± 0.6 
(J-tg RNA/mL/min) 
3.8 ± 1.6 
17.9 0.7 
22.1 ± 0.9 
28.8 .1 
Table 4.1: Comparison of RNase A crosslinking with catalytic activity. a Positive 
crosslinking results were those which showed increased crosslinking compared to 
controls. b Rate calculated from methylene blue RNase A activity assay. Errors are ± 
s.e.m of triplicate readings. Data is that from the 96 hour incubations for each 
dicarbonyL C Controls values are an average of results yielded for each differing (X-
dicarbonyl series, error is the standard error of the mean for these readings. Rate 
expressed as Ilg/mL of RNA cleaved per min. 
In the case of glyoxal, addition of amino guanidine resulted in the maintenance of 
RNase A activity, as observed for methylglyoxal (Table 4.1) (Appendix two, Figure 
I). Aminoguanidine again appeared to be effective at inhibiting crosslinking (Figure 
4.11 A) relative to the incubations that did not contain amino guanidine (Figure 4.11 
B). It has been found that addition of amino guanidine to reaction mixtures containing 
glyoxal and protected lysine, results in the inhibition of some glyoxal-mediated 
crosslinks such as GOLD, but not others such as GOLA (57). 
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Figure 4.11: R- 16o/r SDS-PAGE gel:-, of gly(), a l in ubaLed with R ast: A in the 
ab~ence A .. 0 1 presenc S, o j" ~lmin()guanidi ne. J\bbre \iatiun~ are as for Figure 4.10. 
A I()~s in <leti\-it y of RN 'l~ e A ineuhated with di<tcetyl wa~ oh~erved (Table 4.1) 
(Appendi x t\\'o . Fi gu re 2). Dia tyJ ha~ heen reported to be an argin ine modifier 
(5 8,59). Some react ion h a~ also heen repo rted. where diacet yJ can crossl ink protein 
with a concomittant d crease in measurable lysi ne res idues (60). H' nH1L1ification or 
arg tn In is pn:dominant. these result~ sl'lggest that loss or arginille doc . ., not 
dramati call y affect catalysi ' , although some loss in activit y is ohserved. 
Amim)guanidine agcll lJ1 appeared to maintain the actiyity oj RNase A that had been 
incubated wi th diacely l (Tab le 4.1). lndeed. format ion or tr iazines has been reported 
on the reac tion oj diac Iy l wi th ami noguanidine under mild conditions (61 ). rendering 
di ac 1,1 unable tu react wi th R ase A to inactivate it. C rosslink' ng of R ase A by 
di acetyl and inhi bition by Clmi nop uanid ine is ill ustrated in Figures 4 .1 2 A and 4. 12 S . 
respec tivel y. 
Chapter FOllr 
A 
205 ,Da 
36 
29 
142 
M 0 .3 2 6 24 48 96 Fe Ie 
a) 
high molecular 
weight 
aggregates 
trimer 
dimer 
monomer 
107 
B 
29 kDa 
M 0 3 2 6 24 48 96 Fe Ie 
h) 
Figure 4.12: 8-16% SOS-PAGE gels of diaectyl incubatcd with RNasc A in the 
absence A, or presence B, of aminoguanidinc. Abbreviations arc as for Figurc 4.10. 
4.4.2 DMPC 
Another rcported Maillard reaction inhibitor, OMPC, was included to assess its 
efficiency at preserving the activity of RNase A and inhihiting protein cros. linking. 
Activity of RNasc A. incuhatcd with both methylglyoxal and DMPC was found to 
decrease ovcr time re'iative to the controls (Figure 4.13). This loss in activity 
paralleled activity of RNasc A incubations that did not contain OMPC. 
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Figure 4.13: RNase A acrivity over 96 hours following incuhation with 
mcthylglyoxal in the presence (_) , or abse nce ( ) of 3,5-dimcthylpyrazolc- l -
carboxumidinc. Bars indicate the average of data gencrated from triplicate readings. 
Error hal'S represent thc standard error of thc mean for the triplicate reading. 
Abbreviations are as for Figure 4.10. 
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Another reported function of DMPC is that it acts as a guanidylating agent, converting 
a primary amine to a guanidino functionality (62-64). Interestingly, it has been 
reported that guanidination of 9 RNase A lysine residues oy this method does not 
render the protein catalytically inactive, hut modification of the final lysine (Lys41) 
does (64). This may explain the decrease in the activity of the incubated control 
(lC96) in Figure 4.13 that had heen incuoated in the presence of DMPC relative to the 
incuhated control that did not contain DMPC. Guanidination may have resulted in the 
modification of critical Iysines residues within RNase A. However. an optimal pH of 
9.5 is required for guanidination (65), which was not reached in this work, although 
some enzymatic inactivation has oeen ohserved at pH 7.4 (66). Thus, a pH of 7, 
which the incubations were prepared at. may still favour a small amount of 
guanidination. 
Figure 4.14 reflects the extent of crosslinking ooserved for methyl glyoxal on addition 
ofDMPC. 
205 kDa 
36 
2 9 dimer 
142 
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M 0.3 2 6 24 48 96 FC IC 
Figure 4.14: X-IMIc SDS-PAGE gel of RNase A incuoated w ith methylglyoxal in the 
presence of DMPC. Abbreviations are as for Figure 4.10. 
These results with DMPC are in contrast to aminoguanidine, where crosslinking was 
inhibited and the function of RNase A was maintained. Al though crosslinking of 
RNase hy methylglyoxal is inhihited by DMPC (Figure 4.14), the function of RNase 
A has decreased steadily over time in the presence of this inhibitor. This will he 
fu rther discussed in section 4.5. 
On incubation of protein with glyoxal in the presence of DMP(, the inhibitor 
appeared to he more effective at retaining RNase A activity than methylglyoxal 
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Crable 4.2) (Appendix two, Figure 3). Crosslinking of RNase A by glyoxal was 
inhibited by DMPC (Appendix two, Figure 4). 
No inhibitor 
Crosslinking Rate of reaction 
()lg RNAimLimin) ()lg RNA/mLimin) 
Glyoxal 
Diacetyl 
No Dicarbonyl 
b 
9.4±3.1 
25.4 ± 0.9 
23.6 ± 0.5 
27.1 ± 1.3 
+++ 
+ 
+ 
3.8 ± 1.6 
17.9±0.7 
22.1 ± 0.9 
28.8 ±1.1 
Table 4.2: Comparison of RNase A crosslinking with catalytic activity. a, b error and 
replicates are exactly as outlined in Table 4.1 legend. 
RNase activity was impaired on incubation with diacetyl, and, inclusion of DMPC 
did not appear to have a protective effect with regard to activity of the protein (Table 
4.2) (Appendix two, Figure 5). Inhibition of crosslinking of RNase A was observed 
in incubations containing diacetyl and DMPC (Table 4.2) (Appendix two, Figure 6). 
The differences in RNase A activities in the presence or absence of DMPC suggest 
that modification of RNase A by methyl glyoxal or diacetyl to protein-bound amine is 
favoured over reaction with DMPC, thus activity is not maintained. In the case of 
glyoxal-treated RNase A, maintenance may be due to glyoxal reacting preferentially 
with DMPC over protein-bound amine. 
4.5 General discussion and conclusions 
The work in this chapter probed the relationship of crosslinking to function of a model 
protein. Maillard inhibitors were included to further understand tIns relationship. 
Both amino guanidine and DMPC inhibited the protein crosslinking reaction by all 
three a-dicarbonyl compounds with RNase A. In the presence of aminoguanidine, 
enzyme activity was retained, suggesting that this compound does indeed afford some 
protection against loss of protein function. However, in the presence of DMPC, 
despite the inhibition of protein crosslinking on incubation with RNase A and 
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methyl glyoxal, the activity of the protein was lost. Thus an ability to inhibit protein 
crosslinking by the Maillard reaction does not necessarily guarantee that the 
damaging effects of protein glycation on protein function have been circumvented. 
Figure 4.15 summarises these findings and suggests a possible explanation for the 
difference in behaviour between the two inhibitors. These results support the view 
that amino guanidine is effective at inhibiting crosslinking and preventing inactivation 
of the protein, since it reacts with a-dicarbonyls at a much faster rate than they are 
able to react with proteins. This does not always seem to be the case with DMPC, 
which does not react with methyl glyoxal quickly enough to prevent it from reacting 
with the protein. While it does render the intermediate incapable of protein 
cross linking, the damage, in terms of loss of protein function, is already done (Figure 
4.15). Aminoguanidine may be more effective due to its ability to trap a-dicarbonyls 
via the hydrazine group, which is a better nuc1eophile than the guanidinium 
functionality of DMPC. 
i 0 H ~NH3+ X o CH3 
Lys MG 
!~~~A 
H3C ~ 
T8'N\ ~N~ ~/ 
Function lost 
Crosslinking inhibited 
Inhibitor 
~ .. CH . 3 . H 
Lys MG 
Function maintained 
Crosslinking inhibited 
Figure 4.15: Possible reaction pathways for lysine modification by methyl glyoxal 
reaction with lysine in vitro 
It is tempting to speculate on the mechanism of inactivation of RNase A by 
methylglyoxal. Inactivation may be arising from reaction with lysine via steps 
outlined in Figure 4.15 or by a similar mechanism. Modification of lysine has resulted 
in a loss in function of RNase A (12). Recent work has confirmed that lysines 41 
(critical for catalysis), 1, 7, and 37 are modified in RNase A on reaction with glucose 
(67). Another possibility is that methyl glyoxal may react with arginine residues 
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(Figure 4.16), such that these modifications may ultimately result in the modification 
of enzymatic activity. A small proportion of Lys41 modification by glyoxal was also 
noted by these workers, and may explain the inactivation observed in this work when 
incubating glyoxal with RNase A (67). 
futerestingly, Takahashi suggested that as RNase A could be inactivated by 
phenylglyoxal, a selective arginine modifier under certain conditions, the loss in 
function in the enzyme was due to modification of Arg39 (14). One must consider the 
possibly of arginine-lysine crosslinks (Figure 4.16) which could also potentially 
modify catalytically important lysine and arginine residues. 
RNase A protein 
backbone 
H H2NI(N~~ + 
NH 2+ ~ 
Arg 
Argpyrimidlne MODIC 
Figure 4.16: Possible reaction pathways of arginine on reaction with methylglyoxal 
in the presence of a Maillard reaction inhibitor in vitro (68,69). 
These results demonstrate that preventing protein crosslinking does not necessarily 
preserve enzyme activity. These results cast doubt on the likely efficacy of some 
purported anti-ageing compounds in vivo, and emphasise the danger of generalising 
the results from simple model studies. Based on these results, the efficacy of Maillard 
inhibitors as anti-ageing therapeutics is likely to depend on many complex factors, the 
outcome of which will depend on not only the individual carbonyl moiety in question, 
but also the specific protein affected. 
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Chapter Five 
In search of amadoriase ... developing 
kinetic assays to characterise protein 
deglycating enzymes 
5.1 Introduction 
The previous chapter studied the effect of glycation on protein function. An intimate 
knowledge of the effects of the Maillard reaction on proteins in vitro will shed more 
light on the detailed in vivo processes of diseases, such as diabetes and 
cataractogenesis, which are thought to involve the Maillard reaction. Better strategies 
can be designed to reverse or attenuate this chemistry as more becomes known about 
the physiological effects of glycation. 
Advances in gene technology have meant that exogenous genes can be expressed in 
human systems for medical purposes (1). The approach, termed gene therapy, has 
broadened the scope of alternative approaches to intervention in the Maillard reaction 
to include enzymes that can reverse the Maillard reaction. These enzymes, termed 
deglycating enzymes, can reverse the early stages of the reaction by cleaving the 
Amadori product, generally liberating the original carbonyl compound and amine. 
One promising avenue of research involves the fructosyl amine-oxygen 
oxidoreductase deglycating enzymes that are so far confined to bacteria and fungi. 
These enzymes have the capacity to cleave the Amadori product that forms from the 
reaction between low molecular weight amines and sugars (Figure 5.1) (2-6). These 
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enzymes are commonly referred to as amadoriases (6), due the fact that the Amadori 
product is the substrate that is recognized by the enzyme. 
In more recent years, it has been discovered that humans and mice possess 
deglycating enzymes, the ATP-dependent fructosamine kinases (7-9) (Figure 5.1). 
These also act on the Amadori product, but differ in mode of action from the 
amadoriases, in that they require ATP for their function. 
HtHC=~H 
HO H 
H OH 
H OH 
CH20H 
Carbonyl compound Amine 
e.g. Glucose 
Maillard reaction 
-~-~ 
~-~-
Amadoriase 
Fructosamine kinase 
Amadori product 
e.g. Fructoselysine 
Figure 5.1: Enzymatic reversal of early stages of the Maillard reaction via either 
amadoriase or fructosamine kinase. Abbreviation: R, remainder of amine compound. 
The fructosamine kinases act to phosphorylate the Amadori product formed on 
protein, which subsequently decomposes to regenerate an unmodified lysine residue, 
inorganic phosphate and 3-deoxyglucosone (Figure 5.2). Some enzymes have been 
shown to phosphorylate the third (7), or sixth carbon of fructoselysine, the Amadori 
product formed on reaction of glucose with lysine (Figure 5.2) (9). The spontaneous 
degradation of fructosamine-3-phosphate has been attributed to the fact that the 
phosphate is in close proximity to the carbonyl and thus will be susceptible to 
elimination (7,8). Studies where a fructoselysine 6-kinase was isolated also resulted 
in the discovery of a novel deglycase, fructoselysine-6-phosphate deglycase with a 
molecular weight of 405 kDa, which converted fructoselysine-6-phosphate to glucose-
6-phosphate and lysine (9). 
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HI~H Maillard reaction -~-{CH2)4-< H2N-(CH2k-( 0 H~_~H + ~~- - HO H 
H OH 
H OH H OH 
CH20H CH20H 
Glucose Lysine Amador! Product 
e.g. Fructoselysine 
ATP 
o· 
C:,o .. m,o, kinas. 
I 
HO-~-O· ADP 
0 
i~ H2C-~-(CH2)4-< H H + H2N-(CH2)r< H OH OH ~O Spontaneous O=p-O 3 H H OH or 6· H OH Phosphorylation 
CH20H Deglycase at 
H 6 0H either 
3-Deoxyglucosone Lysine yH2 C3 or C6 
0 
I 
HO-P-O· 
II 
0 
Figure 5.2: The deglycation pathway involving fructosamine kinase. Fructosamine 
kinase can either act at the 3C position (fructosamine-3-kinase) (7,8), or at the 6C 
position (fructoselysine 6-kinase) (9). 
Chapter one highlighted the importance of the Maillard reaction in the progression of 
diseases such as diabetes (10). Thus, intervention in the Maillard reaction is 
paramount and a number of routes have already been explored (Chapter one). 
Ultimately, it is hoped that both types of deglycating enzymes, the amadoriases and 
the fructosamine kinases, could be expressed in patients with Maillard-related 
diseases, via therapy, to provide a means for al1eviating many of the 
physiological complications encountered by diabetics, such as cataracts and 
neuropathy. A considerable barrier to this approach is that the amadoriases cannot act 
on glycated protein, the physiologically relevant substrate (4-6). This later point will 
discussed in more detail later in this chapter. 
Deglycating enzymes have also been considered for use in DNA recombinant 
technology, for stripping off glycation adducts from recombinant proteins to generate 
safe, stable proteins (11). A final potential use for these enzymes is for diagnostics. 
A selection of amadoriase enzymes isolated to date has been cultured, with a view to 
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developing an assay for the quantification of the extent of hemoglobin glycation at the 
N-terminus in diabetic patients (12-14). This is proposed to act as an indicator of the 
extent of Maillard reaction occurring in patients. In vitro protein evolution has aided 
the development of this as a diagnostic tool, by generating a more thennostah1e and 
specific enzyme for the quantification procedure (15). 
The remainder of this chapter will focus on the fructosy1 am me-oxygen 
oxidoreductase, amadoriase I (6), which has not been reported to use glycated protein 
as a substrate. It was hypothesised that this inability to cleave Amadori products 
formed on protein is due to the fact that previous studies have used heavily glycated 
protein substrates (4-6). It may be that the enzyme can use a mildly glycated protein 
substrate, but beyond a certain threshold of glycation, is inactive. 
A key bottleneck in the characterisation of any enzyme is the development of 
accurate, time resolved assays (16). This is true for the amadoriases. Therefore, this 
chapter details the development of two assays: a time-resolved assay for initial 
purification and kinetic characterisation purposes, using fructosyl propyl amine as a 
substrate; and a novel method to assess amadoriase I activity using glycated protein as 
a substrate, based 011 the RNase A activity detailed in Chapter four. 
With assay methods in hand, site-directed mutagenesis studies of amadoriase I was 
undertaken. The amino acids involved in the catalytic mechanism of amadoriase I 
are, to date, undefined. Previous studies proposed three possible modes of catalysis 
(17), consistent with those reported for enzymes that share homology (18,19). Thus, 
two mutants were generated to further probe the catalytic mechanism of this enzyme 
in order to contribute to the current understanding of the enzyme. The mutations were 
performed at sites that were thought to be critical for catalysis. Using the time-
resolved method, the activity of two mutants of amadoriase I, created in collaboration 
with Andrea Uhlmann, Technische Universitat Miinchen, Germany (His357 to Asn) 
and Stephan Hegge, Universitat Hannover, Medizinische Hochschu1e Hannover, 
Germany (S370A), was successfully measured (Appendix four). 
Finally, the second assay method established in this chapter was used to the search for 
deg1ycating enzymes in other organisms that could act on glycated protein. Attempts 
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to isolate a deglycating enzyme from Pseudomonas fluorescens, using this assay 
approach are outlined in Appendix five. This work was undertaken collaboratively 
with Sarah Day, an M.Sc. student at the University of Canterbury. 
5.2 Amadoriase enzymes isolated to date 
A summary of all of the amadoriase enzymes isolated to date, and their reported 
properties, are outlined in Table 5.1. Many of these enzymes have been isolated from 
organisms that have been cultured on low molecular weight Amadori product 
substrates, such as fructosyl aminocaproic acid, i.e. relatively small Amadori products 
with respect to a glycated protein substrate (Figure 5.3). As a result, these enzymes 
do not recognize larger substrates (2,20). Those enzymes that have been shown to 
exhibit an ability to deglycate a number of fructosyl amino acids do not recognise 
glycated protein (2,3). Some enzymes show the capacity to deglycate proteins, but 
only after protease treatment ofthe protein (12,14). A recent publication reports the 
ability of an enzyme that can act on glycated dipeptide (21). 
OH OH 
H02C~Nl~OH 
H 0 OH 
Fructosyl aminocaproic acid 
C02H OH OH H2N~N~OH 
H 0 OH 
Fructoselysine 
Substrates for some deglycating enzymes 
VS. 
Protein backbone 
~ OH OH ~Nl~OH 
H 0 OH 
Glycated protein-bound lysine 
Not a substrate for any amadoriase enzymes 
characterised to date 
Figure 5.3: A selection of substrates employed in amadoriase studies to date. Those 
on the left are recognised by some amadoriases. Glycated protein however, is not 
recognized. The structure on the right is a reaction product of the reaction of glucose 
with protein-bound lysine (22), but has not been characterised in experiments where 
glycated protein has been used as a substrate (3,4). 
Source 
Corynebacterium 
Aspergillus 
Penicillium (18) 
Klebsiella, Corynebacterium 
Fusarium, Acremonium 
Debaromyces 
Penicillium (12) 
Pseudomonas (3) (4) 
Aspergillus terreus (13) 
AspergillusJumigatus (5,21) 
(5) 
Aspergillus nidulans (22) 
Achaetomiella virescens (19) 
MW (Da) a 
44,000* 
,500* 
NR 
NR 
39,000 
106,000 
53,000* 
51,000 
48,000 
50,000 
Substrate 15 Prosthetic group Products C 
Fructosyl glycine FAD Glucosone, glycine, H202 
Fructosyl8-aminocaproate FAD Glucosone, glycine, 
Difructosyllysine NR NR 
Fructosyl valine 1\TR Glucosone, butylamine, H20 2 
Butylamino deoxyfructose 
Fructosyl valine FAD 
Fructosyl 8-aminocaproate NR 6-oxohexanoic acid, fructosamine 
Frutosyllysine 'FAD lysine, glucosone, H20 2 
Fructosyl adamantanamine FAD glucosone, propylamine, H20 2 
adamantanamine FAD glucosone, propylamine, H202 
Fructosyl propylamine FAD Glucosone, 
JtL Fructosyl valyl-histidine Flavin glucosone, valyl-histidine, H20 2 
Table 5.1: Deglycating enzymes (that do not require ATP) isolated thus far. a Molecular weight of monomer as judged by size exclusion 
b '-!Ilh"tr".t" as sole source m experiments to isolate deglycating enzymes. C Products that arise on catalysis of 
model substrates used to characterise the deglycating enzyme. NB. the substrate used for isolation of the deglycating enzyme I.;VIUlllll can 
differ to that used to further characterize the enzyme. * denotes that the protein exists as a dimer, otherwise, protein exists as a monomer. 
Not reported in the source publication. 
(j 
;:s-. 
-§ 
...... (\) 
"l 
~ 
-. ~ 
....... 
tv 
....... 
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Most fructosyl amme-oxygen oxidoreductases characterised cleave the Amadori 
product at the keto amine bond (Figure 5.4 A). One enzyme, however, isolated from 
Pseudomonas, cleaves at the alkylamine bond (Figure 5.4 B) (4,5). Interestingly, 
these enzymes were found to act on ribated protein (protein incubated with ribose), 
but not protein treated with glucose (4). 
Cleavage 
Hoi~ ( H2O H =:N-R \ + NH2-R 0 H OH HO H H OH Amine 
H OH H20 2 CH20H 
H OH 
A CH20H Glucosone 
-H+ 
H 
H2C(-N-R 
HO*~ H OH 
H OH 
CH20H 
Amadori product 
e.g. Fructoselysine 
-H+ 
CCleaVage 
H:i~H' B H!~CR H,O 0 + HAR HO H 
H OH H OH Aldehyde 
H OH H OH 
CH20H CH20H 
Fructoseamine 
Figure 5.4: Deglycation of an Amadori product via enzymes that catalyse A, 
keto amine bond cleavage or B, alkylamine bond cleavage. R denotes the remaining 
portion oflysine. After Gerhardinger et al. (4). 
In recent years, two amadoriase isozymes, amadoriase I and II have been the subject 
of intense study, and as a result, more is becoming known about their mechanisms and 
the amino acid residues required for their function (17,23,25). Our understanding of 
amadoriase regulation and the role it plays in the organism it was originally isolated 
from has been extended by gene regulation studies. These studies show that a 
deglycating enzyme isolated from Aspergillus nidulans could not be induced solely by 
fructosylamines, and the veA gene was a co-requirement for induction of amadoriase 
(24). 
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5.3 The amadoriase I and II isozymes 
Amadoriase I and II were first isolated from Aspergillus Jumigatus that had been 
grown on a highly sterically inhibited Amadori product, in order to mimic the 
structure of a glycated protein. These enzymes were found to cleave at the keto amine 
bond to produce glucosone and free amine from the Amadori product, along with 
hydrogen peroxide (Figure 5.4) (6). The expression of these amadoriases, was found 
to be induced by Amadori compounds. Both enzymes were cloned and expressed in 
E. coli (23,26). Amadoriase I was the deglycating enzyme that was chosen to test 
protein deglycating ability and the two new assay methods. The plasmid bearing the 
gene that encoded for this enzyme was kindly provided by Prof. Vincent Monnier 
(Case Western University, Cleveland, Ohio). 
5.3.1 The proposed catalytic mechanisms of amadoriase I 
Spectral studies showed that amadoriase I contained an FAD prosthetic group (6). 
Mutation of Cys342 of amadoriase I suggested that this was the residue to which the 
FAD prosthetic group was covalently attached (23). Later work showed that 
amadoriase I bound a cyclic ~ isomer of the substrate, fructosyl propylamine (17). 
Also outlined in that work was a pre-steady state analysis of the amadoriase I 
mechanism, in which a complex absorption spectrum for an intermediate was resolved 
(17). 
The proposed kinetic mechanism of amadoriase I is thought to proceed via an ordered 
ternary complex (Figure 5.5). This ternary complex contains three substituents: 
enzyme, reduced flavin and product, and is represented in Figure 5.5 as E~FLred~P. 
The term ordered refers to the fact that substrates must bind to the enzyme in a 
particular sequence. Adherence to this sequence is crucial to the enzyme's ability to 
catalyse the rcaction. For amadoriase I, the binding of the substrate fructosyl 
propylamine (kl ) precedes the binding of oxygen (k6), the second substrate (Figure 
5.5). 
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E-FLox-P 
E-FLox + S ..... __ " E-FLox-S -. ----'lo-. E-FLREO-I --...... E-FLREO-P 
p 
Figure 5.5: The proposed kinetic mechanism for the catalytic cycle of amadoriase 1. 
Thicker arrows represent the actual pathway following turnover. E, enzyme; FLox, 
oxidized flavin; FLred, reduced flavin; S, substrate; I, intermediate; P, product. From 
Wu et al. (17). 
The catalytic mechanism of this famlly of enzymes of which amadoriase I is a 
member, the FAD dependent oxidoreductases that act on secondary or tertiary amino 
acids, is open to debate. Another member of this family, monomeric sarcosine 
oxidase from Bacillus sp. shares 22% sequence homology with amadoriase I (23). 
Inspection of BLAST sequences shows that this is the protein that is most similar to 
amadoriase I with a published X-ray structure (18). Trickey et al. report that the 
structure of the monomeric sarcosine oxidase may provide a model for other members 
ofthis family (18). Inspection of the proposed catalytic mechanisms for this family of 
enzymes suggests three possibilities for the substrate dehydrogenation, a critical step 
in catalysis: a polar nucleophilic mechanism, a carbanion mechanism and a direct 
hydride transfer mechanism (18,27-29). All of these may operate in amadoriase I 
(Figure 5.6) (17), and will each be discussed in tum. 
Before the nucleophilic mechanism can take place, it is thought that ring-opening of 
fructosyl propyl amine must occur (Figure 5.6A 1). Nucleophilic attack of the 
substrate amine at the C4 of the covalently bound flavin then proceeds (Figure 5.6A 
2). Concomitantly, a proton is abstracted from an active site water or amino acid 
residue by the flavin (Figure 5.6A 2). The substrate is deprotonated at the a-carbon 
by thc same active site residue, with subsequent breaking of the covalent bond 
between the flavin and the substrate (Figure 5.6A 3), and the generation of an 
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intennediate (Figure 5.6A 4) which is oxidised to fonn the final products of the 
reaction. His 269 has been proposed to be the active site base in monomeric sarcosine 
oxidase that is involved in this mechanism (18). However, mutational studies have 
shown that this residue is critical for optimizing the orientation of bound substrate 
with respect to electron transfer to the flavin, and attention has been shifted to a 
tyrosine residue situated close to both the flavin and His 269 (30). 
S 
Nucleophilic mechanism 
1 2 
~ Enz's~NrYO 
OH . ~rYNH ~. En~~~~)) _ OH EflZ.S:JN 0 
\"--OH yN~ ~OH o H . OH:?~· 
(, . ~ 
Carbanionic mechanism 
Hydride transfer 
1 
o· 
2 
3 
3 
2 
4 
~ 
Enz's~NI(NyO lAN~NH 
~OHH 0 
\"--OH rN~ 
o H 
4 
Figure 5.6: Three proposed catalytic mechanisms of amadoriase 1. From Wu et ai. 
2001 (17). Abbreviations: Enz-AH, protonated active site amino acid residue A; Enz-
A, deprotonated active site amino acid residue A; Enz-BH, protonated active site 
amino acid residue B; Enz-A, deprotonated active site amino acid residue B. 
An active site base is also a prerequisite for another catalytic mechanism, the 
carbanion mechanism (Figure 5.6 B). Again, ring opening is thought to be required 
for catalysis. An active site base then deprotonates the substrate at the a-carbon of 
the substrate which then attacks the N5 of the flavin ring (Figure 5.6 Bland 2) (31). 
After this, the active site base donates a proton to the substrate and the covalent bond 
to N5 is cleaved (Figure 5.6 B 3) (17,29). However, Wu et ai. note that carbanionic 
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intelmediates are generally unstable and the substrate would not offer any inherent 
stability (17). 
The final mechanism to be detailed here is the direct hydride transfer (Figure 5.6 C). 
This has been suggested for D-amino acid oxidase, a member of the FAD dependent 
oxidoreductases, where the substrate is thought to donate a proton directly to N5 of 
the flavin (Figure 5.6 C 1) (19,32). 
However, none of the intermediates in the proposed catalytic schemes above have 
been identified (17). 
5.3.2 The proposed catalytic mechanisms of amadoriase II 
The catalytic mechanism of amadoriase II has not been characterised to the extent that 
amadoriase I has. However, a substrate specificity study has shown that amadoriase II 
favours binding of a carboxylate group over an uncharged methyl group (Figure 5.7) 
(25). Double mutation of Arg 112 and Arg 114 of amadoriase II to Glu (as are found 
in amadoriase I) suggest that these residues are critical for anionic substrate binding 
but not catalysis (25). 
O~~O OH 
o ~~ 
OH 
O~~O OH 
o N~CO-H 2 
OH 
Amadoriase I substrate Amador!ase II substrate 
Fructosyl propylamlne Glycine Amador! product 
Figure 5.7: Preferred substrates for amadoriase 1 and II respectively. 
5.3.3 Can amadoriase I use glycated protein as a substrate? 
To date, attention has focused primarily on the action of amadoriase 1 on low 
molecular weight substrates. Thus, the research detailed below sought to examine 
whether amadoriase I could catalyse the deglycation of a mildly glycated protein 
substrate. 
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Amadoriase I has been shown to be inactive toward some glycated protein substrates 
derived from hexoses and pentoses, such as glucose and ribose. This study has used 
methyl glyoxal to mildly glycate protein. This a-dicarbonyl was selected due to the 
current view that a-dicarbonyls, some fonned on oxidation of glucose (Chapter one), 
are a more physiologically relevant species in terms of the Maillard reaction in vivo 
than hexoses (e.g. glucose) and pentoses (e.g. ribose) (33). 
Methylglyoxal allows for modification of protein in a short time, minimising possible 
break-down problems with the incubated protein. Also, information regarding the rate 
of protein glycation by methylglyoxal was known from lysine estimation described in 
Chapter two, and was used to gauge the extent of the Maillard reaction. Strictly, 
Amadori product formation on reaction of methylglyoxal with amine does not occur, 
but the reaction may yield a product similar in structure, which may be recognized by 
amadoriase I (Figure 5.8). 
A B 
f'f -(1-Carboxyethyl)lysine Fructoselysine 
Figure 5.8: Reported structures on reaction products of A, methyl glyoxal with protein 
(34) and B, the classical "Amadori product" fructoselysine formed on reaction of 
glucose with protein (35,36). 
5.3.4 Current methods employed to monitor the activity of amadoriases 
Some previous methods to quantify the rate of amadoriase activity have measured the 
rate of oxygen consumption. These methods take advantage of the fact that all 
deglycating enzymes isolated to date are oxygen dependent (Figure 5.9) (2-6). 
An alternative route to measure activity is by quantification of another end product of 
the amadoriase catalysis, glucosone (Figure 5.9) (6,26). However, this method may 
result in underestimation of rate, due to the reported ability of glucosone itself to 
participate in the Maillard reaction (37), and the fact that it will easily fragment under 
oxidative conditions due to its structure (38). 
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More recently, production of hydrogen peroxide by these enzymes has been used as a 
means for assaying amadoriase (Figure 5.9). Hydrogen peroxide acts as a substrate for 
peroxidase and, in the presence of a second chromophoric substrate, the oxidation of 
the chromagen can allow for the measurement of amadoriase activity. Chromophoric 
and fluorogenic substrates have varied, and include quinone dye (26), ABTS (Figure 
5.9) (17), Amplex® red (10-acetyl-3,7-dihydroxyphenoxazine) (24,25), 4-
aminoantipyrine (15) and 4-aminophenazone (12). Determining activity by this 
coupled assay circumvents problems that arise with measurement of rate by the 
glucosone assay discussed above. This assay also provides a simple and reproducible 
means for quantifying amadoriase I activity, without the need for any specialized 
equipment, such as those needed for studies involving measuring oxygen 
consumption. 
OH 
~.O OHH \-O~N~ 
OH H 
Fructosyl propylamine 
Amadoriase 
HOfHC=~ + 
H OH 
H OH 
CHzOH 
Glucosone 
2x 
2x Amax 414 nm 
Figure 5.9: Coupled assay employed for the measurement of amadoriase 1 initial rate. 
After Childs and Bardsley (40). Abbreviations, ABTS, [2,2' -azino-di(3-ethyl-
benzthiazoline-6-sulphonic acid)]. Two molecules of ABTS react with one H20 2 
giving two molecules of radical cation. 
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The work undertaken here used the coupled assay approach, where amadoriase I was 
coupled to peroxidase. This enabled the detection of H20 2 consumption by the laller, 
measured by oxidation of a chromagen to yield a well-defined visible absorption 
spectrum. The chromagen selected was ABTS, due to its commercial availability and 
non-toxicity. In the presence of peroxidases, ABTS reacts with H20 2, produced by 
amadoriase I, to give the radical cation form of ABTS whieh absorbs at 414 nm 
(Figure 5.9). The assay for amadoriase I using ABTS has been previously peliormed 
as a discontinuous microtitre plate-bascd procedure (17). No real time assay for 
amadoriase is currently available and experiments outlined sought to remedy this. 
An existing assay was adapted to a time-resolved, spectrophotometer-based assay, 
which eliminates inaccuracies when measuring initial rate . An assumption that arises 
during discontinuous assays is that the reaction is linear for all of the time prior to the 
last measurement (39). It may he that the reaction is linear for only a portion of the 
time (Figure 5.10). The development of a continuous kinetic assay has allowed for 
the accurate determination of initial rates, and the detection of subtleties of the 
reaction, that may have been overlooked when using the previous methods. 
True initial rate 
X Single measurement 
Estimation of initial rate 
using a discontinuous assay 
Underestimation of initial rate 
Time 
Figure 5.10: Discontinuous assays that measure one point after period of time can 
lead to underestimation of initial rate. 
In addition to improving an existing assay, a new class of assay was developed. Until 
now, amadoriase I activity using glycated protein as a substrate, has been only tested 
by conventional methods such as measuring the consumption of oxygen (4), or the 
formation of glucosone (6). These methods measure substrate loss or product 
formation and only monitor the degree to which glycated protein substrate is turned 
oveL not whether the protein has been restored to the same structural and functional 
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state as it was prior to glycation. Using the conventional assays, false positives may 
occur. For example, a portion of Amadori products may be removed from a protein 
by the amadoriase I enzyme, but the remaining modified residues may be critical for 
catalysis and thus the protein will still be inactive. This is important when 
considering active site lysine and arginine residues, which may not be accessible to 
amadoriase, but their modification can severely decrease activity. 
These problems are circumvented using the novel method developed in this chapter, 
which involves, direct measurement of the activity of the glycated protein after 
treatment with amadoriase I. This method, employed in section 5.7, provides the 
critically important information from a therapeutic perspective: whether the protein 
has been restored to its native function after treatment with amadoriase 1. The assay 
was derived from the RNase A assay outlined in Chapter four. Using this assay, it 
was shown that on incubation with methylglyoxal, RNase A lost activity (Chapter 
four). Thus, after treatment of amadoriase I, it was hypothesised that RNase A would 
have at least some activity restored as the protein was deglycated (Figure 5.11). A 
mildly glycated RNase A substrate was prepared, which showed some loss in activity, 
and this enabled the analysis of whether amadoriase I could at least partially restore 
function to glycated RNase A (Figure 5.11). 
RNase A 
Activity 
RNase A + methylglyoxal 
~ 
+ Amadoriase I 
As shown in 
Chapter 4 
Time 
Partial return of RNase A 
activity as amadoriase I 
deglycates protein 
Figure 5.11: Hypothetical return of activity to RNase A is an indicator of the ability 
of amadoriase I to deglycate protein. 
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Before this deglycating capacity could be assessed, amadoriase I had to be over-
expressed, purified and kinetically characterised. To do this, the time-resolved assay 
was devcloped, which allowed for the accurate measurement of initial rate afforded by 
a continuous assay. Each of these steps is outlined in the following sections. 
5.4 Over-expression and characterisation of amadoriase I 
5.4.1. Transformation ofE. coli with the plasmid containing amadoriase 1 
The pET vector, containing the amadoriase I gene (l.S kb) ligated into the plasmid 
between the BamHI and NdeJ sites (Figure 5.12) (23), was kindly provided by Prof. 
Vincent Monnier. 
BamH1(319) 
_ _ - Ndel (1826) 
His-Tag (1857-1875) 
T7 promoter (1957) 
Figure 5.12: pET ISb vector map containing the amadoriase I insert. The 1.5 kb 
Amadoriasc I insert lies hetween Ndel and BamHI. Vector map was created using 
DNAMAN CLynnon Corporation, Quebec, Canada). The numbers in hrackets denote 
the base number. 
This plasmid was used to transform E coli BL21CDE3)pLysS for over-expression and 
purification of amadoriase 1. This strain was selected due to its compatibility with the 
pET vector in terms of the expression system (41). It contains a T7 polymerase gene 
on the bacterial chromosome, whose expression is induced by isopropyl ~-D-I­
thiogalactopyranoside, IPTG (Figure 5.13). Once induced with IPTG, T7 RNA 
polymerase is produced, which in turn binds to the T7 promoter of the pET vector that 
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controls the expression of the target gene, in this case, amadoriase I (Figure 5.13). E. 
coli BL21(DE3)pLysS offers the advantage that it contains a regulatory plasmid, 
pLysS (Figure 5.13), which contains a gene that produces a small amount of T7 
lysozyme to inactivate any basal levels of T7 RNA polymerase in the absence of 
IPTG (41). Thus, use of this strain allows for easy induction, tight control of 
amadoriase I expression (41), and rapid growth over a short period of time, allowing 
for efficient purification of amadoriase L 
iPTG InductiDJI 
t 
INACTIVE 
'" I 
I 
V 
T7/ysozyme 
I 
I 
T7/ysozym. 
gena 
Figure 5.13: The mode of expression of amadoriase 1 from coli BL21(DE3)pLysS 
containing the pET15b containing the amadoriase I gene (41). 
Antibiotic selection allowed for the strains that were successfully transformed by the 
pET vector (Camr Ampl The appropriate strain carrying the vector was cultured and 
the plasmid DNA purified. Initial problems were noted with the restriction digest 
pattern yielded on cleavage of the pET vector at BamHI and NdeI sites when it had 
been prepared from E. coli BL21 (DE3)pLysS (Figure 5.14 A). 
The restriction digest showed the presence of a 0.5 kb fragment and multiple bands 
around the pET vector size. This was due to the interference of the regulatory 
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plasmid pLysS . pLysS contains a BUll/HI site that will be recognised hy th e enlYl1les 
used in the restriction analysis experiments (42). Hov,·ever. ,tfter inspcc tion of the 
sequence of the parent plasmid, pACYC I ~4, and the T7 lysozy me sClj ucnl'c (inserted 
tl) create the pET vector). no other sites could be round that \vere cut hy these 
cn7ymcs , or their is()schiwmers, that could account for the 0.5 kb band. The multiple 
bands were me st like ly due to the presence of the uncut pLysS vector that has a size 
al around 4.9 kh. These were at ditlercl1t positiolls in thc gel reliltivc to thc cleaved 
vector due to the fact that the Ullcut DNA is in a superco iled form which can alleet its 
migrdtion through the gel (43). 
Transformation or f~ . coli XLI-Blue \\'ith the pET ISh vector Cilulll1venteu this 
prohlem. E coli XL I-Blue was se lec ted due to the fact tilat it does not contain any 
other plasmids that affce t the di gest pattern and it is a common strain used ro r ovcr-
expression or proteins (44 ). Antibiotic selection allowed lor the recovery o f E. coli 
XLI-Blue strains successfully transformed hy the pET vector (Tet', Amp') . The 
expected 1.5 kb insert for amadoriase I was then yielded on digest ion 01 the pET 
vector with Band-II and Ndel (Figure 5. 14B. Ia n I ). The appa rent hi gh molecul ar 
we ight fragments chown in lane 2 of' Figure 5.14B are indicative of uncut, superco il ed 
v cto r DNA, which ha e a differi ng mohili!y to the cut, linear DNA (43). 
A 
vector 
AmadOI lase I 
~w 
(kbl 
2]1 
9 4 
05 
44 
23 
20 
05 
B 
M 
uI IWI ... ~l~ 
ut lJt!clu 
Figure 5.14: Agarosc gel s or restric tion d ig sts of P T l 5h prepared rrom A, E. co ti 
BL2 1 ( DE3 )pLy~ : M, A Cllt w ith HilldHl : 1-6, DNA cut with NdeJ and BOil/ HI B. E. 
coti XLI -Bl ue: M , '"Ie cut with Hilld IIl; I , DNA cut \vith Ndel and BOil/ HI; 2, uncLlt 
DNA. 
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5.4.2 Amadoriase I purification procedure 
Prior to purification, the substrate of amadoriase I, fructosyl propyl amine, was 
synthesised by the method outlined in Takahashi et aT. (6), and characterised by 
NMR, mass spectrometry and melting point analysis. 
Purification of amadoriase I was undertaken as outlined by Wu et al. (23), with minor 
modifications. Purification was facilitated by the fact that the amadoriase I gene was 
expressed with a series of N-terminal repeats of His residues. Amadoriase I could 
therefore be purified by nickel chelating columns, where the His residues chelated 
with the nickel ions immobilized within the resin, to selectively retain the amadoriase 
I protein (45). The protein could then be eluted with imidazole, a competitor for the 
cation. This approach to purification is advantageous as it allows for purification to 
homogeneity in one step. A typical purification table from 1 L of culture is outlined 
in Table 5.2 and the SDS-P AGE gel that depicts the samples before and after elution 
through the column, is shown in Figure 5.15. After the column chromatography, only 
a 50 kDa band remained, which corresponded to the molecular weight of amadoriase 
1. 
Step Specific Yield Purification 
protein activity Activity 
(mgf (Units/'c (Unitslmg) % -fold 
Crude cell extract 109 18,400 169 100 1.0 
His-Trap column 1.5 10,200 6,970 56 40 
Table 5.2: A typical purification table for amadoriase 1. a As determined by Bradford 
assay (46). b One unit of enzyme activity is defined as the amount of enzyme that 
produces 1 /-LM of Hz02 per min. C Activity measured using the ABTS assay with 0.49 
mM fructosyl propylamine used as a substrate concentration of 10 x Km reported by 
Wu et al. (23). 
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55 r.Oa 
45 
135 
M AC 
Figure 5.15: SDS-P G gel ur amadoriase I pmification. M, Marker~ A, purified 
amadoriase I J'oUowing elution rrom the Ni2+ charged colulltn and subseljuent dia lysis; 
C, crude cell extract. 
During early stud ies . a dramatic drop in activity or allladoriasc I 'vvas noted during 
storage. pon storage or the protein at - 0° for 2 da ys. the enzyme was rOll nd to 
retai n 18(j( f it.' activity rdati v to when freshly prepared . Aftcr storage at 4u C ur 
-80°C ror 10 cla ys, the enz me retained 60 7r of act iv ity rdative to freshly prepared 
amadoria.'e I. This loss in activit was con "oll1itant with a deerl'Llse in protein 
concentration as measured by the Bradford assay_ suggesting that the prote in \Va~ 
unstable and degraded over time. This confirms other reports of instability of 
arnadoria~es at 4 and -200 e (5). Further studies showed that arter an initial drop in 
activity to nO Ie relative tn fresh amalioriase L the stUled protein retained this level oj' 
acti\ 'ity for around 2 tl,) -' munths Considering the above results. a storage 
tempnature -SO°C was selected for amadoriase I. 
5.5 Experiments to determine 1(" and ~'"'' of amadoriase I 
The enzymc n . as further characterised hy mcasuring its ,lpp,IITnt kinetic p'lramctc rs . 
Km. VI";" and k" 'I - using the tirne-resolved coupled assay outlined '180\'e . Prior to data 
collection, experiments were undertaken to conl'inn that enzyme concentration wa:-; 
proportional to rate (Figure 5.16). Results ror a typical experiment to determine K", 
,lilt! Vf1l :IX arc depicted in Figure 5.17. along with cOl11parison to existin~ litcr,ltlire 
valucs (Tahle 5.3)_ The suhstrate concentration range v.as hetween 6 K"l and 0.2 K"l 
or the literature value for fruclosyl propylaminc (23). Thi~ range was consistent with 
that stipulated hy Cornish-Bowdell for expniments to determine Kill ami V"I"\ (47). 
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The concentration of oxygen, the second substrate, dissolved in solution at 25°C was 
taken as 0.26 mM (48). 
0.01 
c: 0.008 
'E 
:J 0.006 
.;i 0.004 
\l.) 
& 0.002 
o 
o 
R2 = 0.9933 
50 100 150 200 
Enzyme concentration (fJg/mL) 
Figure 5.16: Enzyme concentration is proportional to rate. Rate is expressed as 
change in absorbance at 414 nm per min. Each point is an average of triplicate 
samples. Error is expressed as standard error of the mean for triplicate samples. 
It appears that the data gained from these experiments fit Michaelis-Menten kinetics 
well (Figure 5.17 A, C, D). The results for each replicate experiment were found to 
be highly reproducible from day to day. The residual plot (Figure 5.1 7 B) shows 
random distribution of residual rate when plotted against concentration of substrate. 
Any ordering of the plot can signify a number of differing aspects of the data 
including that the data are not normally distributed (49). The residual plot for 
amadoriase I does not show any apparent ordering, confirming that the data fit the 
normal distribution. 
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Figure 5.17: Michaelis-Menten kinetics of amadoriase 1 expressed as A, a direct 
Michaelis-Mentcn plot; B, a residual plot; C, a Lineweaver-Burk plot; 0, an Eadie-
Hofstcc plot. R2 of fiL to Michaelis-Menten equation for A, B, 0 = 0.98, P < 0.05. 
Each data point is an average of three readings. 
Assay system K app kent app kcarlKrn rll 
(mM) (sec -I) (M-1 -I) sec 
Glucosone (26) 0.049 1.96 1.31 x 10-" 
Amplex red (25) 0.023 5.8 3.86x j 0-" 
(H20 2 produclion) 
Th' a IS assay 0.0 I I ± 0.0004 3.5 ± 0.3 3.25x105 ± 0.24x105 
Table 5.3: ApparcnL kinctic parameters of amadoriasc 1. a Values are an average of 
triplicate experiments, with duplicate readings of each point within the experiments. 
An apparent KI11 of I I jlM for fructosyl propylamine was calculated from these 
experiments. This shows that half of the maximal velocity of amadoriase I is reached 
at 11 jl-M fructosyl propylamine, thus amadoriase I has a high affinity for fructosyl 
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propylamine. The Michaelis constant reported here is a factor of 2 and 5 lower than 
those previously reported (Table 5.3). This is consistent with previous research 
under-estimating the true initial rate measured as detailed above (Figure 5.10). 
An apparent keat of 3.5 sec-1 was also calculated from the data from these experiments. 
kcat represents the maximum number of substrate molecules converted to products per 
active site per unit time, or the number of times the enzyme turns over per unit time 
(50), at a concentration of 0.26 mM O2• kcaJKm is a measure of catalytic efficiency 
with catalytically "perfect" enzymes operating around 108_109 and those at 105, such 
as amadoriase, still considered very efficient at binding and turning over the substrate 
(50). 
5.6 Substrate specificity of amadoriase I 
To date, amadoriase I work involving substrate specificity has focused on the 
structure of the sugar residue that constitutes part of the substrate (17). Since, 
Amadoriase I shares 22% homology with monomeric sarcosine oxidase isolated from 
Bacillus sp. (section 5.3.1) (23), the possibility of amadoriase I having a capacity to 
tum over any of the substrates of sarcosine oxidase was tested. A number of these 
substrates were tested and the results are summarised in Table 5.4. Each sample was 
trialled at 10 times the quoted literature Km or Kd in order to ensure that the substrate 
tested was not rate-limiting. 
Substrate Literature Km 
(mM)a,b 
N-methyl-DL-alanine 3.3 ± 0.2 (52) 
6.8 (53) 
Sarcosine 4.5 ± 0.1 (52) 
Butyrate 118 (51) 
L-Proline 130 10 (51) 
N-methyl-DL-valine 173 (53) 
Glycine 359 (51) 
[Assay] (mM) 
27.2 (4xKm of ref 52) 
45 (lOxKm of ref 51) 
118 (lxKd ref 53) b 
260 (2xKm of ref 51) 
173 (lxKm of ref 52) 
359 (lxKd of ref 53) 
Substrate for 
Amadoriase 1'7 
No 
No 
No 
No 
No 
No 
Table 5.4: Substrate specificity of amadoriase I tested using sarcosine oxidase 
substrates. a Bold type is Kd data rather than Km data. b Kd in this case is defined as 
the complex dissociation constant, with the complex being the enzyme with substrate 
bound (53). 
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Amadoriase I did not appear to tum over any of the sarcosine oxidase substrates tested 
(Table 5.4). This has also been reported for the enzyme isolated by Yoshida et ai, 
who found that neither of the amadoriases, isolated from Aspergillus and Penicillium, 
were active toward sarcosine (14). 
Fructosyl propyl amine was also tested as a substrate for sarcosine oxidase (obtained 
commercially from Bacillus sp.) in a reverse experiment. Sarcosine oxidase did not 
show any ability to tum over the substrate for Amadoriase I. 
5.7 Does amadoriase return function to mildly glycated protein? 
5.7.1 Preparation of a mildly glycated protein 
From initial work (Chapter two), it was found that immediately following treatment of 
RNase A (20 mMamine) with methyl glyoxal (10 mM), approximately 10% of lysine 
residues reacted (Figure 5.l8), This degree of modification corresponds to around a 
20% drop in activity of RNase A. 
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Figure 5.18: Percentage lysine remaining on incubation of RNase A with 
methyl glyoxal. Grey bars depict methyl glyoxal and RNase A incubations, Black bars 
represent RNase A only incubations. Percentages are calculated relative to the 
appropriate RNase A only time controls. Error is expressed as standard error of the 
duplicate experiments with duplication of each sample within the experiment. 
ChojJ/a Five 14() 
These experiments \vere carried Oll t in phusphate huller due til e ract thut amadori asc 
required st~lhilisatlOI1 during experiments, Sl'lhsritution ur \~' atcr with phosphate builn 
in incubations appeared t slo th break-down or R 'a,-; e A in incubated con trol s 
(lver timc (Chn pte r two ). 
5.7.2 Experimental approach to measuring amac/oriase I activity 
Th e '{({hilil\' of 1I11J({rioriast' I during (!urlr cxpcriJllerz/s 
Initial attempts to determine whether amadori ase I returned activity to g lycated Rl\asl' 
/\ encountered difriculties due to the unstable nature or alll~ldoriase l. S-PAG 
analysi s or ea rly ~ periments confirmed that amadori ase vvas hreaking dmvn during 
inl'uhation ~It 25°C for 6 hours. prior w assay (Figu r 5.1l)). 
55 ~Da 
29 
M 2345678 
Amadonase I 
RNaseAdmer 
RNase A monomer 
Degraded proteIn 
Eigure 5.19: All X- 16()( SDS-PAG ~ gel of incuhation.,> undcrtak n to assess 
amallo riase I stability during incubations. M . Marker; I. methylglyoxal + RNase A 
time 0; 2. RNase A onl y ti me 0: 3. mcrhylgl oxal + R <I .' C;' + amadoriase I time 0; 
4, RNase A + amadoriase r time 0: 5. mcthylglyoxal + R ase A I h with ~ubseqUL:nl 
incuhatiun ror 6 II at 25°C: 6, RNa::;e A only I II with subsequent incuhation for 6 h at 
4°C: 7. lllcthy le: lyoxal + RNasc A + amaduriase [ I h vvith suhsequent incuhation for 6 
l! at 25" : 8, RNase A mly + amadori ase T I h, with ~uhscLJucnt incubation fur () h at 
25°C. 
This nce ssitatcd ~I cI ;JlIge in conditions resulting in the in 'uhation oj' the glycat ed 
~ LIbst rat e for longer Li me pe riods at a lower temperature (4') ). Figure 5. I ( ais() sho\.\~ 
I n increase in di mer aft er the incu hation periods with IHl'lhyglyoxal and the ir 
intensiti ·'~ ur equi valen t in the absence (I an 5) or PI' sence of 'llnadoriase J (lane 7 ), 
relative to the appropriate controh (lanL:s () ~lt1d tI). This demonstrale~ that only a 
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small degree of crosslinking of RNase A by methylglyoxal is occurring, as anticipated 
(Chapter two) . 
The modified method involved incubation of RNase A with mcthylglyoxal in 
phosphate buller for I hour (to form the mildly glycated substrate) . Amaduriase I was 
then added and the samples incubated at 4"C for 3 days. SOS-PAGE confirmed that 
a.llladoriase I was still present in incubation mixtures after 3 days at 4"C (Figure 5.20). 
55 kDa 
Amadori.3se I 
29 RNase A dir lei 
RNase A rna nomer 
3 4 5 6 7 8 
Figure 5.20: An 8-16% SOS-PAGE gel oj" incubations undertaken to assess 
amadoriase L stahility during incubations. M, Markee I, methylglyoxal + RNase A 
time 0; 2, methylglyoxal + RNase A + amadoriase I time 0; 3, RNase A only time 0: 
4 .. RNase A + amadoriase 1 time 0; 5, methylglyoxal + RNase A I h with suhsequent 
incuhation for 3 days at 4°C; 6, methylglyoxal + RNase A + amadoriase I I h with 
subsequent incubation ror J days at 4°C ; 7, incubated control I h with suhsequent 
incubation ror 3 days at 4"C; ~, incubated control + amadoriase I I h. with suhsequent 
incuhation for J days at 4"C. 
The ('ulalylic efJicil'l1cv ojRNuse Aj()llovving g/vcl.1lion und suhsequt'lZl Ireulllll'111 wilh 
{f/7wdoriu.l(, I 
Incubations were included where phosphate buffer was substituted for amadoriase to 
gauge the extent or glycation during the refrigeration period. and to provide a sample 
ror direct comparison with those that contained amadoriase. To obtain a reference 
point to determine the extent or glycation over the initial I hour period or incuhation, 
samples were prepared that had been rrozen immediately on addition or 
methylglyoxal to RNase A (Amadoriase 1 or phosphate was also added at the time or 
rreezing). The activity of RNase A was then measured. If the amadoriase I had been 
successrul in deglycating RNase A. it was expected that RNase A, having been 
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inactivated on glycation by methylglyoxal, would have at least some of its activity 
restored. 
Figure 5.21 shows that RNase following incubation for 1 hour at 37°C in the presence 
of 10 mM methylglyoxal, decreased in activity relative to the protein-only control 
incubated for the same time period (MRI vs. IC 1), confirming the results gained in 
Chapter four with higher concentrations of methylglyoxal. A significant difference in 
the mean activity of protein that had been incubated in the presence of methyl glyoxal 
over time was noted, relative to those incubations that had not (P<O.05) (see 
Appendix three for ANOVA table). Critically, although addition of amadoriase I 
appeared to increase the activity of RNase A, the difference was not significant 
(P=O.l, Appendix three) (e.g. MR(A)l vs. MRl). 
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Figure 5.21: Percentage activity of RNase A in amadoriase I experiments. MR(A)l, 
methylglyoxal + RNase A incubated for 1 h with subsequent addition of amadoriase I; 
IC(A)l, RNase A only incubated for 1 h with subsequent addition of amadoriase I; 
MR I, methylglyoxal + RNase A incubated for I h with subsequent addition of 
phosphate buffer; ICI, RNase A only incubated for 1 h with subsequent addition of 
phosphate buffer, MR(A) 0 , IC(A)O, MRO, ICO. Exactly as above for previous 
incubation but samples were frozen at time ° instead of a 1 h incubation. Activity is 
expressed as a percentage relative to the appropriate controls and is an average of 4 
experiments (with duplicate readings within each experiment). Error is expressed as 
standard error of the mean for 4 experiments. 
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The focal point of this chapter was to assess whether amadoriase I could effectively 
use mildly glycated protein as a substrate. The results reported here suggest that this 
was not possible, which may be due to a number of reasons. Firstly, the amadoriase I 
was incubated in the presence of possible umeacted methylglyoxal, which may have 
resulted in the glycation and subsequent inactivation of amadoriase 1. From analysis 
of SDS-PAGE gels, it appears that the amadoriase I had not been crosslinked, but 
non-crosslinking methyl glyoxal modifications may still exist. More critically, 
dialysis of the glycated sample to remove umeacted methylglyoxal and subsequent 
addition of amadoriase I did not appear to cause a difference in results, suggesting that 
this is unlikely. 
Secondly, the amadoriase I may have not recognized the products from the reaction of 
methylglyoxal with RNase A-bound lysine, even in a mildly glycated state. Finally, if 
the production of a mildly glycated protein results in a small drop in activity, it can be 
difficult to determine whether any change on addition of amadoriase is indeed a true 
result or within experimental error of the experiment. Future work must be 
undertaken to investigate all of these possibilities. 
Wu and Monnier have recently reported that charges on the surface of the protein 
amadoriase I preclude binding of amadoriase I to proteinaceous substrate (54). After 
amidation of the glycated protein carboxylate groups, amadoriase I is able to turn over 
glycated protein substrate (54). It is proposed that amidation changes the surface 
electrostatic interaction between substrate and enzyme. 
5.8 Application of novel assay methods 
The two novel methods outlined here were used in studies detailed in appendix four 
and five. The first study involved the time-resolved coupled assay, which was used to 
test the activity of two mutants of amadoriase I, H357N and S370A, (Appendix four). 
Both enzymes were found to be catalytically inactive by this method (Appendix four). 
Further work must be undertaken to establish whether the drop in activity is due to 
specific active site chemistry or protein misfolding. 
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The second assay method, involving the RNase A assay adapted from chapter four 
that was used in this chapter to assess amadoriase I activity on glycated protein, was 
employed experiments performed to isolate an enzyme that could act on glycated 
protein (Appendix five). Experiments outlined in appendix five examined isolates 
from raw milk for such enzymes, as milk is rich in many of the constituents of the 
Maillard reaction (Appendix five). From initial screening, it appeared that a 
Pseudomonad potentially possessed deglycating activity. Both assays developed in 
this chapter were performed to assess this deglycating activity, using a crude extract 
of this micro-organism. The time-resolved coupled assay used for assaying the 
catalytic activity of the amadoriase I mutants showed no activity in the crude using 
either fructosyl propylamine or the glycated casein as substrates. However, as 
glycated protein was the initial substrate used for culture of the Pseudomonad, the 
ability of the crude mixture to return activity to glycated RNase A was assessed. The 
second assay that was used to assess activity on glycated RNAse was employed to 
corroborate the results obtained using the time-resolved assay. Experiments using this 
assay showed that activity was not returned to glycated RNase A that was incubated 
with the crude mixhlre. These results suggest that the crude mixture did not contain 
an enzyme with deglycating ability. 
5.9 General discussion and conclusions 
This chapter has involved the development of two new assays to measure amadoriase 
activity in a variety of situations. The first, a time-resolved coupled assay to measure 
kinetic parameters of amadoriase I resulted in the generation of a Km of 11 flM for 
fructosyl propyl amine and a kcat/Km of 3.5x105• These both differ with regard to the 
published values for this enzyme. The lower than previously published Michaelis 
constant may be due to the correct estimation of initial rate that is provided by the 
time-resolved assay developed here. Arnadoriase I, with a Km in the low micromolar 
range for fructosyl propyl amine and a kcat/Km in the region of 105, has a high affinity 
for its substrate which is rapidly turned-over. This assay proved to be invaluable for 
purification and substrate specificity studies of amadoriase 1. It has also aided the 
determination of the conditions in which amadoriase I is most stable for storage and 
experiments. 
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The second assay developed in this chapter, allowed for the determination of the 
direct effect amadoriase I had on the activity of a glycated protein. This approach 
provides more physiologically relevant information such as whether the function of 
the protein has been restored following incubation with amadoriase I. Previously 
published methods to ascertain the activity of amadoriase I on glycated protein have 
involved measurement of product formation or a decrease in substrate (4,6). These 
assays are unable to show what effect the amadoriase I has had on the substrate 
protein, beneficial or otherwise. Although amadoriase I did not restore function to 
RNase A, this method has provided a new tool to search for enzymes that can 
deglycate protein from other organisms. The inability of amadoriase I to act on 
protein treated with one of these dicarbonyls, methyl glyoxal , is not advantageous 
from a therapeutic point of view if these are physiologically important species that 
modify protein. 
In summary, this chapter has reported two novel assays to assess the activity of 
amadoriases under a variety of conditions. These have been successfully employed in 
site-directed mutagenesis studies and have provided useful tools to assess the 
deglycating ability of amadoriase I using glycated protein as a substrate and the search 
for amadoriase activity from a bacterium isolated from raw milk. 
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Chapter Six 
Summary and conclusions 
This thesis sought to examine a wide range of aspects of the Maillard reaction, with 
an emphasis on the amino acids required for protein crosslinking, and the effect it had 
on the function of a model protein, ribonuclease A. Three a-dicarbonyls were 
selected to achieve this task: the physiologically relevant glyoxal and methylglyoxal, 
and the structurally related diacety1. One of these, methylglyoxal, was used in later 
stages of this thesis, in studies undertaken to reverse the early stages of the Maillard 
reaction on proteins, using amadoriase I. To monitor this, two novel assays were 
successfully developed. 
During the course of this thesis, diagnostic tools were developed to monitor the 
progression of the Maillard reaction. Chapter two assessed a number of 
methodologies for the experimental conditions required in this thesis. The initial 
approach, which measured the decrease in a-dicarbonyl concentration over time, met 
with limited success. This was attributed to the reactive nature of the a-dicarbonyl 
compounds. A measure of lysine concentration over time during incubation with the 
three a-dicarbonyls was more successful. A dramatic decrease in the lysine residues 
within RNase A following incubation with methylglyoxal was observed. A decrease 
in lysine residues was also observed for glyoxal and diacetyl, albeit at a much slower 
rate than methylglyoxal. The order of a-dicarbonyl reactivity (i.e. methyglyoxal » 
glyoxal ;:::; diacetyl) was mirrored by SDS-P AGE analysis, another method that was 
employed to measure the extent of the Maillard reaction. The extensive crosslinking 
observed on incubation of methyl glyoxal with RNase A was almost immediate. 
Glyoxal and diacetyl again showed much less reactivity, with regard to crosslinking. 
The two methodologies for determining the extent of the Maillard reaction in vitro, 
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lysine analysis and SDS-PAGE, provided useful tools for the experiments that were 
undertaken in subsequent chapters. 
The Maillard reaction has attracted a great deal of attention from those working in the 
medical arena. Central to this study is the effect that the products have on their target 
biomolecules such as circulatory, structural or enzymatic proteins. Little is known 
about the function of these proteins when they are crosslinked as advanced glycation 
end products. However, a class of inhibitors has been developed that is borne out of 
the assumption that cleaving protein crosslinks will return the protein to its native 
function. Furthermore, the amino acids required for the crosslinking process to occur 
have not been examined in detail. Chapters three and four sought to address the issue 
of specificity of the crosslinking reaction and the relationship of crosslinking to 
function of a model protein. 
In this work, the amino acid requirements for crosslinking by the three a-dicarbonyls 
have been studied. Using carefully selected proteins, a lysine-free protein (that 
contained arginine) and an arginine-free protein (that contained lysine), the amino 
acid requirements for crosslinking were addressed. Interestingly, methylglyoxal only 
showed a capacity to crosslink the arginine-free peptide and could not crosslink the 
lysine-free peptide. Glyoxal however, could not crosslink the arginine-free peptide, 
but could crosslink the lysine-free peptide, which was later found to occur via the N-
terminus of the protein. Diacetyl did not show any capacity to crosslink either 
protein, suggesting other routes to crosslink formation that account for the results 
observed during glycation of RNase A. These results demonstrate, for the first time, 
that either a lysine or an N-terminus is essential for crosslinking by a-dicarbonyls to 
occur. Also, arginine was not essential for crosslinking by a-dicarbonyls, under the 
experimental conditions employed in this work. 
The underlying assumption that crosslinking will affect the function of a protein, has 
not been rigorously tested. From work detailed in this thesis it is evident that a loss in 
activity is observed during crosslinking of RNase A, with the three a-dicarbonyl 
compounds. However, it appears that inactivation of protein precedes crosslinking. 
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Thus, non-crosslinking modifications by a-dicarbonyls may be sufficient to inactivate 
protein, rendering crosslink breaking therapeutics ineffective. 
As more becomes known about the complexities of the Maillard reaction, inhibitors 
have been designed at a variety of points in the reaction scheme. One class of 
inhibitors, the amadoriases, provides an enzymatic means for reversal of the early 
stages of the reaction. However, a difficulty has arisen that these cannot act on 
heavily glycated protein. Whether amadoriase I could act on mildly glycated was not 
known. Experiments undertaken in Chapter five sought to investigate this. 
A bottleneck in characterisation of enzymes has been the development of an 
appropriate enzyme assay, and the amadoriases are no exception. Chapter five details 
the successful development of two novel assays to aid further characterisation of the 
amadoriases. The first assay was a time-resolved coupled assay and was used to 
determine the kinetic parameters of amadoriase I. Using this assay, a Km of 11 11M, a 
(kcat) of 3.5 sec-I and a kcaJKm 3.25 x 105 M-1 sec-I were obtained. All of these values 
differ to those that have been previously published and may reflect the determination 
of a true initial rate, rather than an underestimated initial rate, which can result from 
discontinuous assays that have been used in the past. This assay was successfully 
used to monitor the catalytic activity of two amadoriase I mutants, H357N and 
S370A. Both of these enzymes were found to be catalytically inactive following 
mutagenesis. Further studies need to be undertaken to determine whether these amino 
acids are critical for catalysis or that the mutations have caused the protein to misfold. 
The second assay was devised to measure the activity of amadoriase I on glycated 
protein. Traditional assays have generally measured the formation of product or 
consumption of substrate. However, in the case of glycated protein, these do not 
show whether the substrate protein has had its activity restored after deglycation by 
amadoriases. Therefore, the assay outlined in Chapter five sought to address this by 
directly measuring the activity of glycated RNase A before and after treatment with 
methyl glyoxal. It was hypothesised that after incubation with amadoriase I, at least 
some of the activity of RNase A would be restored. However, the results did not 
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show a return to function for RNase A following its treatment with amadoriase I that 
was greater than the error in the measurement. 
Finally, the RNase A assay was used to search for an amadoriase-like enzyme from 
Pseudomonas fluorescens that had been cultured on glycated protein as a sole carbon 
source. However, the crude extract of this Pseudomonad did not show any such 
deglycating ability using either this assay, or the time-resolved assay that was used in 
the amadoriase I mutagenesis studies. 
In summary, this thesis has successfully determined the amino acid requirements for 
protein crosslinking by a-dicarbonyls to occur and the effect crosslinking has on the 
function of a protein. The data presented here will inform the future design of 
Maillard inhibitors. Finally, the development of two novel assays to measure 
amadoriase activity has provided useful tools for researchers working in this 
burgeoning area. 
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hapter Seven 
Experimental 
7.1 Materials 
Unless otherwise stated, aU compounds were purchased from either Sigma-Aldrich 
Pty. Ltd (Australia), Sigma-Aldrich Corp. (USA), BDH Laboratory Supplies, 
Invitrogen, Strata gene or Roche and were analytical grade. Solvents were generally 
purchased from BDH chemicals and were analytical grade. 
RNase A (Type X-IIA, from bovine pancreas), renm substrate tetradecapeptide 
(porcine) and somatostatin (synthetic) were purchased from Sigma-Aldrich Corp. 
(U.S.A.) 
Centrifugation of large volumes (>200 mL) was undertaken using a Heraeus Sepatech 
20RS centrifuge using a Sorval rotor, GS-3 (6 x 500 mL fixed angle rotor, max g-
force 13,680 x g). Centrifugation between 10-200 mL was undertaken using an 
Eppendorf 5403 centrifuge (6 x 85 mL fixed-angle rotor, max g-force 15,000 x g). 
The same centrifuge was employed to perform refrigerated centrifugation steps from 1 
IlL-200 mL of solution (30 x 1.5 mL fixed-angle rotor, max g-force 20,000 x g). RT 
spins under 1.5 mL were undertaken using a Heraeus Biofuge 13 or an Eppendorf 
Mini-Spin Plus centrifuge (12 x 1.5 mL fixed-angle rotor, max g-force, 14,000 x g). 
8-16 and 4-20% SDS-PAGE gels were purchased from Gradipore (NSW, Australia). 
Electrophoresis was performed using either a Bio-Rad mini PROTEANIl) 3 Cell gel kit 
or a Bio-Rad PROTEAN® II xi Cell kit in conjunction with either a Bio-Rad 300 or 
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1000 Powerpac unit. SDS-P AGE gel images were captured using a Nikon D Ix digital 
camera fitted with a Nikon 60 mm macro lens. 
Agarose gel electrophoresis was undertaken in a Hoefer HE33 Mini Horizontal 
Submarine Unit, in conjunction with a Bio-Rad 300 Powerpac unit. Agarose gels, 
following staining, were visualised with an Electrophoresis Documentation and 
Analysis System (Kodak Technologies), comprised of a Kodak digital camera and a 
Sigma T2210 UV transilluminator (302 nm), interfaced with a computer loaded with 
Kodak Digital Science 1 D software. 
Kinetic measurements were carried out using a Hewlett Packard 8452A or 8453 
diode-array spectrophotometer interfaced with a personal computer loaded with UV-
Visible Chemstation software (Agilent Technologies). Temperature controlled 
experiments were undertaken using a water bath attached to the spectrophotometer, 
the temperature was maintained by a He'idolph temperature controller. 
Standard colorimetric assays were undertaken usmg either the above 
spectrophotometers or a Bio-Rad SmartSpec 3000. 
All cuvettes, unless otherwise specified, were 1 cm path length plastic cuvettes from 
Sarstedt Inc., supplied by Global Science. 
Unless otherwise stated, the pH of incubations was adjusted usmg Merck 
Universalindikator pH 0-14 strips. pH adjustment of buffers was performed using an 
UltraBasic Benchtop Meter VB-I 0 with the pH meter calibrated against pH standards 
of 4, 7 and 10. Some pH adjustment was also undertaken using the 718 STAT Titrino 
pH Stat (Metrohm, Switzerland) equipped with a magnetic stirrer. The pH stat was 
controlled by a computer running Tinet v.2.3 software. 
For purification of amadoriase I, Pharmacia Hi-Trap Chelating HP columns were 
employed (Amersham Biosciences). The pumps used to load and elute the columns 
were Gilson Miniplus3 peristaltic pumps. 
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Lyophilisation was undertaken usmg a centrifugal freeze drier (Edwards High 
Vacuum Ltd.). 
The pET I5b vector encoding the amadoriase I gene was a kind gift from Prof. 
Vincent Monnier (Case Western University, Cleveland, Ohio). The bacterial strain 
coli BL2I(DE3)pLysS was kindly supplied by Dr 1. Klena. (University of 
Canterbury). E. coli XL-IBlue supercompetent cells were obtained from Stratagene 
(Global Science, New Zealand). P. jluorescens for amadoriase-like enzyme study 
was isolated by Sarah Day (M.Sc. student, University of Canterbury). 
Nuclear magnetic resonance spectrometry (NMR) was recorded on a Varian Unity 
300 instrument operating at 300 MHz for IH nuclei at 23°C. Multiplicities are 
denoted as singlet (s), triplet (t), multiplet (m) and sextet (sext). 
Melting points were recorded on an electrothermal melting point apparatus and are 
uncorrected. 
Sonication was performed using a Sonics Vibracell sonicator fitted with a CV33 
model probe. 
Fluorescence measurements to detect fibril formation were made using a Varian Cary 
Eclipse fluorescence spectrophotometer interfaced with a PC loaded with Cary 
Eclipse version 2 operating software. Fibrils, on staining with Congo Red, were 
visualised using a cross-polarising microscope (J. Swift and Son, London) fitted with 
45x objectives (NA 0.85). 
Primers for amadoriase I mutagenesis were HPLC grade and purchased from 
Invitrogen (Australia). The QuickChange site-directed mutagenesis kit for the 
creation of amadoriase I mutants was purchased from Stratagene. 
Sterilisation of glycated protein substrate was undertaken using an Ultra-Ium UVC 
515 Ultraviolet multilinker unit (254 nm) at 120,000 IlJ/cm2. 
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7.2 Methods for experiments outlined in Chapter two 
7.2.1 Preparation ofmodel system incubations 
Lysine and a-dicarbonyl incubations 
The adjustment of pH, incubation, storage and controls for all incubations were 
exactly as described below for all the three a-dicarbonyls, methyl glyoxal, glyoxal and 
diacetyl. All incubations were repeated at least in triplicate. 
An equal vol (50 JlL) of a 260 mM a-dicarbonyl solution (pH 7, adjusted with NaOH) 
was added to an equal vol (50 JlL) of 260 mM lysine (pH 7, adjusted with NaOH) to 
give final equimolar concentrations of 130 mM a-dicarbonyl and lysine. The solution 
was incubated at 37°C for the prescribed period of time and stored at -20°C prior to 
analysis. Lysine only controls were prepared exactly as above, with substitution of 
dH20 in place of a-dicarbonyl. One control was frozen immediately in liquid 
nitrogen, whilst the other was incubated with the a-dicarbonyl-containing samples 
and removed at the conclusion of the incubation. An a-dicarbonyl only control was 
prepared by substitution of dH20 in place of lysine and incubated for the same time 
period as those containing lysine. 
RNase A and a-dicarbonyl incubations 
For each a-dicarbonyl, all incubations were prepared at least in triplicate. RNase A 
was solubilised in dH20 to give a final concentration of 50 mg/mL (pH 7, adjusted 
with NaOH). To this, an equal vol of a 260 mM a-dicarbonyl solution (pH 7, 
adjusted with NaOH) was added to give final concentrations of 25 mg/mL RNase A 
(20 mM amine) and 130 mM a-dicarbonyl. The amine concentration of the protein 
was calculated by dividing the mass (25 mg) by the MW of RNase A (13680) and 
multiplying by 11 (10 free lysine groups and 1 N-terminus in RNase A). Solutions 
were incubated at 37°C for the prescribed period of time and stored at -20°C prior to 
analysis. RNase A controls were prepared by substitution of a-dicarbonyl with dH20. 
One control was frozen immediately in liquid nitrogen, whilst the other was incubated 
with the a-dicarbonyl-containing samples and removed at the conclusion of the 
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incubation. An o.-dicarbonyl only control was prepared by the substitution of RNase 
A for dlhO and incubated for the same time period as those containing RNase A. 
For experiments where the effect of phosphate on the rate of crosslinking and lysine 
concentration was assessed, the above incubations and controls were prepared. 
However, final concentrations of 10 mM (instead of 130 mM above) methylglyoxal 
and 25 mg/ml RNase A were prepared. Also, 100 mM sodium phosphate, pH 7.4, was 
substituted where dIhO was employed in previous incubations and controls. 
7.2.2 Determination of a-dicarbonyl concentration ill incubations prepared in 7.2.1 
o-Phenylenediamine assay (oPDA) (1) 
Construction of calibration curves 
From a 500 11M standard solution of o.-dicarbonyl, a range of concentrations were 
prepared in triplicate in dH20 (Table 1.1, middle column). Each of these solutions 
was diluted 1:1 in 10 mM o-phenylenediamine (oPDA) prepared in 80% acetic acid 
(Table 7.1, right hand column), incubated at 50°C for 10 min and the absorbance of 
the sample recorded in a spectrophotometer blanked to dH20. Amax varied for each 
dicarbonyl. The methylglyoxal-containing test solution was measured at A32Q, glyoxal 
at A318 and diacetyl at A328• Controls where 80% acetic acid was substituted for 0.-
dicarbonyl were undertaken to exclude the possibility that change in absorbance was 
due to colouration of oPDA itself. Absorbances were plotted against varying 
concentration and a calibration curve and R2 value generated. 
o.-dicarbonyl 
Methylglyoxal 
Glyoxal 
Diacetyl 
[o.-dicarbonyIJ prior to 
dilution in oPDA (11M) 
50-400 
50-500 
50-300 
[o.-dicarbonylJ after 
dilution in oPDA (11M) 
25-200 
25-250 
25-150 
Table 7.1: o.-Dicarbonyl concentrations used for the oPDA assay 
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Determining a.dicarbonyl concentration of samples prepared in 7.2.1 
Methyl glyoxal, glyoxal and diacetyl-containing incubations were diluted to 
concentrations of 300 11M, 400 11M and 250 11M in dH20 respectively. These 
solutions were prepared in triplicate, and further diluted 1: 1 in 10 mM oPDA prepared 
in 80% acetic acid and assayed as outlined above. These concentrations were selected 
following inspection of the calibration curves prepared above. The above no-
dicarbonyl controls were again included. Furthermore, controls that did not contain 
oPDA (80% acetic acid in place) were included to assess the interference of the a-
dicarbonyl compounds and/or the products formed on the reaction of RNase A with 
a-dicarbonyl in the assay. a-Dicarbonyl concentration was then interpolated from the 
constructed calibration curve. 
p-Hydroxybenzoic acid hydrazide (HBH) assay (2) 
Two varying approaches to a-dicarbonyl estimation by the HBH methods are detailed 
in this section. These involved the use of two forms of the derivitising agent (Table 
7.2). 
Reagent 
Trisodium citrate dihydrate (Na3C6H607.2H20) 
CaCh 
NaOH 
Sodium sulfite (Na2S03) 
HBH 
HBH reagent #1 
[Final] (mM) 
20 
10 
300 
50 
50 
HBH reagent #2 
[Final] (mM) 
50 
20 
500 
100 
100 
Table 7.2: Reagents and concentrations required for preparation ofHBH. 
Reagents were mixed in descending order in dH20 due to solubility issues. The above 
HBH solutions were prepared fresh prior to assay and kept in the dark before each 
assay. 
Due to the varying concentration of derivitising agent, each method involved differing 
ranges of a-dicarbonyl concentration. Each assay method wil1 be outlined below. 
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Construction of calibration curves using HBH reagent #1 
10 ilL of a range of a-dicarbonyl concentrations (Table 7.3, middle column) were 
mixed with 5 mL of HBH reagent #1 to give the final concentrations quoted in the 
right hand column of Table 7.3. 
a-dicarbonyl 
Methyl glyoxal 
Glyoxal 
Diacetyl 
[Initial a-dicarbonyl] (mM) 
5.5-33.4 
2.8-30.8 
4.6-32.4 
[Final a-dicarbonyl] (IlM) 
11-66.8 
2.8-61.6 
9.2-64.8 
Table 7.3: The range of a-dicarbonyl concentrations used for the HBH assay method 
#1 
Samples were heated at 100ce for 5 min then cooled on ice. Once cool, samples were 
mixed and the ~zo recorded in a spectrophotometer, blanked against dHzO. dHzO 
was substituted for a-dicarbonyl to exclude the possibility that change in absorbance 
was not due to colouration of HBH itself over time. Absorbances were plotted against 
varying concentration and a calibration curve and RZ value generated. 
Construction of calibration curves using HBH reagent #2 
1 mL of a range of a-dicarbonyl concentrations (Table 7.4, middle column) were 
mixed with 2 mL of HBH reagent #2 to give final concentrations quoted in the right 
hand column of Table 7.4. The remainder of the assay and controls were carried out 
as outlined for the method employed for the HBH reagent. 
a-dicarbonyl 
Methylglyoxal 
Glyoxal 
Diacetyl 
[Initial a-dicarbonyl] (pM) 
22.2-111 
14.2-128.5 
12-126 
[Final a-dicarbonyl] (PM) 
7.4-37 
4.7-42.8 
4-42 
Table 7.4: The range of a-dicarbonyl concentrations used for the HBH assay method 
#2 
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Determining u-dicarbonyl concentration of incubation samples prepared in 7.2.1 
The concentrations, following dilution in HBH, outlined in Table 7.5, were employed 
for each u-dicarbonyl for both variants of the HBH assay. Following inspection of 
calibration curves, appropriate concentrations of each u-dicarbonyl (after dilution in 
HBH) were selected for both HBH methods as outlined in Table 7.5 
u-dicarbonyl 
Methyl glyoxal 
Glyoxal 
Diacetyl 
[Final] method #1 (JlM) 
55.6 
55.4 
55.6 
[Final] method #2 (PM) 
37.1 
37.1 
37.1 
Table 7.5: u-Dicarbonyl concentrations used for the HBH assay of samples prepared 
in 7.2.1 
Incubation samples were prepared and measured as outlined for the calibration curve 
for each respective assay (method 1 or 2). A no sample control was again included as 
for the calibration curves. Controls that did not contain HBH were included to assess 
the interference of the u-dicarbonyl compounds and/or the products formed on 
reaction of RNase A with the u-dicarbonyl. A background reading, as mentioned for 
the calibration curves, was also taken. Experiments were repeated at least in 
triplicate. 
7.2.3 Determination of protein concentration ill RNase A-containing incubations 
prepared in 7.2.1 (3,4) 
In some experiments, dialysis was required to remove any remaining umeacted u-
dicarbony1 from incubations containing RNase A. This involved dialysing the sample 
against 1 L of cold (4°C) dH20 OIN, with at least one change of fluid in 7,000 
MWCO dialysis cups (Pierce, USA). Protein concentration was then quantified by a 
derivation of the method outlined in the Bio-Rad protein assay instruction manual, 
adapted by Reid (4). 
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Construction oj a calibration curve 
RNase A standards ranging from 20-120 Ilg/mL were prepared in dH20 in triplicate 
by dilution of a 2 mg/mL RNase A stock solution (prepared in dH20). 80 ilL of each 
standard was added to a cuvette containing 720 ilL of a 41.7 Ilg/mL SDS solution and 
well mixed. The assay was initiated by addition of 200 ilL Bradford reagent (Bio-
Rad) and the cuvette thoroughly mixed and incubated for 6 min at R T. The A595 was 
recorded in a spectrophotometer blanked to the SDS solution-Bradford reagent 
mixture, with 80 ilL of water in place of the incubation. Absorbances were plotted 
against varying concentration, and a calibration curve and R2 value generated. 
Experiments were repeated at least in triplicate. 
Determination oJprotein concentration in RNase A containing incubations 
RNase A was diluted in dH20 in triplicate to an expected concentration (60 Ilg/mL in 
dH20) within the linear region of the calibration curve prepared above. 80 ilL of 
sample was added to 720 ilL of a 41.7 Ilg/mL SDS solution and the remainder of the 
assay undertaken as for the calibration curve. Concentration was interpolated from 
the calibration curve. Experiments were repeated at least in triplicate. 
7.2.4 Quantification oj lysine in samples prepared in 7.2.1 using o-phthaldialdehyde 
(5,6) 
Construction oj calibration curves 
For construction of a lysine calibration curve, standards ranging from 0.125 to 1 mM 
(prior to addition to 1 mL of oPA) of lysine were prepared in dH20 in triplicate (from 
a 1.2 mM lysine stock prepared in dH20). For RNase A, standards ranging from 0.5 
to 3.5 mg/mL (prior to addition to 1 mL of oPA) in dlhO were prepared in triplicate 
from a stock solution of 3.5 mg/mL RNase. 
oPA reagent was prepared fresh immediately prior to assay as outlined in Table 7.6. 
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0.1 M Sodium metaborate (NaB02.4H20) 
20% SDS 
40mgoPA 
100% Mercaptoethanol 
dH20 
25 
2.5 
in 1 mL 100% MeOH 
0.1 
21.4 
162 
[Fina]] 
50mM 
1% 
15mM 
0.2% 
Table 7.6: The of oP A reagent. NB., solution was kept in the dark until 
required. 
50 ilL of sample was added to a cuvette containing 1 mL of oP A reagent, thoroughly 
mixed, and incubated for 2 min at RT. The A340 was recorded in a spectrophotometer 
blanked to dH20. Absorbances were plotted against concentration and a calibration 
curve and R2 value generated. 
Determination of amine concentration oj RNase A incubated with a-dicarbonyl 
Incubations containing RNase A, which had been dialysed OIN to remove any 
remaining unreacted a-dicarbonyl and the protein concentration determined, were 
diluted in dH20 to a concentration of 2 mg/mL following inspection of the calibration 
curve. 50 ilL of sample was added to 1 mL oP A, mixed, incubated and the 
absorbance recorded, as outlined for the calibration curve samples. Controls were 
included to assess the interference of the a-dicarbonyl compounds and/or the products 
formed on reaction of RNase A with the a-dicarbonyL For these controls, oPA was 
omitted from the assay. Concentration was interpolated from the calibration curve. 
Experiments were repeated in triplicate. 
Statistical analysis of incubations containing phosphate 
The experiment undertaken to measure the effect of phosphate glycation of protein as 
measured by lysine concentration, was designed as a split plot experiment. The main 
factor for ANOYA was "Phosphate" which was at the plot level, with replicates at the 
subplot level ("Preparation") and nested (i.e. repeated measurements at this level -
"Sub"). A second factor, "Time", was within this repeated measurement. There was 
a second level of nesting where a repeated measurement was taken (of each sample) 
to measure pipetting error within the assay procedure, thus introducing a second level 
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of nesting. A multi-way ANOV A was then performed in S-PLUS and the P values 
calculated manually where required. 
7.3 Methods for experiments outlined in Chapter three 
7.3.1 Preparation of low molecular weight protein + a-dicarbonyl incubations 
Stock solutions were prepared by solubilising the protein in dH20 to give a final 
concentration of 50 mglmL (pH 7, adjusted with 0.1 M NaOH). In the case of N-
acetylated renin substrate, solubilisation necessitated the addition of a minimal 
amount of DMSO. Aliquots of each solution were diluted 1: 1 with a 260 mM a-
dicarbonyl solution (pH 7, adjusted with 0.1 M NaOH) to give final concentrations of 
25 mg/mL protein and 130 mM a-dicarbonyl. The resultant solution was incubated at 
37°C for the prescribed period of time then stored at -20°C prior to analysis. Protein 
only controls were prepared as above with substitution of a-dicarbonyl with dH20 
with one frozen at time 0 in liquid nitrogen, and the other incubated with the a-
dicarbonyl-containing incubations until the conclusion of the incubation. An a-
dicarbonyl only control was prepared by substitution of protein with dH20 and 
incubated for the same time period as those containing protein. Incubations were 
repeated in duplicate. 
7.3.2 SDS-PAGE of low molecular weight proteins and RNase A incubated with 
a-dicarbonyl 
The wells of a Gradipore pre-cast 4-20% SDS-PAGE gel (for low molecular weight 
protein work), 8-16% (for RNase A work), were first rinsed with dH20 to remove any 
residual storage buffer. The gel was then set into the electrophoresis rig and the top 
tank filled with chilled (4°C) Ix tank buffer that had been diluted from a 5x stock 
(Table 7.7) until the electrodes were covered. The space surrounding the outside of 
the gel was filled with Ix tank buffer. 
For low molecular weight proteins, the following method was undertaken. 7 ).lL of a 
25 mg/mL protein sample was diluted in 7 ).lL of 2x treatment buffer prepared as 
outlined in Table 7.8. The sample gently mixed and then boiled for 2 min and the 
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entire vol of the sample loaded into the appropriate well. 7).tL of Sigma ultra-low 
molecular weight marker (Table 7.9) was added to 7 ).tL of 2x treatment bufTer and 
boiled as described for samples. 
Reagents 
Trizma base 
Glycine 
SDS 
Cold dH20 (4°C) 
Amount 
45 g 
216 g 
15 g 
3L 
Table 7.7: Preparation of 5 x Tank Buffer, pH 8.3 (as outlined in the Bio-Rad 
Protean®n xi Cell manual p. 39) (7). Stored at 4°C prior to use. 
The procedure for treatment of RNase A samples was exactly as outlined for the low 
molecular weight proteins with the exception that a wide range marker was employed 
in place of the ultra low molecular weight marker (Table 7.9). Gels were 
electrophoresed at a constant voltage of 150 V for 1.5 h (for 8-16% gels) or 2 h (for 4-
20% gels) at 4°C. 
Reagents Vol ().tL) [Final] 
1 M Tris-HCl pH 6.8 125 27.8 mM 
10% (w/v) SDS 2000 4.4% 
100% Glycerol 1000 22.2% 
100% 2-Mercaptoethanol 500 11.1% 
1 % (w/v) Bromophenol blue 125 0.3% 
dH20 750 
Total 4.5 
Table 7.8: Concentrations required for preparation of 2x treatment buffer. Stored at -
10°C. 
Following electrophoresis, the gel was placed in an airtight container and covered 
with the Coomassie stain (0.1 % Coomassie brilliant blue, 50% MeOH, 10% glacial 
acetic acid, filtered on preparation) (8) and placed on an orbital shaker for 2 h. After 
this time, the stain solution was removed and replaced with destain (5% methanol, 
10% glacial acetic acid) (8), and shaken over a number of hours with at least one 
change of destain. 
Chapter Seven 
Proteins 
Myosin, rabbit muscle 
p-galactosidase, E. coli 
Phosphorylase b, rabbit muscle 
Fructose-6-phosphate kinase, 
rabbit muscle 
Albumin, bovine serum 
Glutamic dehydrogenase, 
bovine liver 
Ovalbumin, chicken liver 
Glyceraldehyde-3-phosphate 
dehydrogenase, rabbit muscle 
Carbonic anhydrase, bovine 
erythrocytes 
Triosephosphate isomerase, 
rabbit muscle 
Trypsinogen, bovine pancreas 
Trypsin inhibitor, soybean 
Myoglobin, horse heart 
a-Lactalbumin, bovine milk 
Aprotinin, bovine lung 
Insulin, chain B oxidised 
Bradykinin 
M.W.(Da.) 
205,000 
116,000 
97,000 
84,000 
66,000 
55,000 
45,000 
36,000 
29,000 
24,000 
20,000 
17,000 
14,200 
6,500 
3,496 
1,060 
Wide-Range a 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
165 
Ultra-Low MW b 
X 
X 
X 
X 
X 
X 
Table 7.9: The SDS-PAGE markers used for electrophoresis work. a Employed in 
work with RNase A. b Employed in work with renin substrate tetradecapeptide and 
somatostatin. 
7.3.3 Congo red staining method for detection of fibrils in RNase A samples 
incubated with a-dicarbonyl (9) 
Samples (~10 ).tL) of 25 mg/mL RNase A incubations containing a-dicarbonyl 
prepared as outlined in section 7.2.1, were fixed onto a POlY-L-lysine-coated glass 
slide by drying at 37°C. This process was repeated to ensure a reasonable amount of 
protein was fixed onto the slide to visualise any fibrils generated from glycation (~40 
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f!L final vol on slide). The slide was placed in working solution I prepared from 
solution A (Tables 7.10 and 7.11), for 20 min. The slide was then transferred to 
working solution II from stock solution B (Tables 7.10 and 7.11) for a further 20 min. 
The slide was then washed in two changes of a solution of 10% formaldehyde, 90%) 
ethanol, which did not exceed 10 sec. Samples were then visualised under a cross-
polarising microscope. Those that emitted a green birefringence under polarising 
light, were deemed to contain fibrils. 
Solution A 
10 gNaCI 
1 L 80% (v/v) Ethanol 
Solution B 
2 g Congo red 
10 g NaCI 
1 L 80% Ethanol 
Table 7.10: Stock solutions required for Congo red fibril experiments. N B. Solutions 
were prepared and stored at RT for 24 h prior to use. These were replaced every 
second month. 
Solution I 
100 mL of Stock solution A 
1 mL 1 % (w/v) NaOH 
Solution II 
100 mL of Stock solution B 
1 mL 1 % (w/v) NaOH 
Table 7.11: Working solutions required for Congo red fibril experiments. N B. Both 
working solutions were filtered following preparation, and as they had a limited shelf 
life, were used within 15 min. 
7.3.4 Thioflavill T assay for detectioll of fibrils ill RNase A samples illcubated with 
a-dicarbollyl Adaptedfrom Waterhouse (10) 
RNase A incubations containing a-dicarbonyl were diluted to a concentration of 0.5 
mM in dH20. 10 f!L was added to a quartz cuvette containing 3 mL of Thioflavin T 
buffer (Table 7.12) (final protein concentration, 22.8 f!g/mL, 1.66 ~M). The cuvette 
was covered, inverted to thoroughly mix and incubated for 3 min. At the conclusion 
of incubation, the cuvette was placed in a fluorometer blanked to Thioflavin T buffer. 
The wavelength of excitation was 450 nm. The complete emission spectra were 
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recorded, over a range that included the wavelength of 482 nm. Both excitation and 
emission slits were set to 5 nm. 
Reagent 
1mM T 
(31.89 mgllOO mL dH20, stored in the dark at 4°C) 
Trizma base 
Amount 
500 JlL 
0.61 g 
0.59 g 
99.5 mL 
[Final] 
50mM 
100mM 
Table 7.12: Preparation of Thioflavin T buffer (PH 7.5, adjusted with cone. HCI). 
N B. The solution was prepared fresh each experiment and where possible kept at 4°C 
in the dark. 
7.4 Methods for experiments outlined in Chapter four 
7.4.1 RNase A activity assays (11) 
The RNase A assay employed here required the preparation of two buffers: MOPS 
buffer (Table 7.13) and methylene blue buffer. 
Reagent 
MOPS 
Na2EDTA'2H20 (0.5 M) 
Amount 
29.03 g 
4mL 
[Final] (mM) 
100 
2 
Table 7.13: Preparation of MOPS buffer. N B. The EDTA was added to the prepared 
MOPS (that had been adjusted to a pH of 7.4 using 10 M NaOH), and the pH re-
checked and adjusted where required. 
Methylene blue buffer was prepared by dissolving 1 mg of methylene blue in 100 mL 
of MOPS buffer. The methylene blue buffer was prepared fresh prior to each assay 
and adjusted to 0.5 ± 0.01 A.D. at 688 nm in a spectrophotometer blanked to dH20. 
As the solution was light sensitive, the buffer was kept in the dark during the assay. 
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Construction of a calibration curve to determine RNA concentration and assays to 
determine that enzyme concentration is proportional to rate 
A series of RNA standards were constructed ranging from 0.25-10 mg/mL in MOPS 
buffer. The volumes outlined in Table 7.14 were dispensed into a cuvette: 
Reagent 
RNA standard (0.25-10 mg/mL) 
Methylene blue buffer 
Vol().lL) 
100 
900 
[Final] ().lg/mL) 
25-1000 
Table 7.14: Volumes required to construct an RNA calibration curve 
Each cuvette was incubated for 10 min in the dark at 25°C. The A688 was recorded in 
a spectrophotometer blanked to dH20. Each concentration was prepared and recorded 
in triplicate and the experiment repeated in duplicate. No-substrate controls were 
included which involved the substitution of RNA with MOPS buffer. 
To confirm that rate was proportional to enzyme concentration the volumes outlined 
in Table 7.15 were dispensed into a cuvette, with the exception of RNase A. 
Reagent 
RNA (10 mg/mL) 
Methylene blue buffer 
RNase A standard (5-60 ).lg/rnL, prepared in MOPS buffer) 
Vol ().lL) [Final] ().lg/mL) 
60 600 
940 
10 0.05-0.6 
Table 7.15: Volumes required to determine if enzyme concentration was proportional 
to rate 
Each cuvette was incubated at 25°C for 10 min in the dark. Then, 10 ).lL of an RNase 
A standard was added, mixed and incubated for 1 min. After this time, the ~A688 was 
recorded for 120 sec. Linearity of time traces over this period was ensured and the 
concentration of RNA was calculated from the calibration curve prepared above. All 
RNase A standards were prepared in triplicate and the experiment repeated at least in 
triplicate. 
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Controls without enzyme and substrate respectively were included as controls to 
ensure that RNase A was solely responsible for the change in rate, and that the 
enzyme was not causing a rate by reaction with any other compound present in the 
cuvette. 
Attempts at determining Kill and V mClx of RNase A via the methylene blue assay 
For this experiment, RNase A concentration was held constant and the amount of 
RNA varied as outlined in the Table 7.16. 
Reagent 
RNA standard (0.25-12 mg/mL) 
Methylene blue buffer 
RNase A (15 flg/mL, prepared in MOPS buffer) 
Vol (flL) 
100 
900 
10 
[Final] (flg/mL) 
(2 s.f.) 
25-1200 
0.15 
Table 7.16: Volumes of reagents required to determine Km and Vrnax of RNase A. 
Incubation and measurement times and rate calculations were undertaken exactly as 
outlined for the experiments to determine if enzyme concentration was proportional to 
rate. All RNA concentrations were prepared in triplicate and the experiment repeated 
at least in triplicate. No-enzyme and no-substrate controls were again included. 
Preparation of RNase A + a-dicarbonyls in the presence of Maillard inhibitors. 
Incubations of RNase A, a-dicarbonyl and inhibitor (either amino guanidine or 3,5-
dimethylpyrazole-l-carboxamidine), were prepared as outlined in section 7.2.1., with 
the inclusion of Maillard inhibitors. Aqueous solutions of the a-dicarbonyls (390 
mM) and inhibitors (390 mM) were prepared, and a 75 mg/ml solution of RNase A 
Equal volumes of each were pipetted into to Eppendorfs to give final concentrations 
of 130 mM a-dicarbonyl and inhibitor, and 25 mg/mL protein. Controls were 
prepared as outlined in section 7.2.1. Where DMSO was required for solubilisation of 
amino guanidine, this was included in the appropriate incubation controls. 
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The influence of a-dicarbonyls and Maillard inhibitors on the catalytic efficiency of 
RNaseA. 
RNase A incubations containing a-dicarbonyl and/or inhibitor was diluted to a 
concentration of 15 flg/mL. The following volumes were dispensed into a cuvette 
with the exception of the sample to be tested. 
Reagent 
RNA (10 mg/rnL) 
Methylene blue buffer 
Sample - RNase A (15 )lglmL, in MOPS buffer) 
± a-dicarbonyl 
± inhibitor 
Vol (flL) 
60 
940 
10 
[Final] ()lglrnL) 
600 
0.15 
Table 7.17: Volumes of reagents required to test the influence of a-dicarbonyls and 
Maillard inhibitors on the catalytic effidency of RNase A 
Incubation, sample addition, measurement times and rate calculations were the same 
as outlined for Km and Vmax. experiments with the sample RNase A added to initiate 
the assay. Incubations were measured in triplicate with at least duplication of the 
experiment. No-enzyme and no-substrate controls were included in all experiments. 
In some cases, the solubilisation of Maillard inhibitors, such as amino guanidine, 
necessitated the addition of solvents such as DMSO. The controls were adjusted 
accordingly (e.g. addition of a volume of DMSO to the reaction mix, equivalent to 
that in the RNase A sample) to ensure solvent was not interfering with the assay. 
7.5 Methods for experiments outlined in Chapter five 
All strain genotypes, media preparation and antibiotic concentrations are outlined in 
Appendix six. 
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7.5.1 Preparation of glycerol freezes of bacterial strains (12) 
A colony selected from an LB-Agar plate (Appendix six), supplemented with the 
appropriate antibiotics, was used to inoculate a 3 mL solution of LB (Appendix six) 
containing the appropriate antibiotics. This was incubated OIN in a 37°C shaking 
water bath. Following incubation, 750 )..tL of culture was aliquoted into a sterile 
Eppendorf and centrifuged at 7,000 rpm for 2 min. The supernatant was discarded 
and the pellet resuspended in a further 750 )..tL of OIN culture and an equal volume of 
sterile 30% glycerol, mixed well, and stored at -80°C. This was carried out in 
triplicate to ensure the appropriate strain had been selected. 
7.5.2 Preparation of competent cells for transformatioll with plasmid DNA 
encoding amadoriase I (12,13) 
An O/N culture of E. coli BL21(DE3)pLysS (400 )..tL), supplemented with 30 )..tg/mL 
Cam, was used to inoculate a 20 mL solution of LB containing 30 )..tg/mL Cam and 
grown to an O.D. of 0.4 at 600 nm (measured in a spectrophotometer blanked to LB). 
When the O.D. was reached, the culture was immediately placed on ice. On cooling, 
the culture was centrifuged at 7,000 rpm for 3 min at 4°C (these centrifugation 
conditions were used for all subsequent steps). The supernatant was discarded and the 
pellet resuspended in 20 mL of cold sdlhO (4°C), centrifuged and the supernatant 
discarded. The pellet was resuspended in 10 mL of cold sdH20 (4°C) and centrifuged 
and the supernatant discarded. The pellet was gently resuspended in the residual 
supernatant and poured into sterile Eppendorfs and centrifuged. The supernatant was 
then gently removed and discarded and the pellet resuspended in 160 )..tL of cold 
sdH20 (4°C). Cells were stored on ice for immediate transformation experiments or 
stored at -80°C. 
7.5.3 Transformation of E. coli BL21(DE3)pLysS or E. coli XLi-Blue with the 
vector containing amadoriase I (12,13) 
Competent cells (40 flL), prepared using the above protocol or purchased (in the case 
of E. coli XLI-Blue), were added to a UV-sterilised electroporation cuvette. l)..tL of 
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plasmid DNA (1-100 ng/mL, pET lSb vector containing amadoriase I gene) was 
added and electroporated at l.S kV in a 0.1 cm gap ccll using an Electroporation 
GenePulserTM (Bio-Rad). The slide chamber and cuvettes were stored on ice prior to 
use. In parallel, sdH20 was substituted for DNA and electroporated as described 
above. Following electroporation, SOO ~L of SOC media (Appendix six) was added 
to the cuvette, gently mixed and transferred into a sterile Eppendorf and incubated for 
l.2S hat 37°C. After incubation, 100 JlL of sample was spread onto LB-Agar plates 
supplemented with either Cam (30 Jlg/mL) and Amp (100 Jlg/mL) for E. coli 
BL21(DE3)pLysS or Tet (20 ~g/mL) and Amp (100 ~g/mL) for XLI-Blue and 
incubated OIN at 3rc. The remainder of the samples were centrifuged at 7,000 rpm 
for 2 min. at RT. As much of the supernatant was decanted and discarded and the 
pellet was resuspended in the residual solution. These suspensions were plated onto 
LB-Agar plates with the appropriatly supplemented antibiotics as outlined above. Six 
transformant colonies were selected from each plate and re-streaked individually onto 
fresh LB agar plates supplemented with appropriate antibiotics according to the strain 
in use and again incubated OIN at 37°C. OIN cultures were prepared from colonies 
selected from the plates and glyccrol freezes prepared and stored as outlined in section 
7.S.l. These transformed strains were referred to as E. coli 
BL21(DE3)pLysS(pET1Sb) or E. coli XL1-Blue(pETlSb). 
7.5.4 Plasmid mini-preparation of pET 15h vector via alkaline lysis method (12) 
OIN culture (l.S mL) was added to a sterile Eppendorf and centrifuged at 7,000 rpm 
for 90 sec, the supernatant discarded and the pel1et resuspended in 100 JlL of solution 
I (Table 7.1S). On solubilisation of the pellet, 200 ~L of solution II (Table 7.1S) was 
added and the Eppendorf gently inverted and rolled until the mixture became viscous. 
Finally, ISO ~L of solution III (Table 7.1S) was added and the tube gently mixing and 
rotated and the flocculent broken up. The resulting mixture was stored on ice for 10 
min then centrifuged at 11,000 rpm for 10 min at RT. The supernatant was poured 
into a sterile Eppendorf containing 2 vol of cold (-20°C) 100% EtOH, mixed and 
cooled on ice for 10 min and the pellet discarded. Following incubation on ice, the 
solution was centrifuged at 11,000 rpm for 10 min at 4°C. After centrifugation, the 
supernatant was aspirated and the pellet washed with SOO JlL of 70% RT EtOH and 
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re-spun at 11,000 rpm for 2 min. The supernatant was discarded and the pellet air-
dried. The dried pellet was then resuspended in 40 )JL of sdH20 or TE buffer (10 mM 
Tris.Hel, 1 mM Na2EDTA'2H20 ( pH 8, autoclaved) and stored at -10°C until further 
required. 
Solution I 
50 mM Glucose 
25 mM Tris-HCI (pH 8) 
10 mM Na2EDTA2H20 (PH 8) 
Solution II 
0.2MNaOH 
I%SDS 
Solution III 
60mL5 MKOAc 
11.5 mL Glacial acetic acid 
28.5 mLdH20 
Table 7.18: Solutions required from plasmid DNA preparation. Solutions I and III 
were prepared and autoclaved and stored at 4°C until required. Solution II was 
prepared immediately before each plasmid preparation and stored at RT. 
7.5.5 Preparation of sequence quality plasmid DNA Adapted from Sambrook 
(12,13) 
A 50 mL OIN culture of coli XLI-Blue(pETI5b) supplemented with the 
appropriate antibiotics was centrifuged at 7,000 rpm for 2 min at RT and the 
supernatant discarded. The pellet was resuspended in solution I, and on solubilisation 
of the pellet, 5 mL of solution II was added and the tube gently inverted and rolled 
until the mixture became viscous. Finally, 5 mL of solution III was added and the 
tube gently mixed and rotated and flocculent broken up. The resulting mixture was 
stored on ice for 10 min, then centrifuged at 11,000 rpm for 10 min at RT. The 
supernatant was transferred to a sterile centrifuge tube containing 0.54 vol of 
isopropanol and stored in ice for 10 min and the pellet discarded. The solution was 
centrifuged at 11,000 rpm for 10 min at 4°C. The DNA pellet was rinsed in 1 vol of 
RT 70% EtOH and centrifuged and dried as previously described for the DNA mini-
preparation (section 7.5.4). 
To remove high molecular weight RNA, the pellet was redissolved in 1 mL of cold 
buffer and iced for 30 min. 1 mL of cold (4°C) 5 M lithium chloride (21.2 g LiCI 
in dH20 100 mL, autoclaved) was then added and the resulting solution iced for 
between 10-30 min. The solution was then centrifuged at 11,000 rpm for 10 min at 
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RT and the supernatant transferred into a fresh centrifuge tube containing 0.54 vol 
isopropanoL The solution was iced for 10 min and spun at 11,000 rpm for 10 min at 
4°C. The pellet was again washed, centrifuged and dried as outlined in section 7.5.4. 
To further remove RNA and any residual protein, the DNA pellet was resuspended in 
200 ilL of TE buffer and transferred to an Eppendorf containing 2 ilL of RNase (10 
mglmL, DNase free) and incubated at 37°C for 30 min. 200 ilL of phenol and 200 ilL 
chloroform:isopropanol (24: 1) was then added to the solution and gently mixed and 
centrifuged at 13,000 rpm for 5 min at RT. After centrifugation, the top layer (-180 
ilL) was transferred into a new Eppendorf containing 180 ilL of 
chloroform:isopropanol (24: 1). The solution was mixed and re-spun at 13,000 rpm 
for 5 min at RT. The top layer (-160 ilL) was again transferred to a new Eppendorf 
containing 20 ilL (1I8th vol) of 2 M potassium acetate in 2 vol of 100% (-20°C) cold 
EtOH. This solution was gently mixed and cooled on ice for 10 min and then spun at 
13,000 rpm for 10 min at 4°C. DNA was rinsed, centrifuged and air-dried as 
described for the mini-preparation. The dried DNA was then resuspended in 20 JlL of 
sdHzO or TE. 
7.5.6. Restriction analysis ofplasmid DNA (12) 
Typically, the following mixture was prepared following assessment of DNA 
concentration by either gel electrophoresis or 260:280 extinction coefficient readings 
(12). 
Digest 
Final volume 
x ilL DNA (0.5 to 5 ilL DNA in sdHzO) 
1.5 ilL lOx buffer (compatible with both restriction enzymes) 
0.2 JlLBamHI (10 units/JlL) 
0.2 ilL NdeI (10 unitS/ilL) 
2\-J+L sdHzO (to adjust to the desired final volume) 
15 ilL 
This mixture was incubated at 37°C for 1-1.5 h. 
Following digestion, samples were treated with 2.5 JlL loading buffer (Table 7.19, left 
hand column) and loaded onto a 1% agarose gel (0.3 g in 30 mL in Ix diluted 
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from SOx TAB, right hand column of Table 7.19), along with 5 flL of marker (A cut 
with HindIII). The gel was electrophoresed at 80 V for ~ 1.5 h in Ix TAE at RT. The 
gel was stained for 10 min in ethidium bromide and visualised on a UV 
transilluminator and photographed with a digital camera interfaced with a computer 
loaded with imaging software. 
Reagents [Final] Reagents Amount 
100% Glycerol 30% Trizma base 242 g 
1 % Bromophenol blue 0.25% 0.5 M EDTA pH 8.0 100mL 
1 % Xylene cyanol 0.25% Glacial acetic acid 57.1 mL 
RJ\T ase (DNase :free) 10 flg/mL dH20 1L 
Table 7.19: Solutions required for DNA agarose electrophoresis. Loading buffer 
prepared and stored at -20°C (left hand column), and 50x TAE, pH 8 stored at 4°C, 
(right hand column). 
The marker for agarose electrophoresis, A cut with HindIII, has fragment sizes of 
23.1,9.4,6.6,4.4,2.3,2.1 and 0.5 (kb). 
7.5.7 peR site-directed mutagenesis of amadoriase I 
Two mutants, H357N and S370A were prepared in collaboration with Andrea 
Uhlmann and Stephan Hegge respectively, according to the protocol outlined in the 
Quikchange site-directed mutagenesis kit instruction manual (14-16). 
Primer designfor the generation ofH357N and S370A mutants 
The primers for PCR were designed to meet the guidelines stipulated by Stratagene 
for successful mutagenesis (14). These were that: 
Both primers contained the desired mutation and annealed to the same 
sequence on opposite strands of the plasmid. 
The primers were between 27 and 37 bases in length 
The primers had a calculated melting temperature (Tm) of greater than 78°C. 
(Tm = 81.5 + 0.41(%GC) - 6751N % mismatch, N is the primer length in 
base pairs). 
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The base changes were in the middle of the primer with at least 10-12 bases of 
correct flanking sequence 
Finally, the primers had a minimum GC content of 40% and terminated in one 
or more CG bases. 
The mutant primer Tm were 78.2°C and 81.51 °C for the H357A and S370A mutants 
respectively and met all the other 4 requirements noted above. 
PCR reaction conditions 
For each mutant, a PCR reaction in thin-walled PCR tubes, was set up as described in 
Table 7.20. This has been shown for only the S370A (the conditions for H357N were 
exactly the same). A diagnostic control for this step was the reversion mutation of 
p Whitescript with mutagenic primers, which were supplied with the mutagenesis kit 
(Table 7.21). The pWhitescript plasmid has a point mutation in the lacZ' gene (p-
galactosidase) generating a stop codon at the ninth position of the coding region. 
Mutagenic primers replace the stop codon with a glutamine codon restoring activity to 
the enzyme and allowing the determination of mutational efficiency by the proportion 
ofblue/white colonies on IPTG/X-gal plates (Appendix six). 
Reagents 
lOx reaction buffer 
Template dsDNA 7.2 kb plasmid 
S370A primer #1 
S370A primer #2 
Vol (/-iL) 
5 
10 
15 
15 
dNTP mix 1 
Double-distilled water (ddH20) 4 
PfuTurbo DNA polymerase (2.5 Units /-iL-') 1 
Final Amount (ng) 
50 
125 
125 
Table 7.20: Volumes required for the amplification of the S370A mutant. 
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lOx reaction buffer 
p Whitescript 4.5-kb control plasmid 
Oligonucleotide control primer#1 34-mer 
Oligonucleotide control primer#2 34-mer 
Vol (ilL) 
5 
2 
1.25 
1.25 
dNTP mix 1 
Double-distilled water (ddH20) 37.5 
PfuTurbo DNA polymerase (2.5 Units ilL-I) 1 
Table 7.21: Vols. required for the control PCR reaction 
Amount (ng) 
10 
125 
125 
177 
Each reaction was overlaid with mineral oil to prevent evaporation and the PCR 
reaction carried out in a thermocycler equipped with a "hot bonnet", which also 
helped to prevent evaporation. Reactions were then cycled through PCR programmes 
outlined in Table 7.22. 
Control reaction Sample reaction 
Step Temperature Time Step Temperature Time 
(OC) (min) eC) (min) 
1 95 0.5 1 95 0.5 
2 95 0.5 2 95 0.5 
3 55 1 55 1 
4 68 12 68 7.2 
5 steps 2-4 eleven times steps 2-4 twelve times 
Table 7.22: PCR cycling parameters for control and mutant reactions 
At this point, agarose gel electrophoresis was used to check for amplification of the 
parent plasmid using the equivalent amount of starting template as a control. 
After amplification, endonuclease enzyme, DpnI (1 ilL, 10 Units ilL-I), was added to 
each of the reactions below the mineral oil. DpnI is a methylated and hemimethylated 
specific enzyme, which digests the parent template DNA, leaving the mutation-
containing newly synthesised DNA intact. The reaction mixture was gently, but 
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thoroughly mixed, centrifuged, and incubated at 37°C for 1 h to digest the parental 
(non-mutated) supercoiled dsDNA. 
Transformation ofE. coli XLi-Blue with mutated plasm ids and DNA sequencing 
Following mutagenesis, each of the plasmids were used to transform E. coli XLI-Blue 
supercompetent cells (Stratagene). Competent cells were gently thawed on ice and 
aliquots (50 I-lL) transferred to pre-chilled Falcon 2059 polypropylene tubes. DNA (1 
I-lL) was added to separate aliquots, mixed gently by pipetting and incubated on ice 
(30 min). The transformation reaction was heat pulsed for 45 seconds at 42°C, and 
then placed on ice for 2 min. NZY+ broth (Appendix six) (0.5 mL, preheated to 
42°C) was added and incubated (37°C for 1 h) with shaking at 225-250 rpm. Plasmid 
DNA was then prepared from each respective strain, E. coli XL 1-Blue (pET 
15bS370A) andE. coli XLI-Blue (pET 15bH357N) as outlined in section 7.5.5. 
DNA sequencing of the above mutants was performed at the Waikato Sequencing 
Facility. Plasmids to be sequenced were prepared to the highest quality, quantified 
spectrophotomectrically (12), and sequenced using the dideoxynucleic acid chain 
termination method (17), using T7 promoter and T7 terminator primers, along with 
the custom primer outlined below. The custom primer was to ensure a complete 
sequence where readthrough from where the T7 promoter would not cover this area of 
sequence. The primer below met the following sequencing requirements as stipulated 
by the DNA sequencing facility (denoted in parentheses are the properties of the 
below primer): between 18-30 bases (24 bases), GC content 40-60% (50%), Tm 55-
75°C (66.77°C), A-T rich at the 3' end. 
5' 1002 GC GCA CGA GAC TTT CTC CAT GAT A 1025 3' 
Bold denotes the base pair number within the amadoriase I gene. 
Restriction analysis ofS3 70A pETi5b plasmid 
Restriction analysis was undertaken as outlined for the wild-type plasmid outlined in 
section 7.5.6, with substitution of Nder for NaeI. Electrophoresis was undertaken as 
outlined for the wild type with a 1.5% agarose gel used in place of a 1 % gel due to the 
formation oflow molecular weight fragments (160-400 bp). A lkb marker was used, 
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along with A cut with HindUI, which contained fragment sizes: 1, 0.9, 0.8, 0.7, 0.6, 
0.5,0.4,0.3,0.2 and 0.1 kb. 
Transformation ofE. coli BL21 (DE3)pLysS with mutated plasm ids 
Following sequencing, the plasmid DNA of each mutant was used to transform E. coli 
BL21(DE3)pLysS to create two strains, E. coli BL21(DE3)pLysS(pET 15bS370A) 
and E. coli BL21(DE3)pLysS(pET 15bH357N), for expression purposes. The 
preparation of competent cells and transformation protocols were undertaken as 
outlined in sections 7.5.2 and 7.5.3. 
7.5.8 Over-expression of amadoriase I isozyme from E. coli (BL21)DE3pLysSpET15b 
Adaptedjrom Wu et al. (18,19) 
Harvest ofE. coli BL21 (DE3)pLysS pET15h and purification of amadoriase I 
25 mL of an OIN culture coli BL21(DE3)pLysSpETI5b was used to inoculate 1 L 
of LB supplemented with the Cam (30 Ilg/mL) and Amp (100 Ilg/mL). The 
inoculated culture was then incubated at 37°C on a shaking platform until the O.D. 
reached between 0.4-1.0 (19). Amadoriase I expression was then induced by adding 1 
mL of 0.25 M IPTG (in dH20, filter sterilised) to the culture and incubated for a 
further 3-4 h. After incubation, the culture was immediately cooled in ice. Cells were 
then harvested by centrifugation at 5,000 x g for 10 min at 4°C. The supernatant was 
discarded and the pellet resuspended in 1 vol of ice cold (4°C) lysis buffer (Table 
7.23). Cells were again centrifuged at 5,000 x g for 10 min at 4°C, the supernatant 
discarded and the pellet resuspended in half a vol of lysis buffer and the cells 
centrifuged as described immediately above. The pellet was resuspended in a 
minimal volume of ice cold lysis buffer and all cells were pooled into a 50 mL 
centrifuge tube, which was then centrifuged as above. The supernatant was discarded 
and the pellet was flash frozen in liquid N2 and thawed OIN at 4°C on ice. The pellet 
was resuspended in around 30 mL of ice cold (4°C) lysis buffer and sonicated on ice 
in 30 sec bursts until the A260 of the extract no longer increased. The extract was 
centrifuged at 13,000 x g for 10 min at 4°C, the pellet discarded and the supernatant 
passed through a 0.45 IlM PVDF filter. 
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Lysis Buffer pH 8 
20 mMNaH2P04 
500 mMNaCI 
pH 8 
20 mM NaH2P04 
500 mMNaCI 
Elute Buffer pH 8 
20 mM N aH2P04 
500 mMNaCI 
20 mM Imidazole 40 mM Imidazole 100 mM Imidazole 
180 
Table 7.23: Buffers the purification of amadoriase 1. All were prepared 
fresh before each purification and stored at 4°C. All buffers were filtered through a 
0.45 )..LM PVDF filtered prior to use with the His-Trap columns. 
The supernatant was loaded onto two Pharmacia His-Trap columns that had been 
connected together, pre-charged with Ne+ and equilibrated with lysis buffer at a flow 
rate of 0.5 mLimin (as described by the manufacturer). The columns then washed 
with 30 mL of wash buffer (Table 7.23). Following the washing step, the protein was 
eluted from the column in 1 mL fractions using elute buffer (Table 7.23). These 
fractions, along with the load and wash, were subjected to SDS-PAGE and activity 
measurements. Active, pure fractions (those with a rate above 1xlO-3 for 20 )..LL of 
sample as judged by a coupled assay (section 7.5.10) at 5-10 x Km of fructosyl 
propylamine and a single band visible by SDS-PAGE, see below) were pooled and 
dialysed against 3 L of 10 mM sodium phosphate buffer (pH 8) for 2 h at 4°C using 
Sigma 12,000-14,000 MW cut-off tubing (Diameter 16 mm, capacity, 60 mLlft, 
prepared as according to the manufacturer's instructions) with at least one change of 
1.5 L of 10 mM sodium phosphate buffer (pH 8). The resulting retentate was tested 
for activity and protein concentration determined (see below), then stored at -80°C. 
amadoriase I was found to lose approximately half its activity after storing at -20°C 
for 24 h amadoriase I stored at -80°C displayed activity similar to that stored at 4°C 
after 24 h. 
SDS-PAGE analysis of amadoriase I purity during purification experiments 
SDS-P AGE experiments to determine the purity of amadoriase I fractions were 
undertaken using exactly the same system outlined for RNase A in section 7.3.2. The 
only differences being the amount of sample analysed, with 20 )..LL of load and wash 
(incubated with 20 )..LL 2x treatment buffer) loaded onto the gel. 5 )..LL of crude was 
added to 5 )..LL 2x treatment buffer. 
Chapter Seven 181 
Estimation of protein concentration during purification of amadoriase I 
The assay method is essentially that outlined for RNase A in section 7.2.3 with BSA 
used as a reference protein in place of RNase A. A 2 mg/mL solution of BSA was 
diluted to the same standard concentrations as RNase A (i.e. 20-]20 Ilg/mL) in dHzO. 
The 41.7 Ilg/mL solution of SDS used in RNase A experiments was substituted with 
dH20 in this work. Triplicate series of dilutions of the sample under study were 
diluted to a concentration in the linear range of the BSA calibration curve and assayed 
as outlined in section 7.2.3. 
Samples containing protein were diluted in dHzO until they gave an absorbance that 
lay in the region of linearity, as defined by the above calibration curve. The 
concentration was interpolated from the curve. 
7.5.9 Synthesis offructosyl propylamine (l-amino-l-deoxY-D-fructose) (20) 
O~HOH 
OH 
o N 
OH H 
l-amino-l-deoxy-D-il-uctose 
Fructosyl propylamine was prepared as follows: 15 g (0.083 mol) of glucose and 20 
mL of propylamine (0.237 mol) were heated to 70°C and stirred until as much of 
sugar as possible was dissolved. After 10 min, the product dissolved and became 
white-yellow and hardened to a gel-like consistency. The mixture was diluted in 200 
mL of isopropanol and poured into 800 mL of diethyl ether. The precipitate was 
filtered and dissolved in 300 mL of boiling dioxane. To this, 20 g of oxalic acid 
dissolved in 200 mL of dioxane was added, and the mixture was heated for 15 min at 
70°C. The resulting precipitate was crystallised from dioxane/methanol (1: 1). The 
oxalate was replaced by chloride using anion exchange chromatography (Sephadex) 
eluted with dlhO. Fractions were dried by either rotary evaporation or by 
lyophilisation. A crystalline light brown product was yielded from this protocol (470 
mg,3.13%). 
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Melting points 
Salt 
Oxalate 
Chloride 
Literature 
138°C (21) 
118-120°C (22) 
? 
182 
This work 
Table 7.24: Literature and observed melting points offmctosyl propylamine 
IH NMR data has been reported previously for the chloride salt (23), and these results 
are in agreement with those obtained by this procedure. 
IH NMR (500 MHz, D20), 80.95 (3H, t, J=7.3,CH3), 1.7 (2H, sext., J=7.3 
CH3CH2CH2), 3.1 (2H, t, CH3CH2CH2NH), 3.3 (2H, s, NHCH2CO), 3.7 (2H, 
m), 3.85 (lH, dd), 4.0 (2H, m). 
EI mass spectrometry revealed a molecular weight of 222 (M'+), which was consistent 
with previous reports (23). 
7.5.10 Coupled assay to determine amadoriase J activity 
Assay for determining activity during purification of amadoriase I 
The appropriate vols. of reagents outlined in Table 7.25 were added to a cuvette, with 
the exception of fructosyl propyl amine. The cuvette was then incubated in a 
spectrophotometer blanked to dH20 in the dark for 5 min at 25°C. 
Reagent Vol (fJL) [Final] 
10 mM HEPES, pH 8 825 
Peroxidase (0.5 mglmLt 40 
ABTS (20 mg/mL)b 100 
Test sample 20 
Fructosyl propyl amine (32.66 mMt ]5 0.49 mM (lOx lit Km) (18) 
Total 1000 
Table 7.25: a Prepared in HEPES buffer. b Prepared in dH20. C Fructosyl propyl amine 
concentration was determined using the coupled assay and Beer's Law where 
A E. C. 1. (EABTS at 414 nm, 3.6xl04). It was assumed that for every 2 ABTS moles 
of radical cation molecules generated, 1 mole of fructosyl propyl amine is consumed. 
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Fructosyl propylamine was added to initiate the reaction, whereupon ilA414 was 
measured for 120 sec. Initial rate was typically calculated from the first 20 sec of the 
reaction, to ensure that true initial rate was measured, i.e, under 10% of the product 
formed. 
A no-substrate control was performed in order to ensure il~14 was not due to any 
other reaction components reacting with the enzyme. A no-enzyme control was 
performed to ensure the M414 was solely due to the action of the enzyme. 
Experiments to determine Km and V max of amadoriase [ 
It was ensured that enzyme concentration was proportional to rate in the above 
experiment. This was undertaken as described for the purification of amadoriase I, 
but with varying enzyme volume (typically a range from 5-50 ilL). Compensation for 
change in volume was made by reducing or increasing the amount of 10 mM HEPES 
added. 
Exactly the same procedure was undertaken for determining the kinetic parameters of 
Amadoriase I as for purification assays. The only difference being the variation of 
substrate to final concentrations of 0.005-0.8 mM in the assay. Each concentration 
was prepared in triplicate, with the experiment undertaken at least in triplicate 
Assessment of substrate specificity of amadoriase I 
Where possible, substrates of sarcosine oxidase were prepared at lOx literature Km, or 
where Km was not quoted, Kd has been employed. Lower concentrations were due to 
solubility issues of the compound under study. A standard assay was as outlined in 
Table 7.26. 
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Reagent 
10 mM HEPES, pH 8 
Peroxidase (0.5 mg/mL)a 
ABTS (20mg/mL)b 
Test sample 
Substrate tested b 
Total 
Vol ilL 
Adjusted with differing 
substrate volumes 
40 
100 
15 
Varied 
1000 
184 
[Final] 
1-10 x litKm 
or Kd 
Table 7.26: Volumes required to determine substrate specificity of amadoriase I a 
Prepared in HEPES buffer. b Prepared in dH20. 
Assay conditions and rate calculations were undertaken as stated in previous sections. 
7.5.11 Over-expression of amadoriase I mutants 
Both mutants, E. coli BL21(DE3)pLysS(pET 15bS370A) and E. coli 
BL21(DE3)pLysS(pET 15bH357N) were over-expressed as described in section 7.5.8 
for the wild-type enzyme. The crude cell extract of both mutants was tested for 
activity via the coupled assay outlined in section 7.5.10. SDS-PAGE of the crude cell 
extract was undertaken as outlined in section 7.5.8. 
7.5.12 Attempts to restore activity to mildly glycated RNase A 
Preparation of RNase A and methylglyoxal incubations (mildly glycated protein) 
RNase A was incubated with methylglyoxal as outlined in the Figure 7.1, with 
incubations at a final concentration of 10 mM methylglyoxal and 25 mg/mL RNase A 
(1:2 a,-dicarbonyl: amine) in 100 mM sodium phosphate buffer (pH 7.4) Appropriate 
controls were prepared and included as outlined in section 7.2.1 and Figure 7.1 
(prepared in duplicate). After preparation of incubations, the quadruplicate samples 
were halved and two were incubated at 37°C for 1 h whilst amadoriase I (20 ilL) or 10 
mM sodium phosphate buffer (pH 8) was added to the remaining two which where 
then immediately frozen in liquid N2. After incubation of the two initial samples at 
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37°C, either 20 ilL of amadoriase I (120 Ilg/mL) or 10 mM sodium phosphate buffer 
(PH 8) was added and the solution incubated at 4°C for 3 days and stored at -80°C at 
the conclusion of incubation. 
Rep 1 Rep2 
Immediate addition Amadoriase I 
to incubations and storage at -80 °e 
VV 
~~ I ~~ 
+A -A 
VVVV 
Rep 3 
-M I 
+R 
+A 
-M I +R 
-A 
-M I 
-R 
+A 
VV 
1 hr incubation of M+R at 37°e 
prior to Amadoriase I addition 
VV 
2 assays from each incubation 
Assay of actvity by 
methylene blue assay 
+M I 
-R 
+A 
Figure 7.1: Experimental design for testing a mildly glycated substrate. For clarity, 
only one branch has been extended. Abbreviations: Rep, replicates prepared on 
different days; M, methylglyoxal; R, RNase A; A, amadoriase I. Controls, -M-R+A, 
+M-R-A, +M-R+A incubations were only prepared in duplicate, not quadruplicate 
due to time considerations. 
Experiments to determine whether glycated RNase A acts as a substrate for 
amadoriase I 
The experimental procedure was undertaken as outlined in section 7.4. However, a 
working concentration of 0.06 Ilg/mL was selected due to batch-wise variation of 
RNase A. It was ensured that enzyme concentration was proportional to rate exactly 
as outlined in section 7.4. The methylene blue assay was carried out on all samples, 
including incubation controls, as outlined for the experiments to dctermine the 
catalytic efficiency of RNase A in the presence or absence of Maillard inhibitors 
(section 7.4). 
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Statistical analysis 
The experiment above was designed as a split plot design with each replicate (Rep) as 
the block effect. The factors for ANOV A, methylglyoxal, amadoriase and time of 
incubation were at the plot level. There was a level of nesting where a repeated 
measurement was taken (of each sample) to measure pipetting error within the assay 
procedure. Considering the above a multi-way ANOVA was then performed using S-
PLUS and the P values calculated where required. 
7.5.13 Attempts to isolate a potential deglycating enzyme from a Pseudomonad 
Preparation of a mildly glycated substrate for bacterial culture 
Dialysis tubing preparation 
Visking 12,000-14,000 MW cutoff tubing (32 mm x 20 mm, Medicell International 
Ltd., London, U.K.) was boiled for 10 min in 1 L of 2% (w/v) of sodium bicarbonate 
and 1 mM Na2EDTA·2H20. Care 'was taken to ensure the tubing remained 
submerged at all times. The tubing was then thoroughly washed in dH20 and boiled 
for a further 10 min in 1 L of 1 mM Na2EDTA2H20. The tubing was washed in 
dH20 and stored, immersed, in 0.1 % (w/v) sodium azide. Immediately before use, the 
tubing was removed from the sodium azide and washed thoroughly with dH20. 
Casein purification and sugar incubation preparation 
Casein (20 g, technical grade) was dissolved in cold dH20 (4°C, I L) and the pH 
adjusted to 8 using 1 M NaOH. This was dialysed against dH20 for 3 days (12,000-
14,000 MWCO tubing prepared as outlined above) at 4°C with at least 3 changes of 
dH20. The retentate was freeze-dried and resulting casein (13 g yield) was used for 
subsequent experiments. 
A solution of 100 mg/mL lactose (200 ilL, prepared in sdH20 pH 7) was diluted in 
200 ilL of 50 mg/mL casein (prepared in sdH20, pH 7), to give final concentrations of 
50 mg/mL lactose and 25 mg/mL casein, then incubated at 3TC for 0, 2 or 5 days. 
Protein only controls for each time period were prepared as above with the 
substitution of lactose with sdH20. Lactose only controls were also prepared with 
sdH20 substituted in place of casein. A day 0 and a day 5 incubation were prepared 
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for the lactose only controls. Once incubated, samples were dialysed against 1 L of 
sdHzO OIN with at least one change of 1 L sdHzO at 4°C as outlined in section 7.2.3. 
Samples were stored at -20°C until required. 
Protein concentration was quantified by the Bradford method using BSA as a standard 
as outlined in section 7.5.7. Casein was also employed as a standard with a range of 
dilutions from 25-250 Ilg/mL were prepared in triplicate. A working final 
concentration of 6 IlglmL casein was selected on inspection of the calibration curve. 
The decrease of lysine concentration was measured using thc oP A method outlined in 
section 7.2.4, using a lysine and a casein calibration curve. A standard solution of 8 
mglmL casein was prepared by dissolving in dHzO. Dilutions from this were 
prepared ranging from, 0.5-6 mg/mL in triplicate and assayed as outlined in section 
7.2.4. From the calibration curve, a working concentration of 4 mg/mL casein (before 
dilution in oP A) was employed for subsequent assays which were undertaken as 
section 7.2.4. 
Glycated substrate sterilisation procedure 
Substrate, the casein and lactose sample, that had been incubated at 37°C for 5 days 
with subsequent dialysis, was irradiated at 120,000 IlJ cm-z for 5 min in glass petri 
dishes. To confirm sterilisation had been effective, sample (final concentration of 1 
mg/mL) was used to inoculate a 3 mL OIN of nutrient broth (Appendix six) and was 
also spread onto a nutrient agar plate (Appendix six) and incubated at 30°C O/N. No 
growth in either media deemed the sterilisation procedure effective. 
Initial isolation of bacterium of interest 
This was undertaken in collaboration with an M.Sc. microbiology student Sarah Day 
(24). 
Purification procedure undertaken to isolate the putative deglycating enzyme (25,26) 
1 L of nutrient broth was inoculated with 1 mL of a P. fluorescens OIN culture and 
induced with a [mal concentration of 1 mglmL of either sterilized, casein + lactose, 
casein only or lactose only incubations. Cultures were grown at 30°C for 17 h. A 
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negative control strain E. coli BL21(DE3)pLysS was included, with 1 mg/mL 
sterilized casein + lactose also added. Each 1 L culture was then cooled to 4°C and 
centrifuged at 5,000 x g for 15 min at 4°C. After centrifugation, the supernatant was 
carefully removed and discarded and the pellet resuspended in Ix vol of cold (4°C) 
minimal salts - (3 g monopotassium hydrogen phosphate, 9.17 g dipotassium 
hydrogen phosphate trihydrate, 0.1 g of ammonium sulfate, 1 mM magnesium sulfate) 
and respun at 5,000 x g for 15 min at 4°C. The supernatant was removed and 
discarded and the pellet resuspended in 50 mM cold (4°C) sodium phosphate pH 7.4, 
containing 1 mM Na2EDTA'2H20 and 0.2 mM phenylmethylsulfonyl fluoride (10 
mLlL of culture). Samples were sonicated at 30% amplitude for bursts sonicated for 9 
sec on, 9 off for 3 min intervals for a total of 12 min. Cellular debris was removed by 
centrifugation at 13,000 x g at 4°C for 10 min. The supernatant was split and stored at 
-20 and -80°C. An 8-16% SDS-PAGE gel of the samples was undertaken of the 
samples (5 f..LL of crude + 5 f..LL of 2x treatment buffer) as outlined in section 7.3.2 for 
RNaseA. 
Assessment of deglycating ability of crude extract via amadoriase J assay 
Activity of the crude sample was tested using the assay outlined in Table 7.25 (section 
7.5.9), with 20 f..LL of the crude sample prepared directly above substituted for 
amadoriase 1. 10 f..LL of 33 mM of fructosyl propylamine (final concentration of 0.49 
mM, lax Km of Amdoriase I quoted by Wu et al.) (18) was added to initiate the 
reaction. Activity of the crude extract was also measured using a final concentration 
of 1 mg/mL casein + lactose solution as a substrate in place of fructosyl propylamine. 
Assessment of deglycating ability of crude extract via RNase A methylene blue assay 
A solution of 20 mM methylglyoxal prepared in 100 mM sodium phosphate buffer 
(pH 7.4) was diluted 1:1 in 50 mg/mL RNase A (in sodium phosphate buffer, pH 7.4) 
to give a final concentrations of 10 mM and 25 mg/mL respectively (1 :2, u-
dicarbonyl: amine). Controls were as outlined for similar studies with amadoriase 1. 
Immediately after mixing, an aliquot of M+R and RNase A only control were frozen 
immediately. The remaining samples were incubated for 1.5 h and then half of the 
M+R samples and half of the protein only controls were incubated with 10 !-lL of the 
crude Pseudomonas that had been cultured on casein + lactose and stored at 4°C for 
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19 h. The remaining samples were incubated with 10 ilL of 50 mM sodium phosphate 
pH 7A containing ImM Na2EDTA'2H20 and 0.2 mM phenylmethylsulfonyl fluoride, 
in place of crude extract and incubated for the same period of time as those containing 
the crude extract. 
Samples were then tested for activity using the RNase A assay outlined in section 
10. The following was dispensed into a cuvette with the exception of the RNase A 
± methylglyoxal incubation (Table 7.27). 
Reagent Vol. (ilL) 
RNA (10 mg/mL) 60 
Methylene blue buffer 940 
Sample - RNase A (6 Ilg/mL, in MOPS buffer) 
± dicarbonyl 10 
± Pseudomonas extract 
[Final] (llg/mL) 
(2 s.f.) 
600 
0.06 
Table 7.27: Vols. required to estimate the deglycating ability of the Pseudomonas 
extract 
The remainder of the assay was undertaken as outlined in section 7 A.l. 
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p-Hydroxybenzoic acid hydrazide (HBB) method 1 quantify a-dicarbonyl 
concentration 
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Figure 1: Calibration curves for a-dicarbonyls A, methylglyoxal; B, glyoxal; C, 
diacetyl. Concentrations above are initial concentrations prior to dilution in RBR. 
Readings for each time point represents an average of three samples. Error is 
expressed as standard error of the mean. 
The first RBR method attempted to quantify a-dicarbonyl decrease in incubations 
that contained RNase A and the results are detailed in Figure 2. 
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Figure 2: A measure of a-dicarhonyl concentration over time for A, glyoxal; B, 
diacetyl; in presence or absence of RNase A. Readings for each time point represents 
an average of three samples. Error is expressed as stand ard error of the mean. 
Appendix One 194 
p-Hydroxybenzoic acid hydrazide (HBH) method 2 to quantify a-dicarbonyl 
concentration 
Calibration curves were constructed for all three a-dicarbonyls and are outlined in 
Figure 3. 
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Figure 3: Standard curves for a-dicarbonyls A, methylglyoxal; B, glyoxal; C, 
diacetyl Concentrations above are initial concentrations before dilution in HBH. 
Readings for each time point represents an average of three samples. Error is 
expressed as standard error of the mean. 
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The results of an attempt to quantify glyoxal decrease in incuhations that contained 
RNase A are detailed in Figure 4. Methylglyoxal was trialled but very large errors 
were obtained. 
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Figure 4: Decrease in glyoxal over time in the presence or absence of RNase A in 
incubations. Readings for each time points are an average of three samples. Enor is 
expressed as standard error for the mean for triplicate samples. 
The effect of phosphate on the crosslin king reaction 
The effect of phosphate on the rate of the Maillard reaction in RNase A containing 
methylglyoxal was assessed by the oPA assay and the data subjected to an analysis of 
variance (ANOY A). The data is represented in Table I. Along with the effect of 
phosphate, the time of incubation was also taken into consideration, but did not have 
an additive eHect to the decrease in lysine concentration. This may be due to the 
hreak-down of RNase A over time as discu ssed in chapter 2 (measurements of time 
ranged from 0 - 48 hours). "Preparation" and "Sub" were duplicate incubations 
prepared from the same stock solution, in order to account for pipetting error within 
the experiment. These arc referred to as repeated measurements, or, nesting. Another 
set of repeated measurements at the residual level was performed during the assay 
itself, to detect any discrepancies within the assay. 
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Treatment df deviance MS F P 
Phosphate 1 5.66 5.66 75.34 0.01 
Time 6 0.12 0.02 0.77 n.s. 
Phosphate: Preparation 2 0.15 0.08 2.05 n.s. 
Time: Phosphate 6 0.08 0.01 0.47 n.s. 
Phosphate: Preparation: Sub 4 0.15 0.04 
Time:Phosphate:Preparation: Sub 36 0.97 0.03 1.55 n.s. 
Residual 43 0.75 0.02 
Total 98 7.9 
Table 1: Multi-way ANOVA of a split-plot design with 2 senes of repeated 
measurements (nesting) at the subpreparation (Sub) and the residual level. n.s, non-
significance, was deemed to be P>0.05. 
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Supplemental graphs and gels for experiments detailed in Chapter four 
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Figure 1: RNase A activity over 96 hours following incubation with glyoxal in the 
presence (l1l\I), or absence ( ) of amino guanidine. Bars indicate the average of data 
generated from triplicate readings. Error bars represent the standard error of the mean 
for the triplicate reading. Abbreviations are fc, frozen control, ic, incubated control, 0-
96 h incubation time of a-dicarbonyl-containing RNase A samples. 
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Figure 2: RNase A activity over 96 hours following incubation with diacetyl in the 
presence (l1l\I), or absence (.) of amino guanidine. Bars indicate the average of data 
generated from triplicate readings. Error bars represent the standard error of the mean 
for the triplicate reading. Abbreviations are as for Figure 1. 
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Figure 3: RNase A activity uver 96 l1llurs following incubatiun with glyoxal III the 
pres nee (. ). o r abse ncc ( ). oj" l .S -d imcthylpyr'lI,olc - l -carhoxamidine, Bars indicate 
the average o f data ge nerated fro m triplicatc readin gs, Error hars represent the 
stand ard e rro r of th e mean J"or the triplicate reading. AI h r vi a tions arc as for Figure I . 
29 kDa 
. i 
I 
M 0 :3 2 6 24 48 96 Fe Ie 
dimer 
monomer 
Figure 4: 8- 16 7r SDS-PAGE ge l RNasc A incubated with glyuxal and DMP 
Abbre viations : M. marke r. 0 -96 ti me o f incuhation of (x-dicarhoJlyl -containing R ase 
A sumpl in th p resence of inh ibitor F . frozen 'ontroL Ie incuhalc.d control. 
Appendix Two lCJ9 
35 J 
30 
fc(O) o 2 6 24 48 96 
Time (hours) 
Figure 5: RNase A activity over 96 hours following incunation with diacetyl in the 
presence (_), or absence ( ) of 3,5-cl imethylpyrazoic-l-carhoxamidine. Bars indicate 
the average of data generated from triplicate readings. Error hars represent the 
standard error of the mean for the triplicate reading. Ahhreviations arc as for Figure 1. 
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Figure 6: ~-16(!r SOS-PAGE gels RNase A incubated with diacetyl and DMPC 
Abbreviations are as for Figure 4. 
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Statistical analysis of data from experiments undertaken in Chapter five to assess 
whether amadoriase I restored glycated RNase A to its native function 
Treatment df deviance MS F P 
Day 3 892.98 0.003 
Amadoriase 1 90.87 90.87 3.53 n.S. 
Sugar 1 161.08 161.08 6.26 0.04 
Time 1 8.66 8.66 0.34 n.S. 
Amadoriase: Sugar 1 5.30 5.30 0.21 n.s. 
Amadoriase:Time 1 14.26 14.26 0.55 n.s. 
Sugar:Time 1 444.47 444.47 17.27 0.003 
Amadoriase: Sugar: Time 1 10.41 10.41 0.40 n.s. 
Amadoriase: Sugar: Time: Subprep 8 205.88 25.73 1.19 n.s. 
Residual 97 2099.83 21.65 
Total 115 3933.744 1080.097 
Table 1: Multi-way ANOVA with one level of nesting at the time level. n.s., non-
significance, was deemed to be P>0.05. 
Each experiment was repeated in quadruplicate on different days (daywise variation 
was assessed in Table 1 by "Day"). As predicted, incubation of RNase A and sugar 
over time showed a significant difference in activity over those that did not contain 
sugar, as measured by the Sugar:Time interaction term. 
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Appendix four 
Site-directed mutagenesis of amadoriase I 
Little is known about the amino acids that are involved in the catalytic mechanism of 
amadoriase 1. This section aimed to address this issue with two mutations to the 
putative active site. The mutations described here were made in collaboration with 
Andrea Uhlmann (His357 to Asn) and Stephan Hegge (Ser370 to Ala mutation), 
during exchange projects from Germany. Initial BLAST and literature searches for 
residues of amadoriase I relevant to substrate binding and catalysis were undertaken 
by myself. Both students were responsible for final selection of which residue to 
mutate, primer design and practical work, which I oversaw. 
Conserved residues within the amadoriases 
Figure 1 outlines sequence alignment data for all amadoriases isolated to date along 
with bacterial sarcosine oxidase mentioned previously. The region ranging from 
residues 340-400 in amadoriase I is highly conserved with respect to other 
amadoriases. This is thought to contain the flavin binding site where the conserved 
Cys residue for flavin binding resides (in the case of Amadoriase I this is Cys342) and 
also residues that may be important in catalysis. Two residues of particular interest 
were serine 370 and histidine 357, which are conserved within all of the amadoriases 
(Figure 1). These residues were mutated to alanine and asparagines respectively to 
probe their role in the catalytic mechanism of amadoriase I, with the schemes 
proposed in section 5.3.1 in mind. 
Amadoriase I 
Amadoriase II 
Amadoriase from A terre us 
Amadoriase from A nldulens 
+ 
342 liTD 
335 
334 
347 
Amadoriase from P. jantlJinefJum 347 
Amadoriase from S. pombe 329 
Sarcosine oxidase Bacillus sp. 316 
381 
374 
373 
386 
386 
378 
355 
Figure 1: A highly conserved region of Amadoriases thought to contain the active 
site of the amadoriases. The area shown here is from Cys342 (in Amadoriase I) to 
Gly 38 L Black blocks denote 100% identity, grey blocks denote 75%-99% identity. 
+ denotes a conserved Cys, that is thought to be the point of FAD covalent 
attachment. * denotes residues that have been mutated. 
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Creation of the amadoriase I mutants 
The primers for both mutants, Ser 370 to Ala (S370A) and His 357 to Asn (H357N), 
are outlined in Table 1. Both mutants were generated by site-directed mutagenesis 
using the Stratagene QuikChange Mutagenesis Kit, according to the manufacturer's 
instructions (1). Sequencing was undertaken using T7 promoter and T7 terminator 
primers, along with a custom primer that bound to DNA in the1002 and 1025 bp 
region of amadoriase I (mutations at 1115 and 1154 bp) to obtain a complete read-
through of the amadoriase I sequence. 
WT 
S370A (#1) 
S370A (#2) 
Primer sequence 
5' GCT GTT GGA GGT TCC GGC AAT GGC GCC 3' 
5' GCT GTT GGA GGT GCC GGC AAT GGC GCC 3' 
5' GGC GCC ATT GCC GGe ACC TCC AAC AGC 3' 
WT 5' C CGT GCT TTC TTG ATC GAT AGA GAA CAC CCC 3' 
CCT GAA CAC CCC 3' H357N (#1) 5' C CGT GCT TTC TTG ATC GAT AGA 
H357N (#2) 5' GGG GTG TTC AGG ATT TCT ATC GAT CAA GAA AGC ACG G 3' 
Table 1: Primers used for site-directed mutagenesis experiments. WT denotes wild 
type sequence for the area of interest. # 1 represents the sense primer. #2 represents the 
antisense primer. The codons of interest are underlined and the bases to be changed, 
are depicted in bold. 
Following successful amplification of each mutant plasmid, coli XLI-Blue was 
successfully transformed with this DNA. In the case of the S370A mutant, the 
plasmid DNA was prepared and examined by restriction analysis to confirm the 
appropriate mutation had been made. This was made possible by the creation of a 
new restriction site, recognized by NaeI as a result of the substitution of T for G 
(Figure 2). The results of the digest are shown in Figure 3. Bands with the sizes of 
3.4, 1.6, 1.3, 0.4, 0.35 and 0.16 kb were expected, with bands at 3.5, l.5, 1.3, 0.39, 
0.29 and 0.16 observed (Figure 3). 
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Figure 2: pET I5b vector map containing the amadoriase I insert with Ser 370 
substituted with Ala. Vector map was created using DNAMAN (Lynnon 
Corporation, Quebec, Canada). The numbers in hrackets denote the base number. 
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Figure 3: An agarose gel of a restriction analysis of mutant S370A plasmid DNA. 
From left to right: A cut with HindIII (sec Figure 5.8 for marker molecular weight); I 
and 2. pETS370A cut with BCllnHI and Noel; lkb marker, molecular weights from top 
to bottom, 1, 0.9,0.8,0.7,0.6,0.5,0.4,0.3,0.2,0.1 kb. 
Unfortunately. creation of a new restriction site was not simple with the H357N 
mutant, and the mutation was confilmed by sequence analysis at the Waikato 
sequencing facility . Subsequent to confirmation of both mutations, the expression 
strain, E. coli BL2I (DE3)pLysS was transformed with the mutant plasmids. 
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Purification and 'anetic assay ofS370A and H357N mutants 
Both strains containing each mutation were cultured and purified as outlined for the 
wild-type enzyme. Assessment of activity involved the use of the coupled assay 
described previously. Interestingly, the crude extract of the S370A mutant did not 
show any activity, yet SDS-PAGE analysis confirmed the over-expression of a protein 
at 50 kDa that corresponded to the molecular weight of amadoriase 1. Work thus far 
suggests that that both mutagenesis experiments have been successful and two 
inactive mutants of amadoriase I have been created. 
The preliminary results reported here are encouragmg, as both mutations have 
resulted in a total loss of amadoriase activity. However, further experiments must be 
undertaken to assess whether these enzymes are critical for catalysis, or the mutation 
has resulted in the formation of a misfolded protein. Future experiments involving 
circular dichroism will seek to test the latter point. 
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Appendix five 
The search for novel deglycating enzymes 
Amadoriase I cannot act on glycated protein, thus, from a therapeutic standpoint, it 
has limited potential. The search for a novel enzyme that can use glycated protein as 
a substrate has become a focal point for research (1). This section outlines work, 
initiated by Sarah Day (Microbiology M.Sc. student working with Dr. John IOena, 
University of Canterbury), aimed to isolate a potential deglycating enzyme (2). In the 
past, micro-organisms that metabolise glycated model amines have generally been 
isolated from soil samples (3). Here, a different environment has been studied, raw 
milk. Milk is rich in casein and sugars, such as lactose, that participate in the 
Maillard reaction (4,5). The glycated substrate for bacterial isolation experiments, 
and assessment of the activity of the successful isolate toward glycated protein was 
undertaken by myself. Sarah Day was responsible for the culturing, isolation and 
identification of the bacteria from raw milk that were found to grow successfully on a 
glycated protein substrate compared to protein only or sugar only controls (2). 
Selection and generation of a suitable substrate 
Casein is an excellent candidate for in vitro glycation experiments, as it is present in 
milk and commercially available at little expense. Additionally, this protein is 
reported to be extremely heat stable (6), and as a result, has been intensively studied 
by those Maillard chemists working in the food industry. Casein comprises 80% of 
the milk proteins which constitutes 3.3 % of milk (5), and is divided into four groups, 
Usl-, U s2-, ~- and lC-casein. Casein exists in large colloidal micelles with calcium 
phosphate and has almost no secondary or tertiary structure (5,6). Maillard-type 
reactions between casein and lactose have been found to result in the gelling of milk 
(5). A decrease in lysine concentration and concomitant increase in AGEs have been 
reported in casein on treatment with aldoses, ketoses and u-dicarbonyls. (4,7) 
Melanoidin pigments, fonned in the later stages of the Maillard reaction have been 
reported also in sugar-casein systems (6). 
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Lactose (Figure 1) is a disaccharide that is the predominant sugar in milk, comprising 
5% of the content of milk (5). The sugar has been studied in Maillard systems where 
it has been found to modify p-lactoglobulin, another milk protein (8). 
OHOH 
~ OH HO o~--o o HO~OH 
OH 
Figure 1: The structure oflactose: galactose and glucose monomer linked by a P 1-4 
glycosidic linkage. 
On reaction of lactose with lysine, the Amadori product, lactuloselysine, can be 
formed following Amadori rearrangement (Reviewed in (9)). The structure of this 
compound, which has been used as a marker of early glycation in milk, is outlined in 
Figure 2. Interestingly, CML, introduced in Chapter one, is isolated from human 
tissue, can be formed from this compound (Reviewed in (9)). 
OHOH , ~ ____ 0' OH 
HO~O~t\ 
HO~o 
"L 
Figure 2: The structure oflactuloselysine (9). 
Generation of the glycated substrate protein involved the incubation of casein with 
either lactose or xylose. Lactose was selected due to is predominance in milk, making 
it a most likely candidate for modifying residues within casein. Thus, if a deglycating 
enzyme did exist, in milk, it would most likely recognize this form of glycated 
protein. Xylose was selected due to its mild glycating ability and the fact that its role 
in the Maillard reaction is reasonably well-studied (10,11 ). 
The extent of the Maillard reaction was measured by the decrease in lysine 
concentration as determined by using the oP A method. Calibration curves for lysine 
and casein were both prepared (Figures 3 A and B ). 
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Figure 3: Calibration curves of A, lysine and B, casein to measure lysine content via 
the oP A method and protein concentration via the Bradford assay respectively. Each 
point is an average of triplicate concentration samples. Error is expressed as standard 
error of the mean of triplicate samples. 
Following inspection of the calibration curves, the appropriate assay concentrations 
were selected. The decrease in lysine concentration in casein in the presence of either 
xylose (Figure 4) or lactose (Figure 5) was then measured. In these experiments, a 
protein only control was included for each time point incubation, and used as a 
reference for calculation of lysine percentage. Initial work with xylose was not 
extended due to the fact that xylose can reversibly modify protein (12), and thus could 
causc false positive results. After extensive testing, the conditions of 50 mg/mL 
lactose and 25 mg/mL casein incubated for 2 and 5 days at 37°C were selected for 
ensuing experiments. 
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Figure 4: Percentage lysine remaining in casein following incubation with xylose, 
Readings are expressed as percentages of the protein only control prepared for each 
appropriate time point and are an average of triplicate experiments. Error is expressed 
as standard error of the mean for triplicate experiments. 
100 
.--.. 90 :::R ~ 
Ol 
c 
'2 80 
'ro 
E 
~ 70 Q) 
,£ 
If) 
3' 60 
50 
2 5 
Time (days) 
Figure 5: Percentage lysine remaining in casein on incubation with lactose. Readings 
are expressed as percentages of the protein only control prepared for each appropriate 
time point are an average of duplicate experiments. Error is expressed as standard 
error of the mean for duplicate experiments. 
The increase in lysine residues from day two to day five (Figure 5) may be due to the 
break-down of casein during incubation with the lactose. This increase of lysine over 
time was also noted for RNase A in chapter two. 
Appendix Five 209 
A significant result from the work undertaken by Sarah Day, was the isolation of a 
bacterium, Pseudomonas jluorescens, that exhibited the capacity to grow more 
efficiently on glycated protein substrate than protein or lactose alone (2). When 
supplemented with casein only, this bacterium was shown to commence growth after 
72 h. However, when supplemented with the glycated substrate, growth was almost 
immediate. The difference in growth was the most apparent using a 25 mg/mL casein 
+ 50 mg/mL lactose solution that had been incubated for 5 days at 37°C. 
The next phase of this research, after finding a promising bacterial candidate, was to 
attempt to isolate the enzyme( s) that enabled the bacterium to grow more efficiently 
on the glycated substrate as opposed to the controls. The above incubation conditions 
for the preparation of the glycated substrate were employed for all subsequent 
experiments to isolate the enzyme that allowed for the rapid growth of P. jluorescens 
on a glycated substrate. Initial work to create a glycated substrate involved tracking 
the progress of the reaction byJysine analysis. After two days of incubation with 
lactose at 37°C, 74% of lysine remained available within casein. After 5 days 
however, it appears that this is raised to around 90%. However, this may be due to 
issues encountered in Chapter two where the breakup of the protein over time 
overshadows perceptible lysine loss. 
Isolation of an "amadoriase-like" enzyme from P. fluorescens 
In order to isolate the putative enzyme, P. jluorescens was cultured in the presence of 
glycated substrate. It is essential to include the substrate during the growth of the 
bacterium, as the expression of some amadoriases is induced by the glycated substrate 
(13). To ensure the absence of contaminating bacteria within the substrate, samples 
were UV-irradiated prior to use. The period of exposure was kept to a minimum to 
ensure that protein structure was not disrupted but bacterial contaminants were 
eliminated. This was also undertaken in initial experiments undertaken to isolate 
deglycating bacteria (2). Attempts to use less harsh methods of sterilization such as 
filter sterilization resulted in difficulties (2). The purification protocol adopted was 
that outlined by Gerhardinger et al. and Saxena et at. who isolated proteins from a 
Pseudomonad that could either bind glycated low molecular weight amme or 
enzymatically cleave glycated low molecular weight amine (14-16). 
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Testing the cell extract for "amadoriase-like" activity 
Once the cells were harvested using methods described by Gerhardinger et al. and 
Saxena et al., the crude sample was tested for activity using two approaches. The first 
involved the coupled ABTS assay that had been used to determine the kinetic 
parameters of amadoriase I earlier in this chapter (section 5.4.2), with the crude 
extract in place of amadoriase 1. The first attempt used fructosyl propyl amine, the 
substrate that had been used for the kinetic study of amadoriase I, but gave a negative 
result. It was thought that perhaps as the bacterium had always been cultured using 
glycated protein as a substrate that the enzyme may not recognize glycated low 
molecular weight amines. Thus, glycated protein was substituted for fructosyl 
propyl amine in the coupled assay. This again resulted in negative readings, which 
may be due to the fact that this enzyme does not produce hydrogen peroxide. This 
has been reported to be the case for one deglycating enzyme isolated from a 
Pseudomonad (16). 
A second approach was undertaken to circumvent difficulties noted using the coupled 
assay, as outlined in the paragraph above. The crude mixture was assessed for its 
ability to deglycate RNase A, and thus effect a return to function, which could be 
measured by the RNase A activity assay (section 5.7). This experiment was trialed 
using the mildly glycated protein that had been used in section 5.7.1 for the 
amadoriase 1. Briefly, a 10 mM methyl glyoxal, 25 mglmL RNase A solution was 
incubated at 37°C for 1 hour. After this the crude extract was added and incubated 
overnight at 4°C. The experiment was undertaken exactly as for the amadoriase work 
and a negative result was obtained (Figure 6). 
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Figure 6: Attempts to return activity from glycated RNase A by the jluorescens 
crude extract. Abbreviations, MR+E, methyl glyoxal + RNase incubated for 1 hour 
followed by addition of Pseudomonas extract and incubation overnight at 4°C; R+E, 
RNase incubated for 1 hour followed by addition of Pseudomonas extract and 
incubation overnight at 4°C; MR-E, methylglyoxal + RNase incubated for 1 hour 
followed by addition of 50 mM sodium phosphate buffer (containing 1 mM EDTA 
and 0.2 mM PMSF) and incubated overnight at 4°C; R-E, RNase incubated for 1 hour 
followed by addition of 50 mM sodium phosphate buffer (containing 1 mM EDTA 
and 0.2 mM PMSF) and incubated overnight at 4°C; MRO, methyl glyoxal + RNase A 
frozen immediately, RO, RNase A frozen immediately. Readings are an average of 
duplicate experiments and are expressed as a control for the appropriate RNase 
control. Error is expressed as standard error ofthe mean for duplicate experiments. 
On inspection of Figure 6 it is evident that RNase A activity is lowered in the 
methyl glyoxal and RNase A incubations that had been treated with the crude extract. 
Although RNase A is a stable protein and a serine protease inhibitor in the form of 
PMSF, has been added to the crude sample, either break-up of the protein is occurring 
or inhibitors are binding to RNase A to lower activity. The crude extract does not 
appear to aid the return to function of the glycated protein that was hypothesised. 
Although attempts were unsuccessful to isolate a deglycating enzyme from milk 
isolates it must be considered that there may be a protein that can bind the glycated 
substrate in the crude mixture, but not cleave, as has been noted elsewhere in 
experiments with Pseudomonas (14). 
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Appendix six 
Strains, media and solutions required for molecular biology and protein expression 
in Chapter five. 
Strain list 
Sh'ain Genotype 
E. coli BL2I(DE3)pLysS E. coli B P- dcm ompT hsdS(rB_mB_) gal ,,-(DE3) 
[pLysS Camr] 
E. coli BL2I(DE3)pLysS 
(pET I5b) 
E. coli B P- dcm ompT hsdS(rB.mB_) gal "-(DE3) 
[pLysS Camr] [PET I5b::amaI Ampr] 
E. coli BL2I(DE3)pLysS E. coli B F- dcm ompT hsdS(rB.mB_) gal ,,-(DE3) 
(PET I5bS370A) [pLysS Can{] [pET I5b::amaIS370A Ampr] 
E. coli BL2I(DE3)pLysS B P- dcm ompT hsdS(rB_mB_) gal ,,-(DE3) 
(pET I5bH357N) [pLysS Camr] [pET 15b::ama1H357NAmpr] 
E. coli XLI-Blue 
E. coli XL 1-Blue 
(PET 15b) 
E. coli XL I-Blue 
(PET I5bS370A) 
coli XLI-Blue 
(PET 15bH357N) 
LB-Agar plates 
recAI endAI gyrA96 thi-l hsdRl7 supE44 relAI lac [FI 
proAB lacf4Zf1M15 TnI0 (Td)] 
recAI endAI gyrA96 thi-I hsdRl7 supE44 relAI lac [FI 
proAB lacf4Zf1M15 Tn} 0 (Tetj] [pET I5b amaI Ampr] 
recAI endAI gyrA96 thi-l hsdRl7 supE44 relAI lac [FI 
proAB lacf4Zf1M15 TniO (Td)] [pET I5b amaJS370A 
Ampr] 
recAI endAI gyrA96 thi-l hsdRl7 supE44 relAI lac [FI 
proAB lacflZf1M15 TnlO (Ten] [pET I5b ama1H357N 
Arnpr] 
20 g ofLB and 15 g of agar were added to 1 L of dH20, mixed and autoc1aved before 
use. On cooling to 50°C, antibiotic was added where required, and the LB-Agar was 
poured into Petri dishes and the surface of the molten agar flamed to removed 
bubbles. Plated were then dried for 10 min in a biohazard hood. 
Appendix Six 214 
NA-Agar plates 
13 g of nutrient broth and 20 g of agar were added to 1 L of dH20, mixed and 
autoclaved prior to use. On cooling, media was poured into Petri dishes and the 
surface of the molten agar flamed to removed bubbles. Plates were then dried for 10 
min in a biohazard hood. 
LB for liquid culture 
20g LB was added to 1 L of dH20, mixed and autoclaved before use, 
Nutrient broth for liquid culture 
13g of nutrient broth was added to 1 L of dH20, mixed and autoc1aved before use. 
Preparation of antibiotics and IPTG for bacterial selection and induction 
All stocks were prepared at 1000x concentration 
Chloroamphenicol: 30 mg/mL dissolved m 100% EtOH, stored at -20°C until 
required. 
Ampicillin: 100 mg/mL dissolved in sdH20, filter-sterilised and stored at -20°C until 
required. 
Tetracyline: 20 mg/mL dissolved in 100% EtOH and stored at -20°C until required. 
250 rnM IPTG stock: 297.9 mg IPTG in 5 mL of sdH20, filter-sterilized stored at -
20°C. 
SOC media for electro po ration experirnents 
2% w/v bactotryptone 
0.5% 2/v yeast extract 
10 mM sodium chloride 
2.5 mM potassium chloride 
10 mM magnesium chloride 
10 mM magnesium sulfate 
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0.36% w/v glucose 
prepared in dlhO and autoclaved prior to use. 
Preparation of X-gal plates for site-directed mutagenesis experiments 
100 ilL of 10 mM !PTG (prepared in dH20, filter-sterilised) and 100 J.tL of 2% 5-
bromo-4-chloro-3-indoyl-~-D-galactopyranoside (X-gal, prepared in DMF) was 
spread onto LB-Agar plates containing the appropriate antibiotics and then dried in a 
biohazard hood to remove DMF. This was undertaken 30 min prior to plating out 
transformants. 
NZY + broth for transfonnation of XL1-Blue with Amadoriase I mutants plasmids 
NZ amine (10 g), yeast extract (5 g), and NaCl (5 g) was added to ddH20 (1 L). The 
pH was adjusted to 7 with the addition of NaOH before the media was sterilised by 
autoclave. Following this, MgCh (1 M, 12.5 mL), MgS04 (1 M, 12.5 mL), and 
glucose (20%, 20 mL) were added (all were filter-sterilised prior to addition). 
